DCN-1 modulating compound solid forms and methods of use thereof
Solid forms of Compound I provide improved solubility and stability, effectively modulating DCN-1 to treat hemoglobin-related disorders like sickle cell disease and thalassemia, enhancing treatment efficacy and reducing hydroxyurea toxicity.
Patent Information
- Application Number
- PCT/US2026/026479
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
Smart Images

Figure US2026026479_12112026_PF_FP_ABST
Abstract
Description
DCN-1 MODULATING COMPOUND SOLID FORMS AND METHODS OF USE THEREOFCROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U. S. C. §119(e) of U. S. Provisional Application No. 63 / 800,153 filed on May 5, 2025, the entirety of which is incorporated herein by reference.TECHNICAL FIELD OF THE DISCLOSURE
[0002] The present disclosure relates to solid forms of compound N-((4S,5S)-3-((R)-l-cyanamidoethyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide (Compound I), compositions thereof, and their uses in the treatment of hemoglobin-related disorders including sickle cell disorders, diseases, and conditions, and thalassemia.BACKGROUND OF THE DISCLOSURE
[0003] Hemoglobinopathies are diseases that affect hemoglobin that include sickle cell disease and thalassemia. Sickle cell disease or disorder is a group of inherited red blood cell disorders that affect hemoglobin and can block blood flow to the body. Specifically, a defective beta hemoglobin chain in sickle cell patients twists and changes the shape of each red blood cell from a doughnutlike shape into a “sickled” or croissant shape that can clog small blood vessels and prevent the delivery of oxygen around the body. Sickle-cell disease is characterized by various acute and chronic complications, which are associated with significant morbidity and mortality in an afflicted subject. Thalassemia is also an inherited red blood cell disorder that is caused by a defect in the beta-globin gene, controlling the production of the beta-globin chains of hemoglobin. Accordingly, a patient suffering from thalassemia can’t make enough normal hemoglobin and thus has relatively fewer red blood cells and lower blood oxygen levels than people who do not suffer from the disease. Thalassemia patients may not make enough of either or both of the alpha or beta proteins in hemoglobin.
[0004] The cullin family of ubiquiti nation E3s are the most well-characterized substrates of neddylation. Upon neddylation, the cullins constellate the cullin-RING E3 UB ligase family (CRLs), which has approximately 300 members. The CRLs regulate diverse biological processes 1335841422 CENC-005 / 01WO 360899-2046including cell cycle, signal transduction, DNA replication, and viral modulation. CRL dysfunction is implicated in a number of human diseases, including cancer. Drug discovery efforts targeting the CRLs and the associated proteasomal protein degradation machinery have been extensive and continue to grow. The neddylation pathway has been successfully targeted by MLN4924 (Pevonedistat), an inhibitor of NEDD8’s El enzyme, that completely blocks NEDD8 ligation to substrates. MLN4924 is currently being tested in oncology clinical trials. An inhibitor of the COP9 signalosome, responsible for de-neddylation of the CRLs, has been reported and also displays antitumor activity. Defective in cullin neddylation 1 (DCN-1) is a protein that interacts with cullins and is required for neddylation. DCN-1 is also known as DCUN1D1, DCNL1 or Squamous Cell Carcinoma-related Oncogene (SCCRO). DCN-1 is the most well characterized isoform due to its common amplification as part of a large 3q26.3 amplicon in squamous cell carcinomas (SCC) and other tumors. DCN-1 amplification in SCC negatively correlates with cause-specific survival, suggesting that targeting DCN-1 may be of clinical utility in cancers. Its role in other diseases remains under-explored.
[0005] There remains a need to find therapeutic agents, methods, and therapies for the treatment of hemoglobin-related disorders including sickle cell disorders, diseases and conditions and thalassemia. The present invention fulfils this need and provides other related advantages.SUMMARY OF THE DISCLOSURE
[0006] Compound I solid forms of the present disclosure, and pharmaceutical compositions thereof, are effective at modulating DCN-1 and useful for treating a variety of diseases, disorders, or conditions associated with DCN-1 as described in detail herein. In some embodiments, a disease, disorder, or condition associated with DCN-1 is a hemoglobin-related disorder. In some embodiments, a hemoglobin-related disorder is a sickle cell disorder, disease or condition. In some embodiments, a hemoglobin-related disorder is a thalassemia disorder, disease or condition. Compound I is represented by the chemical structure below:2335841422 CENC-005 / 01WO 360899-2046BRIEF DESCRIPTION OF THE FIGURES
[0007] FIG. 1 depicts a conversion map among different forms of Compound I.
[0008] FIG. 2 depicts overlaid XRPD patterns of Compound I Forms A - F.
[0009] FIG. 3 depicts overlaid XRPD patterns of Form A samples.
[0010] FIG. 4 depicts an XRPD pattern of Form A sample #1.
[0011] FIG. 5 depicts DSC and TGA Thermograms of Form A sample #1.
[0012] FIG. 6 depicts DSC and TGA thermograms of Form A sample #2.
[0013] FIG. 7 depicts an XRPD pattern of Form A sample #3.
[0014] FIG. 8 depicts DSC and TGA Thermograms of Form A sample #3.
[0015] FIG. 9 depicts DSC and TGA Thermograms of Form A sample #4.
[0016] FIG. 10 depicts overlaid XRPD patterns of Form B samples.
[0017] FIG. 11 depicts an XRPD pattern of Form B sample #1.
[0018] FIG. 12 depicts DSC and TGA Thermograms of Form B sample #1.
[0019] FIG. 13 depicts DSC and TGA Thermograms of Form B sample #2.
[0020] FIG. 14 depicts an XRPD pattern of Form C sample #1.
[0021] FIG. 15 depicts DSC and TGA Thermograms of Form C sample #1.
[0022] FIG. 16 depicts DSC and TGA Thermograms of Form C sample #2.
[0023] FIG. 17 depicts an XRPD pattern of Form D.
[0024] FIG. 18 depicts DSC and TGA Thermograms of Form D.
[0025] FIG. 19 depicts an XRPD pattern of Form E.
[0026] FIG. 20 depicts DSC and TGA Thermograms of Form E.
[0027] FIG. 21 depicts an XRPD pattern of Form F.3335841422 CENC-005 / 01WO 360899-2046
[0028] FIG. 22 depicts DSC and TGA Thermograms of Form F.
[0029] FIG. 23 A, 23B and 23C show induction of fetal hemoglobin in humanized mice by treatment with Compound I vs. hydroxyurea (HU) control. Human hematopoietic stem cell-reconstituted NBSGW mice were treated with the indicated doses of hydroxyurea (HU) or Compound I for three weeks. Fetal hemoglobin protein (HbF) expression was assessed by AlphaLISA™ and the results are shown in FIG. 23A. Fetal hemoglobin gene expression (HBG1) were assessed by Nanostring™ and the results are shown in FIG. 23B. The ratio of fetal (HBG) to adult hemoglobin gene (HBB) expression induced by Compound I was compared to that induced by hydroxyurea and the results are shown in FIG. 23C.
[0030] FIG. 24 depicts a graph showing fetal hemoglobin protein (HbF) expression for various dosages of Compound I (Experiment 1), and Compound I compared to vehicle and hydroxyurea (Experiment 2). In FIG. 24, the data show expression of fetal hemoglobin (HbF) in CD34+ humanized mouse models.
[0031] FIG. 25A, 25B and 25C show Nanostring data on induction of the HbF gene, HBG1 by Compound R1 and Compound I. FIG. 25A shows expression based on normalization to housekeeping genes. FIG. 25B shows the amount of fetal hemoglobin gene expression (HBG1) relative to total hemoglobin (fetal plus adult beta chain hemoglobin genes (HBG1+ HBB)). FIG.25C shows expression based on normalization to the number of glycophorin A (GlyA), a surface marker found on red blood cells, positive human erythroid precursor cells in the bone marrow.
[0032] FIG. 26A shows HbF protein detected from FACS sorted GlyA+ human erythroid precursor cells exposed to Compound I and Compound Rl. FIG. 26B shows HbF protein detected from unsorted bone marrow cells but then normalized to the percentage of GlyA+ cells in the bone marrow.
[0033] FIG. 27 is FACS results showing the percentage of GlyA+ cells which also have detectable HbF protein levels in them (called F-cells).
[0034] FIG. 28 shows ratio of fetal to adult beta-hemoglobin mRNA in bone marrow cells of humanized mice treated with hydroxyurea (HU) and / or Compound I. The treatment combination of HU and Compound I induced a greater ratio of fetal HBG1 to total beta hemoglobin mRNA (fetal HBG1 plus adult-type HBB) than in mice treated with either compound alone. Statistical differences were determined using ordinary one-way ANOVA and Tukey’s ad hoc testing versus DMSO. ns: non statistically significant, ***p<0.001 and ****p<0.0001.4335841422 CENC-005 / 01WO 360899-2046
[0035] FIG. 29 shows expression of fetal hemoglobin (HbF) levels in glycophorin A-expressing cells in treated humanized mice by HPLC. Bone marrow cells expressing GlyA were isolated by flow cytometry and analyzed for expression of fetal (HbF) and adult (HbB) hemoglobin. Results are expressed as the ratio of fetal hemoglobin in relationship to the total beta hemoglobin (HbF plus HbB) expression level. Statistical significance was determined by non-parametric t-test (Kolmogrov-Smirnov).
[0036] FIG. 30 shows ratio of fetal to adult beta-hemoglobin mRNA in bone marrow cells of humanized mice treated with hydroxyurea and / or Compound I. Treatment combination of HU and Compound I induced a greater ratio of fetal HBG1 to total beta hemoglobin mRNA (fetal HBG1 plus adult-type HBB) than in mice treated with either compound alone. The dose levels are lower than the dose levels shown in FIG. 28.
[0037] FIG. 31 shows the HbF protein level by HPLC in cells exposed to Compound I, HU or a combination thereof.
[0038] FIG. 32A and 32B show F-cell and HbF AlphaLISA analysis for cells exposed to Compound I and Compound Rl. In FIG. 32A, all treatment groups show increased percentage of HbF expression in GlyA+ cells. In FIG. 32B, most treatment groups show increased HbF protein levels when normalized for % GlyA+ cells.
[0039] FIG. 33A, 33B and 33C show increased HBG1 expression compared to vehicle by Compound I and Compound Rl at various doses and treatment regimes. Data shown both as HBG1 alone or as HBG1 to total beta hemoglobin mRNA (fetal HBG1 plus adult-type HBB).
[0040] FIG. 34A, 34B, 35 A, 35B and 35C show additional compounds R2 and R3 that were evaluated for their ability to induce fetal hemoglobin protein (FIG. 34) as shown by percentage F-cells (flow-cytometry) and HPLC. HBG1 expression, is shown both as HBG1 alone or as HBG1 to total beta hemoglobin mRNA (fetal HBG1 plus adult-type HBB), both measured by NanoString.
[0041] FIG. 36 depicts an XRPD pattern of starting material.
[0042] FIG. 37 depicts DSC and TGA Thermograms of starting material.
[0043] FIG. 38 depicts overlaid XRPD patterns of samples in slurry conversion at room temperature.
[0044] FIG. 39 depicts overlaid XRPD patterns of samples in slurry conversion at 50 °C.
[0045] FIG. 40 depicts overlaid XRPD patterns of samples in anti-solvent crystallization.
[0046] FIG. 41 depicts overlaid XRPD patterns of samples in vapor-solid diffusion.5335841422 CENC-005 / 01WO 360899-2046
[0047] FIG. 42 depicts overlaid XRPD patterns of samples in slow evaporation in single solvent.
[0048] FIG. 43 depicts DSC and TGA Thermograms of Form A.
[0049] FIG. 44 depicts DVS isotherm plot of Form A.
[0050] FIG. 45 depicts overlaid XRPD patterns of Form A pre and post DVS testing.
[0051] FIG. 46 depicts overlaid XRPD patterns of Form G samples.
[0052] FIG. 47 depicts an XRPD pattern of Form G.
[0053] FIG. 48 depicts DSC and TGA Thermograms of Form G sample #1.
[0054] FIG. 49 depicts DSC and TGA Thermograms of Form G sample #2.
[0055] FIG. 50 depicts overlaid XRPD patterns of Compound I Forms A and H.
[0056] FIG. 51 depicts an XRPD pattern of Form H.
[0057] FIG. 52 depicts overlaid XRPD patterns of Form J samples.
[0058] FIG. 53 depicts an XRPD pattern of Form J.
[0059] FIG. 54 depicts DSC and TGA Thermograms of Form J.
[0060] FIG. 55 depicts DSC and TGA Thermograms of Form K.
[0061] FIG. 56 depicts overlaid XRPD patterns of Form K samples.
[0062] FIG. 57 depicts an XRPD pattern of Form K.
[0063] FIG. 58 depicts overlaid XRPD patterns of samples in competitive slurry 1.
[0064] FIG. 59 depicts overlaid XRPD patterns of samples in competitive slurry 2.
[0065] FIG. 60 depicts overlaid XRPD patterns of samples in competitive slurry 3.
[0066] FIG. 61 depicts overlaid XRPD patterns of samples in competitive slurry 4.
[0067] FIG. 62 depicts overlaid XRPD patterns of samples in solubility evaluation - Form A.
[0068] FIG. 63 depicts overlaid XRPD patterns of samples in solubility evaluation - Form C.
[0069] FIG. 64 depicts overlaid XRPD patterns of samples in stability evaluation - Form A.
[0070] FIG. 65 depicts overlaid XRPD patterns of samples in stability evaluation - Form CDETAILED DESCRIPTION OF THE DISCLOSURE1. General Description of Certain Aspects of the Disclosure
[0071] The International Patent Application No. PCT / US2024 / 054133 (the ‘133 application, published as WO 2025 / 096956, the entirety of which is incorporated herein by reference) describes 6335841422 CENC-005 / 01WO 360899-2046certain compounds, which are effective at modulating DCN-1 and inducing fetal hemoglobin and are useful in treating hemoglobin-related disorders including sickle cell disorders, diseases and conditions and thalassemia. Such compounds include Compound I:
[0072] It would be desirable to provide solid forms of Compound I, which impart characteristics such as improved aqueous solubility, stability, and ease of formulation. Accordingly, the present disclosure provides solid forms of Compound I.
[0073] It is contemplated that Compound I can exist in a variety of physical forms. For example, Compound I can be in solution, suspension, or in solid form. In certain embodiments, Compound I is in solid form. When Compound I is in solid form, said compound may be amorphous, crystalline, or a mixture thereof. Exemplary solid forms are described in more detail below.
[0074] In some embodiments, the present invention provides a method of making a Compound I solid form by dissolving Compound I in a suitable solvent and precipitating a Compound I solid form out of the solvent. In some embodiments, the suitable solvent is selected from the group consisting of DCM, MeOH, THF, EtOH, Peanut oil, MEK, Acetone, EA, TPAc, MTBE, Water, ACN, n-Butyl ether, MeCYH, Xylene, Hept, DMSO, 2-MeTHF, n-Butanol, Anisole, CPME, Et2O, MIBK, n-Octanol, DMC, CYH, IPE, Toluene, PE, n-Pentane, or a mixture thereof. In certain embodiments, Compound I is crystalline. In certain embodiments, Compound I is amorphous.
[0075] In some embodiments, the present invention provides a method of making a Compound I solid form by dissolving Compound I in a suitable solvent and precipitating a Compound I solid form out of the solvent. In some embodiments, the suitable solvent is selected from the group consisting of DCM, MeOH, THF, EtOH, Peanut oil, MEK, Acetone, EA, IP Ac, MTBE, Water, ACN, n-Butyl ether, MeCYH, Xylene, Heptane, DMSO, 2-MeTHF, n-Butanol, Anisole, CPME, Et2O, MIBK, n-Octanol, DMC, CYH, IPE, Toluene, PE, n-Pentane, DMF, isopropanol, n- 7335841422 CENC-005 / 01WO 360899-2046propanol, 1,4-dioxane, anisole, dimethylacetamide or a mixture thereof. In certain embodiments, Compound I is crystalline. In certain embodiments, Compound I is amorphous.
[0076] In some embodiments, the present disclosure provides a form of Compound I substantially free of impurities. As used herein, the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter. Such extraneous matter may include different forms of Compound I, residual solvents, or any other impurities that may result from the preparation of, and / or isolation of, Compound I. In certain embodiments, at least about 95% by weight of a form of Compound I is present. In still other embodiments of the disclosure, at least about 99% by weight of a form of Compound I is present. In some embodiments, the residual solvent is selected from the group consisting of DCM, MeOH, THF, EtOH, Peanut oil, MEK, Acetone, EA, IPAc, MTBE, Water, ACN, n-Butyl ether, MeCYH, Xylene, Hept, DMSO, 2-MeTHF, n-Butanol, Anisole, CPME, Et2O, MIBK, n-Octanol, DMC, CYH, IPE, Toluene, PE, n-Pentane, or a mixture thereof.
[0077] In some embodiments, the residual solvent is selected from the group consisting of DCM, MeOH, THF, EtOH, Peanut oil, MEK, Acetone, EA, IPAc, MTBE, Water, ACN, n-Butyl ether, MeCYH, Xylene, Hept, DMSO, 2-MeTHF, n-Butanol, Anisole, CPME, Et2O, MIBK, n-Octanol, DMC, CYH, IPE, Toluene, PE, n-Pentane, DMF, isopropanol, n-propanol, 1,4-dioxane, anisole, dimethylacetamide or a mixture thereof.
[0078] According to one embodiment, a form of Compound I is present in an amount of at least about 97.0, 97.5, 98.0, 98.5, 99.0, 99.5, 99.8 weight percent where the percentages are based on the total weight of the composition. According to another embodiment, a form of Compound I contains no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram. In other embodiments, a form of Compound I contains no more than about 1.0% area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram.
[0079] The structure depicted for a form of Compound I is also meant to include all tautomeric forms of Compound I. Additionally, structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structure except for the replacement of hydrogen by deuterium or 8335841422 CENC-005 / 01WO 360899-2046tritium, or the replacement of a carbon by a13C- or14C-enriched carbon are within the scope of this disclosure.
[0080] It has been found that Compound I can exist in a variety of solid forms. Exemplary forms include polymorphs such as those described herein.
[0081] As used herein, the terms “about” or “approximately” have the meaning of within 20% of a given value or range. In some embodiments, the term “about” refers to within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of a given value.
[0082] As used herein, the term “polymorph” refers to the different crystal structures into which a compound, or a salt or solvate thereof, can crystallize.
[0083] The term “solvate” as used herein refers to a crystalline form of Compound I, such as a polymorph form of the compound, where the crystal lattice comprises one or more solvents of crystallization. The source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent. Examples of solvents or solvates include, but are not limited to, DCM, MeOH, THF, EtOH, Peanut oil, MEK, Acetone, EA, IP Ac, MTBE, Water, ACN, n-Butyl ether, MeCYH, Xylene, Hept, DMSO, 2-MeTHF, n-Butanol, Anisole, CPME, Et2O, MIBK, n-Octanol, DMC, CYH, IPE, Toluene, PE, n-Pentane, DMF, isopropanol, n-propanol, 1,4-di oxane, anisole, dimethylacetamide or a mixture thereof. A solvate wherein water is the solvent molecule is typically referred to as a “hydrate.” Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water. In some embodiments, the polymorphs can also exist as various solvates, such as with DCM, MeOH, THF, EtOH, Peanut oil, MEK, Acetone, EA, IPAc, MTBE, Water, ACN, n-Butyl ether, MeCYH, Xylene, Hept, DMSO, 2-MeTHF, n-Butanol, Anisole, CPME, Et2O, MIBK, n-Octanol, DMC, CYH, IPE, Toluene, PE, n-Pentane, DMF, isopropanol, n-propanol, 1,4-dioxane, anisole, dimethylacetamide or a mixture thereof. Mixtures of such solvates can also be prepared.
[0084] In certain embodiments, Compound I is a crystalline solid. In other embodiments, Compound I is a crystalline solid substantially free of amorphous Compound I. As used herein, the term “substantially free of amorphous Compound I” means that the compound contains no significant amount of amorphous Compound I. In certain embodiments, at least about 95% by9335841422 CENC-005 / 01WO 360899-2046weight of crystalline Compound I is present. In still other embodiments of the disclosure, at least about 99% by weight of crystalline Compound I is present.
[0085] It has been found that Compound I can exist in at least six distinct polymorphic forms. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form A. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form B. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form C. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form D. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form E. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form F.
[0086] It has been found that Compound I can exist in at least ten distinct polymorphic forms. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form A. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form B. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form C. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form D. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form E. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form F. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form G. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form H. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form J. In certain embodiments, the present disclosure provides a polymorphic form of Compound I referred to herein as Form K.
[0087] In some embodiments, Compound I is amorphous. In some embodiments, Compound I is amorphous, and is substantially free of crystalline Compound I.
[0088] In some embodiments, the present disclosure provides a composition comprising a solid form of Compound I as described herein and a pharmaceutically acceptable carrier or excipient.10335841422 CENC-005 / 01WO 360899-2046
[0089] In some embodiments, the present invention provides a method of treating a hemoglobinopathy disorder or disease in a subject in need thereof, comprising administering to said patient a solid form of Compound I or a composition thereof as described herein. In some embodiments, a hemoglobinopathy disorder or disease is selected from those as described herein.
[0090] In some embodiments, the present invention provides a method of increasing red blood cell levels and / or hemoglobin levels in a subject in need thereof, comprising administering to said subject a solid form of Compound I or a composition thereof as described herein, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof. In some embodiments, a subject has a disease, disorder, or condition as described herein.
[0091] In some embodiments, the present invention provides a method of treating or preventing an anemia, or treating sickle-cell disease, or treating one or more complications of sickle-cell disease, in a subject in need thereof, comprising administering to said subject a solid form of Compound I or a composition thereof as described herein, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.
[0092] In some embodiments, the present invention provides a method of treating a hemoglobinopathy disorder or disease in a subject in need thereof, comprising administering to said patient a solid form of Compound I or a composition thereof as described herein, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof. In some embodiments, a hemoglobinopathy disorder or disease is selected from those as described herein.
[0093] In some embodiments, the present invention provides a method of increasing efficacy and / or reducing toxicity of hydroxyurea treatment in a subject undergoing said treatment, comprising administering to the subject a solid form of Compound I or a composition thereof as described herein. In some embodiments, a subject has a disease, disorder, or condition as described herein.
[0094] In some embodiments, the present invention provides a method of decreasing the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof a solid form of Compound I or a composition thereof as described herein, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof, wherein the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of the hemoglobinopathy disorder or disease is less than the dose needed for treatment in the subject using hydroxyurea or 11335841422 CENC-005 / 01WO 360899-2046a pharmaceutically acceptable salt thereof as a monotherapy. In some embodiments, a subject has a disease, disorder, or condition as described herein.
[0095] In some embodiments, Form A of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.1 below.Table 1.1 - XRPD Peak Positions for Form A of Compound I12335841422 CENC-005 / 01WO 360899-20461In this and all subsequent tables, the position 20 is within ± 0.2.
[0096] In some embodiments, Form A of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.2 below.Table 1.2 - XRPD Peak Positions for Form A of Compound I13335841422 CENC-005 / 01WO 360899-204614335841422 CENC-005 / 01WO 360899-20461In this and all subsequent tables, the position 20 is within ± 0.2.
[0097] As used herein, the term “about” in the context of peaks at degrees 20 means that a peak can be the given 20 value ± 0.2, or the given 20 value ± 0.1, or the given value. For example, a peak of “about 12.020” means a peak can be 11.820, 11.920, 12.020, 12.1 20, or 12.220.
[0098] In some embodiments, Form A of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 7.9, about 6.7, and about 10.3 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 7.9, about 6.7, and about 10.3 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 7.9, about 6.7, and about 10.3 degrees 2-theta.
[0099] In some embodiments, Form A of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 7.9, about 6.7, about 10.3, about 20.7, and about 18.0 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 7.9, about 6.7, about 10.3, about 20.7, and about 18.0 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 7.9, about 6.7, about 10.3, about 20.7, and about 18.0 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 7.9, about 6.7, about 10.3, about 20.7, and about 18.0 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 7.9, about 6.7, about 10.3, about 20.7, and about 18.0 degrees 2-theta.
[0100] In some embodiments, Form A of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 8.5, about 7.8, and 15335841422 CENC-005 / 01WO 360899-2046about 20.7 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 8.5, about 7.8, and about 20.7 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 8.5, about 7.8, and about 20.7 degrees 2-theta.
[0101] In some embodiments, Form A of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 8.5, about 7.8, about 20.7, about 21.0, and about 9.1 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 8.5, about 7.8, about 20.7, about 21.0, and about 9.1 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 8.5, about 7.8, about 20.7, about 21.0, and about 9.1 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 8.5, about 7.8, about 20.7, about 21.0, and about 9.1 degrees 2-theta. In some embodiments, Form A of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 8.5, about 7.8, about 20.7, about 21.0, and about 9.1 degrees 2-theta.
[0102] In certain embodiments, the X-ray powder diffraction pattern of Form A of Compound I is substantially similar to the XRPD provided in FIG. 4. In certain embodiments, the X-ray powder diffraction pattern of Form A of Compound I is substantially similar to the XRPD provided in FIG. 7. In certain embodiments, the X-ray powder diffraction pattern of Form A of Compound I is substantially similar to an XRPD provided in FIG. 3.
[0103] In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form A of Compound I is substantially similar to the DSC provided in FIG. 5. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form A of Compound I is substantially similar to the DSC provided in FIG. 6. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form A of Compound I is substantially similar to the DSC provided in FIG. 8. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form A of Compound I is substantially similar to the DSC provided in FIG. 9.16335841422 CENC-005 / 01WO 360899-2046
[0104] In certain embodiments, the Thermogravimetric Analysis (TGA) of Form A of Compound I is substantially similar to the TGA provided in FIG. 5. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form A of Compound I is substantially similar to the TGA provided in FIG. 6. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form A of Compound I is substantially similar to the TGA provided in FIG. 8. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form A of Compound I is substantially similar to the TGA provided in FIG. 9.
[0105] In some embodiments, Form A of Compound I can be characterized by substantial similarity to two or more FIG.s simultaneously (e.g., the XDPD, DSC, and TGA of any one of FIGs. 3-9).
[0106] Method for preparing Form A of Compound I is described infra.
[0107] In some embodiments, the present invention provides Form A of Compound I. In some embodiments, Form A of Compound I is an isostructural solvate or hydrate. In some embodiments, Form A of Compound I is a solvate with EtOH, or water, or a mixture thereof. In some embodiments, Form A of Compound I is a solvate with acetone, or water, or a mixture thereof. In some embodiments, Form A of Compound I is solvate with DCM, or Hept, or a mixture thereof.
[0108] In some embodiments, Form A of Compound I is an anhydrate.
[0109] In some embodiments, Form A of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from FIG. 45.
[0110] In some embodiments, the present invention provides Form A of Compound I, wherein said compound is substantially free of amorphous Compound I.
[0111] In some embodiments, the present invention provides Form A of Compound I, wherein said compound is substantially free of impurities.
[0112] In some embodiments, the present invention provides a solid form of Compound I, wherein said solid form of Compound I has an XRPD substantially similar to that depicted in FIGs.4 or 7.
[0113] In some embodiments, Form B of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.3 below.Table 1.3 - XRPD Peak Positions for Form B of Compound I17335841422 CENC-005 / 01WO 360899-20461In this and all subsequent tables, the position 20 is within ± 0.2.
[0114] As used herein, the term “about” in the context of peaks at degrees 20 means that a peak can be the given 20 value ± 0.2, or the given 20 value ± 0.1, or the given value. For example, a peak of “about 12.020” means a peak can be 11.820, 11.920, 12.020, 12.1 20, or 12.220.
[0115] In some embodiments, Form B of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 18.0, about 6.5, and about 7.0 degrees 2-theta. In some embodiments, Form B of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 18.0, about 6.5, and about 7.0 degrees 2-theta. In some embodiments, Form B of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 18.0, about 6.5, and about 7.0 degrees 2-theta.18335841422 CENC-005 / 01WO 360899-2046
[0116] In some embodiments, Form B of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 18.0, about 6.5, about 7.0, about 21.1, and about 13.0 degrees 2-theta. In some embodiments, Form B of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 18.0, about 6.5, about 7.0, about 21.1, and about 13.0 degrees 2-theta. In some embodiments, Form B of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 18.0, about 6.5, about 7.0, about 21.1, and about 13.0 degrees 2-theta. In some embodiments, Form B of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 18.0, about 6.5, about 7.0, about 21.1, and about 13.0 degrees 2-theta. In some embodiments, Form B of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 18.0, about 6.5, about 7.0, about 21.1, and about 13.0 degrees 2-theta.
[0117] In certain embodiments, the X-ray powder diffraction pattern of Form B of Compound I is substantially similar to the XRPD provided in FIG. 11. In certain embodiments, the X-ray powder diffraction pattern of Form B of Compound I is substantially similar to an XRPD provided in FIG. 10.
[0118] In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form B of Compound I is substantially similar to the DSC provided in FIG. 12. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form B of Compound I is substantially similar to the DSC provided in FIG. 13.
[0119] In certain embodiments, the Thermogravimetric Analysis (TGA) of Form B of Compound I is substantially similar to the TGA provided in FIG. 12. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form B of Compound I is substantially similar to the TGA provided in FIG. 13.
[0120] In some embodiments, Form B of Compound I can be characterized by substantial similarity to two or more figures simultaneously (e.g., the XDPD, DSC, and TGA of any one of FIGs. 10-13).
[0121] Method for preparing Form B of Compound I is described infra.
[0122] In some embodiments, the present invention provides Form B of Compound I. In some embodiments, Form B of Compound I is an isostructural solvate. In some embodiments, Form B of Compound I is a solvate with toluene, or xylene, or a mixture thereof.19335841422 CENC-005 / 01WO 360899-2046
[0123] In some embodiments, the present invention provides Form B of Compound I, wherein said compound is substantially free of amorphous Compound I.
[0124] In some embodiments, the present invention provides Form B of Compound I, wherein said compound is substantially free of impurities.
[0125] In some embodiments, the present invention provides a solid form of Compound I, wherein said solid form of Compound I has an XRPD substantially similar to that depicted in FIG.11.
[0126] In some embodiments, Form C of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.4 below.Table 1.4 - XRPD Peak Positions for Form C of Compound I20CENC-005 / 01WO 360899-2046-->1In this and all subsequent tables, the position 20 is within ± 0.2.
[0127] As used herein, the term “about” in the context of peaks at degrees 20 means that a peak can be the given 20 value ± 0.2, or the given 20 value ± 0.1, or the given value. For example, a peak of “about 12.020” means a peak can be 11.820, 11.920, 12.020, 12.1 20, or 12.220.
[0128] In some embodiments, Form C of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.6, about 24.5, and about 17.8 degrees 2-theta. In some embodiments, Form C of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 6.6, about 24.5, and about 17.8 degrees 2-theta. In some embodiments, Form C of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 6.6, about 24.5, and about 17.8 degrees 2-theta.
[0129] In some embodiments, Form C of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.6, about 24.5, about 17.8, about 15.1, and about 11.5 degrees 2-theta. In some embodiments, Form C of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 6.6, about 24.5, about 17.8, about 15.1, and about 11.5 degrees 2- 21335841422 CENC-005 / 01WO 360899-2046theta. In some embodiments, Form C of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 6.6, about 24.5, about 17.8, about 15.1, and about 11.5 degrees 2-theta. In some embodiments, Form C of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 6.6, about 24.5, about 17.8, about 15.1, and about 11.5 degrees 2-theta. In some embodiments, Form C of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 6.6, about 24.5, about 17.8, about 15.1, and about 11.5 degrees 2-theta.
[0130] In certain embodiments, the X-ray powder diffraction pattern of Form C of Compound I is substantially similar to the XRPD provided in FIG. 14. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form C of Compound I is substantially similar to the DSC provided in FIG. 15. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form C of Compound I is substantially similar to the DSC provided in FIG. 16. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form C of Compound I is substantially similar to the TGA provided in FIG. 15. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form C of Compound I is substantially similar to the TGA provided in FIG. 16.
[0131] In some embodiments, Form C of Compound I can be characterized by substantial similarity to two or more figures simultaneously (e.g., the XRPD, DSC, and TGA of any one of FIGs. 14-16).
[0132] Method for preparing Form C of Compound I is described infra.
[0133] In some embodiments, the present invention provides Form C of Compound I. In some embodiments, Form C of Compound I is an anhydrate.
[0134] In some embodiments, the present invention provides Form C of Compound I, wherein said compound is substantially free of amorphous Compound I.
[0135] In some embodiments, the present invention provides Form C of Compound I, wherein said compound is substantially free of impurities.
[0136] In some embodiments, the present invention provides a solid form of Compound I, wherein said solid form of Compound I has an XRPD substantially similar to that depicted in FIG.14.22335841422 CENC-005 / 01WO 360899-2046
[0137] In some embodiments, Form D of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.5 below.Table 1.5 - XRPD Peak Positions for Form D of Compound I23335841422 CENC-005 / 01WO 360899-20461In this and all subsequent tables, the position 20 is within ± 0.2.
[0138] As used herein, the term “about” in the context of peaks at degrees 20 means that a peak can be the given 20 value ± 0.2, or the given 20 value ± 0.1, or the given value. For example, a peak of “about 12.020” means a peak can be 11.820, 11.920, 12.020, 12.1 20, or 12.220.
[0139] In some embodiments, Form D of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 7.6, about 6.6, and about 20.7 degrees 2-theta. In some embodiments, Form D of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 7.6, about 6.6, and about 20.7 degrees 2-theta. In some embodiments, Form D of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 7.6, about 6.6, and about 20.7 degrees 2-theta.
[0140] In some embodiments, Form D of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 7.6, about 6.6, about 20.7, about 20.3, and about 18.4 degrees 2-theta. In some embodiments, Form D of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 7.6, about 6.6, about 20.7, about 20.3, and about 18.4 degrees 2-theta. In some embodiments, Form D of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 7.6, about 6.6, about 20.7, about 20.3, and about 18.4 degrees 2-theta. In some embodiments, Form D of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 7.6, about 6.6, about 20.7, about 20.3, and about 18.4 degrees 2-theta. In some embodiments, Form D of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 7.6, about 6.6, about 20.7, about 20.3, and about 18.4 degrees 2-theta.
[0141] In certain embodiments, the X-ray powder diffraction pattern of Form D of Compound I is substantially similar to the XRPD provided in FIG. 17. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form D of Compound I is substantially similar to the DSC24335841422 CENC-005 / 01WO 360899-2046provided in FIG. 18. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form D of Compound I is substantially similar to the TGA provided in FIG. 18.
[0142] In some embodiments, Form D of Compound I can be characterized by substantial similarity to two or more figures simultaneously (e.g., the XRPD, DSC, and TGA of FIGs. 17 or 18).
[0143] Method for preparing Form D of Compound I is described infra.
[0144] In some embodiments, the present invention provides Form D of Compound I. In some embodiments, Form D of Compound I is a solvate. In some embodiments, Form D of Compound I is an / / -Butyl ether solvate.
[0145] In some embodiments, the present invention provides Form D of Compound I, wherein said compound is substantially free of amorphous Compound I.
[0146] In some embodiments, the present invention provides Form D of Compound I, wherein said compound is substantially free of impurities.
[0147] In some embodiments, the present invention provides a solid form of Compound I, wherein said solid form of Compound I has an XRPD substantially similar to that depicted in FIG.17.
[0148] In some embodiments, Form E of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.6 below.Table 1.6 - XRPD Peak Positions for Form E of Compound I25335841422 CENC-005 / 01WO 360899-20461In this and all subsequent tables, the position 20 is within ± 0.2.
[0149] As used herein, the term “about” in the context of peaks at degrees 20 means that a peak can be the given 20 value ± 0.2, or the given 20 value ± 0.1, or the given value. For example, a peak of “about 12.020” means a peak can be 11.820, 11.920, 12.020, 12.1 20, or 12.220.
[0150] In some embodiments, Form E of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 5.2, about 20.7, and about 11.6 degrees 2-theta. In some embodiments, Form E of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 5.2, about 20.7, and about 11.6 degrees 2-theta. In some embodiments, Form E of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 5.2, about 20.7, and about 11.6 degrees 2-theta.
[0151] In some embodiments, Form E of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 5.2, about 20.7,26335841422 CENC-005 / 01WO 360899-2046about 11.6, about 5.5, and about 7.9 degrees 2-theta. In some embodiments, Form E of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 5.2, about 20.7, about 11.6, about 5.5, and about 7.9 degrees 2-theta. In some embodiments, Form E of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 5.2, about 20.7, about 11.6, about 5.5, and about 7.9 degrees 2-theta. In some embodiments, Form E of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 5.2, about 20.7, about 11.6, about 5.5, and about 7.9 degrees 2-theta. In some embodiments, Form E of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 5.2, about 20.7, about 11.6, about 5.5, and about 7.9 degrees 2-theta.
[0152] In certain embodiments, the X-ray powder diffraction pattern of Form E of Compound I is substantially similar to the XRPD provided in FIG. 19. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form E of Compound I is substantially similar to the DSC provided in FIG. 20. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form E of Compound I is substantially similar to the TGA provided in FIG. 20.
[0153] In some embodiments, Form E of Compound I can be characterized by substantial similarity to two or more figures simultaneously (e.g., the XRPD, DSC, and TGA of FIGs. 19 or 20).
[0154] Method for preparing Form E of Compound I is described infra.
[0155] In some embodiments, the present invention provides Form E of Compound I. In some embodiments, Form E of Compound I is a solvate. In some embodiments, Form E of Compound l is a heterosolvate of CPME, or Hept, or a mixture thereof.
[0156] In some embodiments, the present invention provides Form E of Compound I, wherein said compound is substantially free of amorphous Compound I.
[0157] In some embodiments, the present invention provides Form E of Compound I, wherein said compound is substantially free of impurities.
[0158] In some embodiments, the present invention provides a solid form of Compound I, wherein said solid form of Compound I has an XRPD substantially similar to that depicted in FIG.19.27335841422 CENC-005 / 01WO 360899-2046
[0159] In some embodiments, Form F of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.7 below.Table 1.7 - XRPD Peak Positions for Form F of Compound I28335841422 CENC-005 / 01WO 360899-20461In this and all subsequent tables, the position 20 is within ± 0.2.
[0160] As used herein, the term “about” in the context of peaks at degrees 20 means that a peak can be the given 20 value ± 0.2, or the given 20 value ± 0.1, or the given value. For example, a peak of “about 12.020” means a peak can be 11.820, 11.920, 12.020, 12.1 20, or 12.220.
[0161] In some embodiments, Form F of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, about 13.5, and about 19.8 degrees 2-theta. In some embodiments, Form F of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, about 13.5, and about 19.8 degrees 2-theta. In some embodiments, Form F of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 6.4, about 13.5, and about 19.8 degrees 2-theta.
[0162] In some embodiments, Form F of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, about 13.5, about 19.8, about 23.3, and about 15.4 degrees 2-theta. In some embodiments, Form F of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, about 13.5, about 19.8, about 23.3, and about 15.4 degrees 2-29335841422 CENC-005 / 01WO 360899-2046theta. In some embodiments, Form F of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, about 13.5, about 19.8, about 23.3, and about 15.4 degrees 2-theta. In some embodiments, Form F of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 6.4, about 13.5, about 19.8, about 23.3, and about 15.4 degrees 2-theta. In some embodiments, Form F of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 6.4, about 13.5, about 19.8, about 23.3, and about 15.4 degrees 2-theta.
[0163] In certain embodiments, the X-ray powder diffraction pattern of Form F of Compound I is substantially similar to the XRPD provided in FIG. 21. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form F of Compound I is substantially similar to the DSC provided in FIG. 22. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form F of Compound I is substantially similar to the TGA provided in FIG. 22.
[0164] In some embodiments, Form F of Compound I can be characterized by substantial similarity to two or more figures simultaneously (e.g., the XRPD, DSC, and TGA of FIGs. 21 and 22).
[0165] Method for preparing Form F of Compound I is described infra.
[0166] In some embodiments, the present invention provides Form F of Compound I. In some embodiments, Form F of Compound l is a solvate. In some embodiments, Form F of Compound I is a DMSO solvate.
[0167] In some embodiments, the present invention provides Form F of Compound I, wherein said compound is substantially free of amorphous Compound I.
[0168] In some embodiments, the present invention provides Form F of Compound I, wherein said compound is substantially free of impurities.
[0169] In some embodiments, the present invention provides a solid form of Compound I, wherein said solid form of Compound I has an XRPD substantially similar to that depicted in FIG.21.
[0170] In some embodiments, Form G of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.8 below.30335841422 CENC-005 / 01WO 360899-2046Table 1.8 - XRPD Peak Positions for Form G of Compound T31335841422 CENC-005 / 01WO 360899-20461In this and all subsequent tables, the position 20 is within ± 0.2.
[0171] As used herein, the term “about” in the context of peaks at degrees 20 means that a peak can be the given 20 value ± 0.2, or the given 20 value ± 0.1, or the given value. For example, a peak of “about 12.020” means a peak can be 11.820, 11.920, 12.020, 12.1 20, or 12.220.
[0172] In some embodiments, Form G of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 5.9, about 19.9, and about 17.8 degrees 2-theta. In some embodiments, Form G of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 5.9, about 19.9, and about 17.8 degrees 2-theta. In some embodiments, Form G of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 5.9, about 19.9, and about 17.8 degrees 2-theta.
[0173] In some embodiments, Form G of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 5.9, about 19.9, about 17.8, about 13.7, and about 7.7 degrees 2-theta. In some embodiments, Form G of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 5.9, about 19.9, about 17.8, about 13.7, and about 7.7 degrees 2-theta. In some embodiments, Form G of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 5.9, about 19.9, about 17.8, about 13.7, and about 7.7 degrees 2-theta. In some embodiments, Form G of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 5.9, about 19.9, about 17.8, about 13.7, and about 7.7 degrees 2-theta. In some embodiments, Form G of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 5.9, about 19.9, about 17.8, about 13.7, and about 7.7 degrees 2-theta.
[0174] In certain embodiments, the X-ray powder diffraction pattern of Form G of Compound I is substantially similar to the XRPD provided in FIG. 48. In certain embodiments, the Differential32335841422 CENC-005 / 01WO 360899-2046Scanning Calorimetry (DSC) of Form G of Compound T is substantially similar to the DSC provided in FIGs. 49 or 50. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form G of Compound I is substantially similar to the TGA provided in FIGs. 49 or 50.
[0175] In some embodiments, Form G of Compound I can be characterized by substantial similarity to two or more figures simultaneously (e.g., the XRPD, DSC, and TGA of FIGs. 48, 49 and 50).
[0176] Method for preparing Form G of Compound I is described infra.
[0177] In some embodiments, the present invention provides Form G of Compound I. In some embodiments, Form G of Compound l is a solvate. In some embodiments, Form G of Compound I is a 1,4-dioxane solvate.
[0178] In some embodiments, the present invention provides Form G of Compound I, wherein said compound is substantially free of amorphous Compound I.
[0179] In some embodiments, the present invention provides Form G of Compound I, wherein said compound is substantially free of impurities.
[0180] In some embodiments, the present invention provides a solid form of Compound I, wherein said solid form of Compound I has an XRPD substantially similar to that depicted in FIG.48.
[0181] In some embodiments, Form H of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.9 below.Table 1.9 - XRPD Peak Positions for Form H of Compound I1In this and all subsequent tables, the position 20 is within ± 0.2.33335841422 CENC-005 / 01WO 360899-2046
[0182] As used herein, the term “about” in the context of peaks at degrees 20 means that a peak can be the given 20 value ± 0.2, or the given 20 value ± 0.1, or the given value. For example, a peak of “about 12.020” means a peak can be 11.820, 11.920, 12.020, 12.1 20, or 12.220.
[0183] In some embodiments, Form H of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 5.4, and about 9.6 degrees 2-theta. In some embodiments, Form H of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 5.4, and about 9.6 degrees 2-theta. In some embodiments, Form H of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 5.4, and about 9.6 degrees 2-theta.
[0184] In some embodiments, Form H of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 5.4, about 9.6, about 8.1, and about 10.8 degrees 2-theta. In some embodiments, Form H of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 5.4, about 9.6, about 8.1, and about 10.8 degrees 2-theta. In some embodiments, Form H of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 5.4, about 9.6, about 8.1, and about 10.8 degrees 2-theta. In some embodiments, Form H of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 5.4, about 9.6, about 8.1, and about 10.8 degrees 2-theta. In some embodiments, Form H of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 5.4, about 9.6, about 8.1, and about 10.8 degrees 2-theta.
[0185] In certain embodiments, the X-ray powder diffraction pattern of Form H of Compound I is substantially similar to the XRPD provided in FIG. 52.
[0186] Method for preparing Form H of Compound I is described infra.
[0187] In some embodiments, the present invention provides Form H of Compound I. In some embodiments, Form H of Compound I is a solvate. In some embodiments, Form H of Compound I is an IPA / Heptane solvate.
[0188] In some embodiments, the present invention provides Form H of Compound I, wherein said compound is substantially free of amorphous Compound I.34335841422 CENC-005 / 01WO 360899-2046
[0189] In some embodiments, the present invention provides Form H of Compound T, wherein said compound is substantially free of impurities.
[0190] In some embodiments, the present invention provides a solid form of Compound I, wherein said solid form of Compound I has an XRPD substantially similar to that depicted in FIG.52.
[0191] In some embodiments, Form J of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.10 below.Table 1.10 - XRPD Peak Positions for Form J of Compound I35335841422 CENC-005 / 01WO 360899-20461In this and all subsequent tables, the position 20 is within ± 0.2.
[0192] As used herein, the term “about” in the context of peaks at degrees 29 means that a peak can be the given 20 value ± 0.2, or the given 20 value ± 0.1, or the given value. For example, a peak of “about 12.020” means a peak can be 11.820, 11.920, 12.020, 12.1 20, or 12.220.
[0193] In some embodiments, Form J of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 8.4, about 18.8, and about 12.1 degrees 2-theta. In some embodiments, Form J of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 8.4, about 18.8, and about 12.1 degrees 2-theta. In some embodiments, Form J of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 8.4, about 18.8, and about 12.1 degrees 2-theta.
[0194] In some embodiments, Form J of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 8.4, about 18.8, about 12.1, about 15.3, and about 24.5 degrees 2-theta. In some embodiments, Form J of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 8.4, about 18.8, about 12.1, about 15.3, and about 24.5 degrees 2-theta. In some embodiments, Form J of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 8.4, about 18.8, about 12.1, about 15.3, and about 24.5 degrees 2-theta. In some embodiments, Form J of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 8.4, about 18.8, about 12.1, about 15.3, and about 24.5 degrees 2-theta. In some embodiments, Form J of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 8.4, about 18.8, about 12.1, about 15.3, and about 24.5 degrees 2-theta.36335841422 CENC-005 / 01WO 360899-2046
[0195] In certain embodiments, the X-ray powder diffraction pattern of Form J of Compound I is substantially similar to the XRPD provided in FIG. 54. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form J of Compound I is substantially similar to the DSC provided in FIG. 55. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form J of Compound I is substantially similar to the TGA provided in FIG. 55.
[0196] In some embodiments, Form J of Compound I can be characterized by substantial similarity to two or more figures simultaneously (e.g., the XRPD, DSC, and TGA of FIGs. 54 and 55).
[0197] Method for preparing Form J of Compound I is described infra.
[0198] In some embodiments, the present invention provides Form J of Compound I. In some embodiments, Form J of Compound I is a solvate. In some embodiments, Form J of Compound I is an ethyl acetate solvate.
[0199] In some embodiments, the present invention provides Form J of Compound I, wherein said compound is substantially free of amorphous Compound I.
[0200] In some embodiments, the present invention provides Form J of Compound I, wherein said compound is substantially free of impurities.
[0201] In some embodiments, the present invention provides a solid form of Compound I, wherein said solid form of Compound I has an XRPD substantially similar to that depicted in FIG.54.
[0202] In some embodiments, Form K of Compound I has at least 1, 2, 3, 4 or 5 XRPD spectral peak(s) selected from the peaks listed in Table 1.11 below.Table 1.11 - XRPD Peak Positions for Form K of Compound I37335841422 CENC-005 / 01WO 360899-20461In this and all subsequent tables, the position 20 is within ± 0.2.
[0203] As used herein, the term “about” in the context of peaks at degrees 20 means that a peak can be the given 20 value ± 0.2, or the given 20 value ± 0.1, or the given value. For example, a peak of “about 12.020” means a peak can be 11.820, 11.920, 12.020, 12.1 20, or 12.220.
[0204] In some embodiments, Form K of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 8.8, and about 17.8 degrees 2-theta. In some embodiments, Form K of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 8.8, and about 17.8 degrees 2-theta. In some embodiments, Form K of Compound I is characterized in that it has all three peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 8.8, and about 17.8 degrees 2-theta.
[0205] In some embodiments, Form K of Compound I is characterized in that it has one or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 8.8,38335841422 CENC-005 / 01WO 360899-2046about 17.8, about 6.8, and about 18.9 degrees 2-theta. In some embodiments, Form K of Compound I is characterized in that it has two or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 8.8, about 17.8, about 6.8, and about 18.9 degrees 2-theta. In some embodiments, Form K of Compound I is characterized in that it has three or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 8.8, about 17.8, about 6.8, and about 18.9 degrees 2-theta. In some embodiments, Form K of Compound I is characterized in that it has four or more peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 8.8, about 17.8, about 6.8, and about 18.9 degrees 2-theta. In some embodiments, Form K of Compound I is characterized in that it has all five peaks in its X-ray powder diffraction pattern selected from those at about 18.1, about 8.8, about 17.8, about 6.8, and about 18.9 degrees 2-theta.
[0206] In certain embodiments, the X-ray powder diffraction pattern of Form K of Compound I is substantially similar to the XRPD provided in FIG. 58. In certain embodiments, the Differential Scanning Calorimetry (DSC) of Form K of Compound I is substantially similar to the DSC provided in FIG. 56. In certain embodiments, the Thermogravimetric Analysis (TGA) of Form K of Compound I is substantially similar to the TGA provided in FIG. 56.
[0207] In some embodiments, Form K of Compound I can be characterized by substantial similarity to two or more figures simultaneously (e.g., the XRPD, DSC, and TGA of FIGs. 56 and 58).
[0208] Method for preparing Form K of Compound I is described infra.
[0209] In some embodiments, the present invention provides Form K of Compound I. In some embodiments, Form K of Compound I is a solvate. In some embodiments, Form K of Compound I is an ethyl acetate solvate.
[0210] In some embodiments, the present invention provides Form K of Compound I, wherein said compound is substantially free of amorphous Compound I.
[0211] In some embodiments, the present invention provides Form K of Compound I, wherein said compound is substantially free of impurities.
[0212] In some embodiments, the present invention provides a solid form of Compound I, wherein said solid form of Compound I has an XRPD substantially similar to that depicted in FIG.58.39335841422 CENC-005 / 01WO 360899-20462. General Methods of Providing Solid Forms of Compound I
[0213] Solid Forms of Compound I are prepared according to the methods described in detail herein.
[0214] In some embodiments, the present disclosure provides a method for preparing a solid form of compound I comprising one or more steps of removing a solvent and adding a solvent to compound I. In some embodiments, an added solvent is the same as the solvent removed. In some embodiments, an added solvent is different from the solvent removed. Means of solvent removal are known in the synthetic and chemical arts and include, but are not limited to, any of those described herein and in the Examples. In some embodiments, a solvent is selected from the group consisting of DCM, MeOH, THF, EtOH, Peanut oil, MEK, Acetone, EA, IP Ac, MTBE, Water, ACN, n-Butyl ether, MeCYH, Xylene, Hept, DMSO, 2-MeTHF, n-Butanol, Anisole, CPME, Et2O, MIBK, n-Octanol, DMC, CYH, IPE, Toluene, PE, n-Pentane, or a mixture thereof.
[0215] In some embodiments, a solvent is selected from the group consisting of DCM, MeOH, THF, EtOH, Peanut oil, MEK, Acetone, EA, IP Ac, MTBE, Water, ACN, n-Butyl ether, MeCYH, Xylene, Hept, DMSO, 2-MeTHF, n-Butanol, Anisole, CPME, Et2O, MIBK, n-Octanol, DMC, CYH, IPE, Toluene, PE, n-Pentane, DMF, isopropanol, n-propanol, 1,4-dioxane, anisole, dimethylacetamide or a mixture thereof.
[0216] In some embodiments, the present disclosure provides a method for preparing a solid form of compound I comprising one or more steps of adding a reagent and solvent followed by removal of solvent and the reagent. In some embodiments, the added solvent is the same as the removed solvent. In some embodiments, the added reagent is the same as the reagent removed. In some embodiments, the added reagent is different from the reagent removed. In some embodiments, the added solvent if different from the solvent removed. Means of solvent removal as well as the reagent removal are known in the synthetic and chemical arts and include, but are not limited to, any of those described herein and in the Examples. In some embodiments, a solvent is selected from the group consisting of DCM, MeOH, THF, EtOH, Peanut oil, MEK, Acetone, EA, IP Ac, MTBE, Water, ACN, n-Butyl ether, MeCYH, Xylene, Hept, DMSO, 2-MeTHF, n-Butanol, Anisole, CPME, Et20, MIBK, n-Octanol, DMC, CYH, IPE, Toluene, PE, n-Pentane, or a mixture thereof.
[0217] In some embodiments, a solvent is selected from the group consisting of DCM, MeOH, THF, EtOH, Peanut oil, MEK, Acetone, EA, IP Ac, MTBE, Water, ACN, n-Butyl ether, MeCYH,40335841422 CENC-005 / 01WO 360899-2046Xylene, Hept, DMSO, 2-MeTHF, n-Butanol, Anisole, CPME, Et20, MTBK, n-Octanol, DMC, CYH, IPE, Toluene, PE, n-Pentane, DMF, isopropanol, n-propanol, 1,4-dioxane, anisole, dimethylacetamide or a mixture thereof.
[0218] In some embodiments, the method for preparing a solid form of compound I comprises one or more steps of heating or cooling a preparation.
[0219] In some embodiments, the method for preparing a solid form of compound I comprises one or more steps of agitating or stirring a preparation.
[0220] In some embodiments, the method for preparing a solid form of compound I comprises slow evaporation of the solvent. In some embodiments, the method for preparing a solid form of compound I comprises slow evaporation of the solvent through exposure to ambient atmosphere at room temperature. In some embodiments, the method for preparing a solid form of compound I comprises evaporation of the solvent under a flow of an inert gas, e.g, nitrogen gas.
[0221] A solid form of compound I can precipitate out of the reaction mixture, or be generated by removal of part or all of the solvent through methods such as evaporation, distillation, filtration (e.g., nanofiltration, ultrafiltration), reverse osmosis, absorption, by adding an anti-solvent such as heptane or water, by seeding the solution with crystals of compound I, by cooling, or by different combinations of these methods.
[0222] In certain embodiments, a solid form of compound I crystallizes from the mixture. In another embodiment, a solid form of compound I precipitates from the mixture. In some embodiments, a solid form of compound I crystallizes from solution following adding an antisolvent, such as heptane or water, to the solution, and cooling the solution. In other embodiments, a solid form of compound I crystallizes from solution following seeding of the solution (z.e?., adding crystals of compound I to the solution).
[0223] As described generally above, a solid form of compound I is optionally isolated. It will be appreciated that a solid form of compound I may be isolated by any suitable physical means known to one of ordinary skill in the art. In certain embodiments, precipitated a solid form of compound I is separated from the supernatant by filtration. In other embodiments, precipitated solid form of compound I is separated from the supernatant by decanting the supernatant. In certain embodiments, a solid form of compound I is separated from the supernatant by centrifugation. In certain embodiments, isolated solid form of compound I is dried under reduced pressure,41335841422 CENC-005 / 01WO 360899-2046optionally at elevated temperature. In other embodiments, an isolated solid form of compound I is dried in air.
[0224] In certain embodiments, compound I is crystallized from EtOH / Water (1 / 1, v / v) to obtain Form A of compound I as a crystalline solid.
[0225] In certain embodiments, compound I is crystallized from Acetone / Water (1 / 2, v / v) to obtain Form A of compound I as a crystalline solid.
[0226] In certain embodiments, compound I is crystallized from DCM / Hept (1 / 5, v / v) to obtain Form A of compound I as a crystalline solid.
[0227] In certain embodiments, compound I is crystallized from DMC / Hept (9 / 95, v / v) to obtain Form A of compound I as a crystalline solid.
[0228] In certain embodiments, compound I is crystallized from EtOH / Water (1 / 3, v / v) to obtain Form A of compound I as a crystalline solid.
[0229] In certain embodiments, compound I is crystallized from toluene to obtain Form B of compound I as a crystalline solid.
[0230] In certain embodiments, compound I is crystallized from xylene to obtain Form B of compound I as a crystalline solid.
[0231] In certain embodiments, compound I is crystallized from a mixture of toluene and xylene to obtain Form B of compound I as a crystalline solid.
[0232] In certain embodiments, compound I is crystallized from IPE to obtain Form C of compound I as a crystalline solid.
[0233] In certain embodiments, compound I is crystallized from a solvent mixture containing IPE to obtain Form C of compound I as a crystalline solid.
[0234] In certain embodiments, compound I is crystallized from / / -Butyl ether to obtain Form D of compound I as a crystalline solid.
[0235] In certain embodiments, compound I is crystallized from CPME, or Hept, or a mixture thereof, to obtain Form E of compound I as a crystalline solid.
[0236] In certain embodiments, compound I is crystallized from DMSO, or water, or a mixture thereof, to obtain Form F of compound I as a crystalline solid.
[0237] In certain embodiments, compound I is crystallized from heptane, 1,4-di oxane, or a mixture thereof, to obtain Form G of compound I as a crystalline solid.42335841422 CENC-005 / 01WO 360899-2046
[0238] In certain embodiments, compound I is crystallized from TPA, heptane, or a mixture thereof, to obtain Form H of compound I as a crystalline solid.
[0239] In certain embodiments, compound I is crystallized from ethyl acetate, heptane or a mixture thereof, to obtain Form J of compound I as a crystalline solid.
[0240] In certain embodiments, Form K of compound I is obtained after drying Form J.3. Methods of Use
[0241] It has now been found that Compound I, and solid forms and compositions thereof, can modulate DCN-1 (also referred to herein as DCN1) and are useful in treating disorders, diseases, and conditions associated with DCN-1. In some embodiments, modulating DCN-1 is inhibiting or reducing the activity of DCN-1. Without being limited to a specific mechanism, as shown herein, inhibiting or reducing the activity of DCN-1 results in reduced neddylation and other downstream effects. It has also been found that Compound I, and solid forms and compositions thereof, can modulate DCN-2 (also referred to herein as DCN2) and are useful in treating disorders, diseases, and conditions associated with DCN-2. In some embodiments, modulating DCN-2 is inhibiting or reducing the activity of DCN-2. Without being limited to a specific mechanism, as shown herein, inhibiting or reducing the activity of DCN-2 results in reduced neddylation and other downstream effects.
[0242] ‘ ‘As used herein, the terms “subject” and “patient” are used interchangeably and refer to organisms to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and, most preferably, includes humans.
[0243] The term “ICso” is art-recognized and refers to the concentration of a compound that is required to achieve 50% inhibition of the target. The potency of an inhibitor is usually defined by its IC50 value. The lower the IC50 value the greater the potency of the antagonist and the lower the concentration that is required to inhibit the maximum biological response. In certain embodiments, an inhibitor has an IC50 and / or binding constant of less than about 100 pM, less than about 50 pM, less than about 1 pM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.
[0244] As used herein, the term “inhibitor” is defined as a compound that binds to and / or inhibits the target with measurable affinity. In some embodiments, inhibition in the presence of 43335841422 CENC-005 / 01WO 360899-2046the inhibitor is observed in a dose-dependent manner. In some embodiments, the measured signal (e.g., signaling activity or biological activity) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% lower than the signal measured with a negative control under comparable conditions.
[0245] The terms “measurable affinity” and “measurably inhibit,” as used herein, means a measurable change or inhibition in target activity between a sample comprising a compound of the present invention, or composition thereof an equivalent sample comprising target, in the absence of said compound, or composition thereof.
[0246] As used herein, the term “effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results (e.g., a therapeutic, ameliorative, inhibitory, or preventative result). An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.
[0247] As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating, or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof. In some embodiments, treatment can be administered after one or more symptoms have developed. In other embodiments, treatment can be administered in the absence of symptoms. For example, treatment can be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment can also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.
[0248] In one aspect, the present disclosure provides a method of modulating the activity of DCN-1 in vitro or in vivo, comprising contacting DCN-1 with Compound I, or a solid form or composition thereof. In one aspect, the present disclosure provides a method of modulating the activity of DCN-2 in vitro or in vivo, comprising contacting DCN-2 with Compound I, or a solid form or composition thereof.44335841422 CENC-005 / 01WO 360899-2046
[0249] In some embodiments, the present disclosure provides a method of modulating the activity of DCN-1 and / or DCN-2 in a subject, comprising administering to the subject Compound I, or a solid form or composition thereof.
[0250] In one aspect, the disease, disorder, or condition associated with DCN-1 or DCN-2 is a hemoglobinopathy such as sickle cell disorder or disease, or thalassemia disorder or disease.
[0251] In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is selected from one of those described in He et al. (Int Journal of Biological Macromolecules 227, 2024, 134541). In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is cancer (e.g., non-small cell lung cancer or gastric cancer), liver injury (e.g., non-alcoholic fatty liver disease), cardiac remodeling (e.g., atherosclerosis) or neurodegenerative disease (e.g., frontotemporal lobar degeneration). In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is characterized by overexpression of DCN-1 and / or DCN-2. In some embodiments, the disease, disorder, or condition associated with DCN-1 and / or DCN-2 overexpression is cancer (e.g., non-small cell lung cancer or gastric cancer).
[0252] In one aspect, the disclosure provides use of Compound I, or a solid form or composition thereof, for the treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. In one aspect, Compound I, or a solid form or composition thereof described herein, induce HbF (fetal hemoglobin; expressed by the gamma globin genes HBG1 and HBG2). It should be appreciated that induction of HbF allows for the treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. Thus, in one aspect, the disclosure provides use of Compound I, or a solid form or composition thereof, for the treatment of sickle cell disease.
[0253] In one aspect, the disclosure provides use of Compound I, or a solid form or composition thereof, for the treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. In one aspect, Compound I, or a solid form or composition thereof described herein, induce HbF (fetal hemoglobin; expressed by the gamma globin genes HBG1 and HBG2) and reduce HbA (adult hemoglobin; expressed by the beta globin gene HBB), thus inducing production of fetal hemoglobin and reducing the expression of the hemoglobin beta gene. It should be appreciated that induction of HbF and reduction of HbA allows for the treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. Thus,45335841422 CENC-005 / 01WO 360899-2046in one aspect, the disclosure provides use of Compound I, or a solid form or composition thereof, for the treatment of sickle cell disease.
[0254] In some embodiments, Compound I, or a solid form or composition thereof described herein, is an irreversible covalent inhibitor of DCN-1 and / or DCN-2. In some embodiments, an irreversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, an irreversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease. In some embodiments, Compound I, or a solid form or composition thereof described herein, is a reversible covalent inhibitor of DCN-1 and / or DCN-2. In some embodiments, a reversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, a reversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease. In some embodiments, Compound I, or a solid form or composition thereof described herein, is a reversible inhibitor of DCN-1 and / or DCN-2. In some embodiments, a reversible inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, a reversible covalent of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease.
[0255] In some embodiments, Compound I, or a solid form or composition thereof, irreversibly covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, Compound I, or a solid form or composition thereof, irreversibly covalently modify Cysll5 of DCN-1 and / or DCN-2.
[0256] In one aspect, the disclosure provides use of Compound I, or a solid form or composition thereof, for the treatment of a disease, disorder, or condition associated with DCN-1 and / or DCN-2. In some embodiments, the disclosure provides use of Compound I, or a solid form or composition thereof, for the treatment of sickle cell disease. In some embodiments, Compound I, or a solid form or composition thereof, reversibly covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, Compound I, or a solid form or composition thereof, reversibly covalently modify Cysll5 of DCN-1 and / or DCN-2.
[0257] In one aspect, the disclosure provides use of Compound I, or a solid form or composition thereof, for the treatment of a disease, disorder, or condition associated with DCN-1 or DCN-2. In one aspect, the disclosure provides use of Compound I, or a solid form or composition thereof, for the treatment of sickle cell disease.46335841422 CENC-005 / 01WO 360899-2046
[0258] In some embodiments, Compound I, or a solid form or composition thereof, irreversible covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the cysteine is Cysll5 of DCN-1 and / or DCN-2. In some embodiments, Compound I, or a solid form or composition thereof, reversible covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the cysteine is Cysll5 of DCN-1 and / or DCN-2.
[0259] In one aspect, the disclosure provides a DCN-1 that is covalently modified at Cysl 15. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-1 in a subject. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-1 Cys-115 in a subject. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-1 Cys-115 in a subject for the treatment of sickle cell disease.
[0260] In one aspect, the disclosure provides a DCN-2 that is covalently modified at Cysl 15. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-2 in a subject. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-2 Cys-115 in a subject. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-2 Cys-115 in a subject for the treatment of sickle cell disease.
[0261] In one aspect, the present disclosure provides a method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof Compound I, or a solid form or composition thereof disclosed herein. In another aspect, the present disclosure provides a method of inducing or increasing production of fetal hemoglobin. Such methods are useful, for example, in treating hemoglobin-related disorders including sickle cell disorders, diseases and conditions and thalassemia.
[0262] In some embodiments, the hemoglobinopathy is a sickle cell disorder or disease.
[0263] In some embodiments, the hemoglobinopathy is a thalassemia disorder or disease.
[0264] In one aspect, the present disclosure provides a method to increase red blood cell levels and / or hemoglobin levels in a subject in need thereof, treat or prevent an anemia in a subject in need thereof, treat sickle-cell disease in a subject in need thereof, or treat one or more complications of sickle-cell disease in a subject in need thereof, comprising administering to a subject in need thereof Compound I, or a solid form or composition thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.47335841422 CENC-005 / 01WO 360899-2046
[0265] In one aspect, the present disclosure provides a method to increase fetal hemoglobin levels in a subject in need thereof, treat or prevent an anemia in a subject in need thereof, treat sickle-cell disease in a subject in need thereof, or treat one or more complications of sicklecell disease in a subject in need thereof, comprising administering to a subject in need thereof Compound I, or a solid form or composition thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.
[0266] In some embodiments, the present disclosure provides a method for the treatment of a DCN-1 associated disease. In some embodiments, the present disclosure provides a method for the treatment of a DCN-2 associated disease. In some embodiments, the present disclosure provides a method for the treatment of cancers, premalignant conditions (e.g., hyperplasia, metaplasia, and dysplasia), benign tumors, hyperproliferative disorders, and benign dysproliferative disorders. Such methods comprise the step of administering to a subject in need thereof Compound I, or a solid form or composition thereof. In some embodiments, the cancer is characterized by overexpression of DCN-1 and / or DCN-2.
[0267] In some embodiments, cancers and related disorders that can be treated or prevented by methods disclosed herein include, but are not limited, to the following: a squamous cell carcinoma, a metastatic squamous cell carcinoma, a non-small cell lung carcinoma, a uterine carcinosarcoma, an embryonal rhabdomyosarcoma, a glioblastoma, a medulloblastoma, an osteosarcoma, or an adrenocortical tumor. In some embodiments, the cancer and related disorders include a cancer of the lung, cervix, ovary, uterus, esophagus, prostate, or head and neck.
[0268] In some embodiments, the cancer of the lung includes a non-small cell lung cancer, including, but not limited to a squamous cell carcinoma, adenocarcinoma, or large cell-undifferentiated carcinoma.
[0269] In some embodiments, cancers and related disorders include a hematological malignancy such as a leukemia, a lymphoma, a myeloma, a multiple lymphoma, a B-cell nonHodgkin’s lymphoma, or an acute myeloid leukemia.
[0270] In some embodiments, the present disclosure provides a method for the treatment of a cancer, including, but not limited to, leukemia, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, polycythemia vera, Lymphoma, Hodgkin’s disease, non-Hodgkin’s 48335841422 CENC-005 / 01WO 360899-2046disease, multiple myeloma, Waldenstrom’s macroglobulinemia, heavy chain disease, solid tumors, sarcomas and carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms’ tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.
[0271] In some embodiments, the present disclosure provides a method for the treatment of leukemia, including, but not limited to, acute leukemia, acute lymphocytic leukemia; acute myelocytic leukemia, including, but not limited to, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia and myelodysplastic syndrome; chronic leukemia, including, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas, including, but not limited to, Hodgkin's lymphoma, non-Hodgkin's lymphoma; myeloma, including, but not limited, to smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas, including, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma, rhabdomyosarcoma, synovial sarcoma; brain tumor, including, but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma; breast cancer, including, but not limited to, adenocarcinoma, lobular 49335841422 CENC-005 / 01WO 360899-2046(small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease, and inflammatory breast cancer; adrenal cancer, including, but not limited to, pheochromocytom and adrenocortical carcinoma; thyroid cancer, including, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary cancers, including, but not limited to, Cushing's disease, prolactinsecreting tumor, acromegaly, and diabetes insipius; eye cancer, including, but not limited to, ocular melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; vaginal cancer, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancer, including, but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancer, including, but not limited to, endometrial carcinoma and uterine sarcoma; ovarian cancers, including, but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; esophageal cancer, including, but not limited to, squamous cancer, adenocarcinoma, adenoid cyctic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancer, including, but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphom, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancer; rectal cancer; liver cancer, including, but not limited to, hepatocellular carcinoma and hepatoblastoma, gallbladder cancer, including, but not limited to, adenocarcinoma; cholangiocarcinoma, including, but not limited to, pappillary, nodular, and diffuse; lung cancer, including, but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; testicular cancer, including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, and choriocarcinoma (yolk-sac tumor); prostate cancer, including, but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penal cancers; oral cancer, including, but not limited to, squamous cell carcinoma; basal cancers; salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancer,50335841422 CENC-005 / 01WO 360899-2046including, but not limited to, squamous cell cancer, and verrucous; skin cancer, including, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, and acral lentiginous melanoma; kidney cancer, including, but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and / or uterer); Wilms’ tumor; bladder cancer, including, but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. In addition, cancer includes myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas.
[0272] In some embodiments, the present disclosure provides a method for the treatment of liver injury. Without being limited to a specific mechanism, targeting neddylation provides a method for the treatment of liver fibrosis and liver injury. (See e.g., Zubiete-Franco et al. Hepatology 65 (2) 2017, 694-709). Thus, in some embodiments, the present disclosure provides a method for the treatment of hepatitis, Non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, cirrhosis, hemochromatosis, jaundice, autoimmune liver disorders, liver cancer, galactosemia, alpha-1 antitrypsin deficiency, Wilson disease, oxalosis, liver adenoma, Alagille syndrome, primary biliary cholangitis (PBC), and lysosomal acid lipase deficiency (LAL-D).
[0273] In some embodiments, the present disclosure provides a method for the treatment of heart disease. Without being limited to a specific mechanism, targeting neddylation, provides a method for the treatment of heart disease (See e.g., Kandala et al., Am. J. Cardiovasc. Dis 4, 2014, 140). Thus, in some embodiments, the present disclosure provides a method for the treatment of arrhythmia, heart failure, coronary artery disease, heart valve disease, congenital heart disease, angina, cardiomyopathy, pericarditis, peripheral artery disease, aortic aneurysm, aortic stenosis, deep vein thrombosis, Marfan syndrome and rheumatic heart disease.
[0274] In some embodiments, the present disclosure provides a method for the treatment of neurodegenerative diseases (See e.g., Villa et al., Eur J. Neurol. 16 (7) 2009, 870. Thus, in some embodiments, the present disclosure provides a method for the treatment of amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple system atrophy, tauopathies and prion diseases.51335841422 CENC-005 / 01WO 360899-2046
[0275] In some embodiments, the method optionally comprises co-administration of a second therapeutic agent. In some embodiments, the second therapeutic agent is hydroxyurea or a pharmaceutically acceptable salt thereof.
[0276] In one aspect, the present disclosure provides a method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof Compound I, or a solid form or composition thereof, in combination with a second agent such as hydroxyurea or a pharmaceutically acceptable salt thereof.
[0277] In some embodiments, the hemoglobinopathy is a sickle cell disorder or disease.
[0278] In some embodiments, the hemoglobinopathy is a thalassemia disorder or disease.
[0279] In some embodiments, the compound or pharmaceutically acceptable salt thereof and the hydroxyurea or a pharmaceutically acceptable salt thereof act synergistically.
[0280] In one aspect, the present disclosure provides a method of increasing efficacy and / or reducing toxicity of hydroxyurea treatment in a subject undergoing said treatment, comprising administering to the subject Compound I, or a solid form or composition thereof. In some embodiments, the hydroxyurea treatment is for a hemoglobinopathy. In some embodiments, the hydroxyurea treatment is for sickle cell disease. In some embodiments, the hydroxyurea treatment is for a thalassemia disorder.
[0281] In some embodiments, the method further comprises the step of decreasing an amount of hydroxyurea being administered to the subject.
[0282] In some embodiments, the amount of hydroxyurea being administered is decreased by 10-90%.
[0283] In one aspect, the present disclosure provides a method of decreasing the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof Compound I, or a solid form or composition thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof, wherein the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of the hemoglobinopathy disorder or disease is less than the dose needed for treatment in the subject using hydroxyurea or a pharmaceutically acceptable salt thereof as a monotherapy.
[0284] In some embodiments, the dose of hydroxyurea or a pharmaceutically acceptable salt thereof co-administered with Compound I, or a solid form or composition thereof, is reduced by 52335841422 CENC-005 / 01WO 360899-2046at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% relative to the dose needed for treatment in the subj ect using hydroxyurea or a pharmaceutically acceptable salt thereof as a monotherapy.
[0285] In some embodiments, the present disclosure provides a method to treat or prevent one or more complications of sickle cell disease including, for example, anemia, anemia crisis, splenomegaly, pain crisis, chest syndrome, acute chest syndrome, blood transfusion requirement, organ damage, pain medicine (management) requirement, splenic sequestration crises, hyperhemolytic crisis, vaso-occlusion, vaso-occlusion crisis, acute myocardial infarction, sicklecell chronic lung disease, thromboemboli, hepatic failure, hepatomegaly, hepatic sequestration, iron overload and complications of iron overload (e.g., congestive heart failure, cardiac arrhythmia, myocardial infarction, other forms of cardiac disease, diabetes mellitus, dyspnea, hepatic disease and adverse effects of iron chelation therapy), splenic infarction, acute and / or chronic D renal failure, pyelonephritis, aneurysm, ischemic stroke, intraparenchymal hemorrhage, subarachnoid hemorrhage, intraventricular hemorrhage, peripheral retinal ischemia, proliferative sickle retinopathy, vitreous hemorrhage, and / or priapism; comprising administering to a subject in need thereof a disclosed compound or pharmaceutically acceptable salt thereof, optionally in combination with a second therapeutic agent such as hydroxyurea or a pharmaceutically acceptable salt thereof.
[0286] In some embodiments, Compound I, or a solid form or composition thereof, acts synergistically in combination with the second therapeutic agent, e g., hydroxyurea or a pharmaceutically acceptable salt thereof.4. Combination Therapies
[0287] In one aspect, Compound I, or a solid form or composition thereof, are used advantageously in combination with a second therapeutic agent. Such a second therapeutic agent includes, in some embodiments, hydroxyurea or a pharmaceutically acceptable salt thereof.
[0288] In some embodiments, the disclosure provides methods for using Compound I, or a solid form or composition thereof, or combination therapy (for example, a disclosed compound or pharmaceutically acceptable salt thereof in combination with hydroxyurea or a pharmaceutically acceptable salt thereof) to treat or prevent vascular occlusion (vaso-occlusion) in a sickle-cell disease patient in need thereof as well as various complications associated with vaso-occlusion in 53335841422 CENC-005 / 01WO 360899-2046a sickle-cell disease patient (e.g., vaso-occlusion crisis, pain crisis, etc.). In some embodiments, the disclosure provides methods for using Compound I, or a solid form or composition thereof, or combination therapy to treat or prevent anemia in a sickle-cell disease patient in need thereof as well as various complications associated with anemia in a sickle-cell disease patient (e.g., aplastic crisis, hyperhemolytic crisis, etc.). In such methods, Compound I, or a solid form or composition thereof, or combination therapy can be used to increase red blood cell levels while reducing the need for red blood cell transfusions and / or iron chelation therapy, and thereby reduce morbidity and mortality associated with iron accumulation in vulnerable tissues / organs. In such methods, Compound I, or a solid form or composition thereof, or combination therapy can also be used to reduce the need for other supportive therapies for treating sickle-cell disease [e.g., treatment with hydroxyurea, treatment with an EPO or other EPO agonist, and / or pain management (e.g., treatment with one or more of opioid analgesic agents, non-steroidal anti-inflammatory drugs, and / or corticosteroids)]. In part, Compound I, or a solid form or composition thereof, or combination therapy can be used in combination with existing supportive therapies for sickle-cell disease including, for example, transfusion of red blood cells, iron chelation therapy, hydroxyurea therapy, EPO or EPO agonist therapy, and / or pain management therapy. Optionally, Compound I, or a solid form or composition thereof, or combination therapy can be used to reduce the amount, duration, etc. of an existing supportive therapy for sickle-cell disease. For example, while transfusion of red blood cells and iron chelation therapy may help treat certain complications of sickle-cell disease, they sometimes result in adverse side effects. Therefore, in certain aspects, Compound I, or a solid form or composition thereof, or combination therapy can be used to reduce the amount of a second supportive therapy, e.g., reduce blood cell transfusion burden or reduce the dosage of a chelation therapeutic. In certain aspects, the disclosure provides uses of Compound I, or a solid form or composition thereof, or combination therapy (optionally in combination with one or more supportive therapies for sickle-cell disease) for making a medicament for the treatment or prevention of sickle-cell disease, particularly one or more complications of sickle-cell disease as disclosed herein.5. Compositions
[0289] The present disclosure also provides compositions that comprise or deliver Compound I, or a solid form thereof, as provided herein. In some embodiments, the present disclosure provides 54335841422 CENC-005 / 01WO 360899-2046compositions comprising Compound I, or a solid form thereof provided herein, with one or more other components.
[0290] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
[0291] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil / water or water / oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see e.g., Martin, Remington’s Pharmaceutical Sciences, 15thEd., Mack Publ. Co., Easton, PA
[1975] ,
[0292] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
[0293] As a general matter, compositions specifying a percentage are by weight unless otherwise specified.
[0294] In some embodiments, provided compositions comprise and / or deliver Compound I, or a solid form thereof described herein. In some embodiments, a provided composition is a pharmaceutical composition that comprises and / or delivers Compound I, or a solid form thereof provided herein and further comprises a pharmaceutically acceptable carrier.
[0295] Pharmaceutical compositions typically contain an active agent (e g., a compound described herein) in an amount effective to achieve a desired therapeutic effect while avoiding or minimizing adverse side effects. In some embodiments, provided pharmaceutical compositions comprise Compound I, or a solid form thereof described herein and one or more carriers or excipients (e.g., fillers, disintegrants, lubricants, glidants, anti -adherents, and / or anti-statics, etc.) Provided pharmaceutical compositions can be in a variety of forms including oral dosage forms, topical creams, topical patches, iontophoresis forms, suppository, nasal spray and / or inhaler, eye drops, intraocular injection forms, depot forms, as well as injectable and infusible solutions.55335841422 CENC-005 / 01WO 360899-2046
[0296] Provided pharmaceutical compositions can be prepared with any appropriate available technologies.
[0297] In some embodiments, Compound I, or a solid form thereof, are formulated in a unit dosage form for ease of administration and uniformity of dosage. The expression “unit dosage form” as used herein refers to a physically discrete unit of an active agent (e.g., a compound described herein) for administration to a subject. Typically, each such unit contains a predetermined quantity of active agent. In some embodiments, a unit dosage form contains an entire single dose of the agent. In some embodiments, more than one unit dosage form is administered to achieve a total single dose. In some embodiments, administration of multiple unit dosage forms is required, or expected to be required, in order to achieve an intended effect. A unit dosage form may be, for example, a liquid pharmaceutical composition containing a predetermined quantity of one or more active agents, a solid pharmaceutical composition (e g., a tablet, a capsule, or the like) containing a predetermined amount of one or more active agents, a sustained release formulation containing a predetermined quantity of one or more active agents, or a drug delivery device containing a predetermined amount of one or more active agents, etc.
[0298] Provided compositions may be administered in accordance with a dosing regimen (i.e., that includes a single dose or multiple doses separated from one another in time, administered via a particular route of administration) that is (e.g., has been demonstrated to be) effective for treating (e g., delaying onset of and / or decreasing incidence and / or intensity of) a disease or disorder, for example as described herein.
[0299] The present disclosure also provides methods of preparing pharmaceutical compositions provided herein. In some embodiments, provided methods comprise (i) providing Compound I, or a solid form thereof; and (ii) formulating Compound I, or a solid form thereof, with suitable excipients to give a pharmaceutical composition.EXEMPLIFICATION
[0300] As depicted in the Examples below, exemplary compounds are prepared according to the following general procedures and used in biological assays and other procedures described generally herein. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and 56335841422 CENC-005 / 01WO 360899-2046species of each of these compounds, as described herein. Similarly, assays and other analyses can be adapted according to the knowledge of one of ordinary skilled in the art.Example 1: Synthesis of Intermediate Compound 5: rac-N-((4R,5R)-7-ethyl-4-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridine-5-yl)-3-(trifluoromethyl)benzamideNMR:
[0301] 'H NMR spectrum was recorded on Bruker 400 MHz and Varian 400 MHz instruments internally referenced to a tetramethylsilane (TMS) signal. Chemical shifts (8) and coupling constants (J) were expressed in parts per million and hertz, respectively.LCMS:
[0302] Method-A: LCMS_X-Select (Formic acid); Column: X-Select CSH C18 (3.0*50) mm 2.5p; Mobile Phase: A: 0.05% Formic acid in water: I (95:5) B: 0.05% Formic acid in ACN; Inj Volume: 2.0pL, Column oven temperature: 50 C; Flow Rate: 1.2 mb / min. Gradient program: 0% B to 98 % B in 2.0 minute, hold till 3.0 min, at 3.2 min B cone is 0 % up to 4.0 min.
[0303] Method-B: Column: X-Bridge C18 (3.0*50) mm 2.5p; Mobile Phase: A: 2.5 mM Ammonium Bicarbonate in water; B: Acetonitrile; Flow Rate: 1.2 mL / min; Column oven temp.50°C; Gradient program:0% B to 98 % B in 2.0 minute, hold till 3.0 min, at 3.2 min B cone is 0 % up to 4.0 min.HPLC:
[0304] Column: X-Bridge CSH C18 (150 X 4.6mm, 3.5pm); Mobile Phase-A: 5mM NH4HCO3 in water; Mobile Phase-B: I; Programme / B%: 0.01 / 2,2 / 2,12 / 90,16 / 90; Flow: 1.0 mL / min.; Diluent: I: WATER (80:20).Synthesis of Intermediate Compound 557335841422 CENC-005 / 01WO 360899-2046i. ACN, n-BuLi,THF, -78°C to RT, 12 hImidazole, TBDMSCI,ii. PhNHNH2, PhCI,° \ /
[0305] Step-1: Synthesis of ethyl 2-((tert-butyldimethylsilyl)oxy)acetate (1):
[0306] To stirred solution of compound (SMI) (25 g, 240.1 mmol) in DMF (125 mL) was added imidazole (27.6 g, 312.2 mmol) and TBDMSCI (47.04 g, 312.2 mmol) at 0°C. The reaction mixture was stirred at room temperature for 16 h. After consumption of the starting material (by TLC), the reaction mixture was quenched with water (1.2 lit) and extracted with EtOAc (2x500 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated to afford crude compound. The obtained crude compound was purified by using flash column chromatography eluting with 0-20% EtOAC in Heptane. Pure fraction was collected and concentrated under vacuum to afford compound (1) (24 g, 46.1%) as colorless liquid.
[0307] *H NMR (400 MHz, DMSO-d6): 84.21 (s, 2H), 4.09 (q, J= 6.8 Hz, 2H), 1.18 (t, J = 6.8 Hz, 3H), 0.88 - 0.82 (m, 9H), 0.06 - 0.07 (m, 6H).58335841422 CENC-005 / 01WO 360899-2046
[0308] Step-(2i): Synthesis of 3-(((tert-butyldimethylsilyl)oxy)methyl)-l-phenyl-lH-pyrazol-5-amine (2A):
[0309] To a stirred solution of acetonitrile (15 mL) in THF (750 mL), n-butyl lithium (2.5 mol / 1) in hexanes (115 ml, 290 mmol) was added at -78° C. The reaction mixture was stirred at -78 °C for 30 min. after 30 mins, compound (1) (40 g, 183.18 mmol) dissolved in THF (750 mL) was added to the reaction mixture slowly at same temperature. Slowly allowed the reaction mixture to room temperature and maintained the same for 12 h. Reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was quenched with water and adjusted pH to 4-5 using 2N aq. HCl solution. The reaction solution was extracted with 2x500 mL ethyl acetate. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude compound (2A) (37 g, 94.67%) as a pale-brown oil.
[0310] Step-(2ii): Synthesis of 5-[[tert-butyl(dimethyl)silyl] oxymethyl]-2-phenyl-pyrazol-3-amine (2B):
[0311] To a stirred solution of compound (2A) (37 g, 173.42 mmol) in chlorobenzene (110 mL), phenylhydrazine (19 g, 173.94 mmol) was added at room temperature. Raised the reaction mass temperature to 140 °C. The reaction mixture stirred at same temperature for 16 h. Reaction progress was monitored by TLC. After completion of starting material, the reaction mixture was quenched with water (100 mL) and extracted with ethyl acetate (2x500 mL). Combined organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure to afford crude compound. The obtained crude compound was purified by column chromatography eluting with 15-20% ethyl acetate in pet ether to afford compound (2B) (26.0 g, 35.07%) as ayellow solid.
[0312] ' H NMR (400 MHz, DMSO-d6): 57.54-7.58 (m, 2H), 7.43-7.48 (m, 2H), 7.29 (dt, J = 7.4, 1.2 Hz, 1H), 5.47 (s, 1H), 5.30 (s, 2H), 4.50 (s, 2H), 0.87-0.91 (m, 9H), 0.07 (s, 6H).LC-MS (Method-B) = 304.7 [M+H]+; 70.73 % atRT 2.16 min.
[0313] Step-3: Synthesis of rac-N-((4R,5R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridine-5-yl)-3-(trifluoromethyl) benzamide (3):
[0314] To a stirred solution compound (2B) (26 g, 85.67 mmol) and Int-B (29.19 g, 85.67 mmol) in chlorobenzene (78 ml), tin (II) chloride (1.64 g, 8.56 mmol) was added at room temperature. The reaction mixture was stirred at 140-150 °C for 16 h. Reaction progress was monitored by TLC. After completion of reaction, the reaction mixture was quenched with water 59335841422 CENC-005 / 01WO 360899-2046(100 mL) and filtered through celite bed and washed with DCM (500 mL). Filtrate was washed with water and extracted with DCM (2x500 mL). Organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained crude was purified by column chromatography by eluting with 20-30% ethyl acetate in pet ether to afford compound (3) (30 g, 48.6 %) as yellow solid.
[0315] 'H NMR (400 MHz, DMSO-d6): 5 11.06 (s, 1H), 8.36 (d, J= 3.4 Hz, 1H), 8.07 (s, 2H), 7.89 (d, J= 7.3 Hz, 1H), 7.58-7.71 (m, 4H), 7.49-7.55 (m, 2H), 7.40 (d, J= 6.8 Hz, 1H), 7.03-7.08 (m, 1H), 6.95 (s, 1H), 5.24-5.34 (m, 1H), 4.69 (d, J= 6.8 Hz, 1H), 4.56-4.62 (m, 1H), 4.40-4.46 (m, 1H), 0.73 (s, 5H).
[0316] LC-MS (Method-A) = 639.29 [M+H]+; 88.73 % at RT 2.48 min.
[0317] Step-4: Synthesis of rac-N-((4R,5R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-7-ethyI-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridine-5-yl)-3-(trifluoromethyl)benzamide (4):
[0318] To a stirred solution of compound (3) (30 g, 41.33 mmol) inDMF (300 mL), potassium carbonate (7.50 g, 53.73 mmol) and bromoethane (5.45 g, 49.60 mmol) were added at room temperature. The reaction mixture was stirred at room temperature for 16 h. Reaction progress was monitored by TLC. After completion of SM, the reaction mixture was quenched with water and extracted with ethyl acetate. Organic layer was dried over anhydrous sodium sulfate and evaporated under vacuum. The obtained crude was purified by column chromatography by eluting with 15-20% ethyl acetate in heptane to afford compound (4) (15 g, 48.3%) as yellow solid.
[0319] 1HNMR(400MHz, DMSO-d6)(D2O): 88.05-8.10 (m, 2H), 7.91 (d, J=7.1 Hz, 1H), 7.68-7.74 (m, 1H), 7.49-7.64 (m, 5H), 7.03-7.10 (m, 2H), 6.90-6.95 (m, 2H), 5.41 (d, J= 7.2 Hz, 1H), 4.65-4.69 (m, 1H), 4.62 (d, J= 12.5 Hz, 1H), 4.45 (d, J= 12.4 Hz, 1H), 2.94-3.08 (m, 2H), 0.79-0.92 (m, 3H), 0.70 (s, 9H), -0.12 (s, 6H).
[0320] LC-MS (Method-B) = 667.5 [M+H]+; 83.38 % at RT 2.52 min.
[0321] Step-5: Synthesis of rac-N-((4R,5R)-7-ethyl-4-(4-fluorophenyl)-3- (hydroxymethyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridine-5-yl)-3-(trifluoromethyl)benzamide (5):
[0322] To a stirred solution of compound (4) (20 g, 24.90 mmol) in acetonitrile (100 mL), hydrochloric acid (20 mL, 120 mmol) was added. The reaction mixture was stirred at room temperature for 16 h. Reaction progress was monitored by TLC. After completion of reaction, the 60335841422 CENC-005 / 01WO 360899-2046reaction mixture was quenched with ice water (1000 mL) and extracted with ethyl acetate (2x1500 mL). Organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum to afford crude compound. The crude material was washed with 10% diethyl ether in pentane and dried under vacuum to afford 5 (12.00 g, 83.75%) as a pale-yellow solid.
[0323] 'H NMR (400 MHz, DMSO-d6, 25°C): 88.53 (d, J= 7.3 Hz, 1H), 8.12-8.17 (m, 2H), 7.92 (d, J= 7.8 Hz, 1H), 7.64-7.74 (m, 3H), 7.50-7.61 (m, 3H), 7.10 (t, J= 8.9 Hz, 2H), 6.93-7.05 (m, 2H), 5.50 (t, J = 7.3 Hz, 1H), 5.11(t, J= 6.0 Hz, 1H), 4.72 (d, J = 7.3 Hz, 1H), 4.35-4.41 (m, 1H), 4.24-4.30 (m, 1H), 3.87-3.94 (m, 1H), 2.98-3.08 (m, 1H), 0.91 (t, J= 7.1 Hz, 3H).
[0324] LC-MS (Method-B) = 553.2 [M+H]+; 96.44% at RT 2.26 min.
[0325] HPLC: 95.87 % at RT 9.15 min.Example 2: Synthesis of Compound INMR;
[0326] 1H NMR spectrum was recorded on Bruker 400 MHz and Varian 400 MHz instruments internally referenced to a tetramethylsilane (TMS) signal. Chemical shifts (8) and coupling constants (J) were expressed in parts per million and hertz, respectively.LC-MS:
[0327] Method-A: LC-MS_X-Select (Formic acid); Column: X-SelectCSHC18 (3.0*50) mm 2.5p.
[0328] Mobile Phase: A: 0.05% Formic acid in water: I (95:5) B: 0.05% Formic acid in ACN.
[0329] Inj Volume: 2.0pL, Column oven temperature: 50 C; Flow Rate: 1.2 mL / min.
[0330] Gradient program: 0% B to 98 % B in 2.0 minute, hold till 3.0 min, at 3.2 min B cone is 0 % up to 4.0 min.
[0331] Method-B: Column: X-Bridge BEH C18, (50mm*3.0mm,2.5p) Mobile Phase A:2.5mM Ammonium Bicarbonate in Water + 5% I Mobile Phase B: 100% I Flow rate: 1.0 mL / min. Column temperature: 40°C Gradient Program (B%):0.0 / 2, 0.3 / 2, 2.0 / 98, 2.8 / 98, 3.0 / 2, 3.7 / 2.HPLC:
[0332] Method-A: Column: X Select CSH C18(150 x 4.6) mm,3.5p; Mobile phase A:0.1% FA in Water: I (95:05); Mobile phase B: Acetonitrile; Gradient Programme: T / B%:0.01 / 5, 1 / 5, 8 / 100, 12 / 100, 14 / 5, 18 / 5; Flow rate:1.2 mL / min.61335841422 CENC-005 / 01WO 360899-2046
[0333] Method-B: Column: X-Bridge CSH Cl 8 (150 X 4.6mm, 3.5gm); Mobile Phase-A: 5mMNH4HCO3 in water; Mobile Phase-B: I; Programme / B%: 0.01 / 2,2 / 2,12 / 90,16 / 90; Flow: 1.0 mL / min.; Diluent: I: WATER (80:20).
[0334] Method-C: Column Name: CHIRALPAK-IK (250X4.6mm,5|im) MobilePhase A: n-HEXANE MobilePhase B: ETOH: MEOH(50 / 50) Column ID: M-ARDCAL\OLD-028 Flow rate: l. Oml / min.
[0335] Method-D: Column Name: CHIRALPAK-IC (250X4.6mm,5gm) Column ID: M-ARD-CAL / OLD-005 MobilePhase A: 0.1% DEA n-Hexane MobilePhase B: DCM: IPA (50:50) Flow rate: l. O ml / min.
[0336] Method-E: COLUMN: CHIRALPAK-IG (250X4.6mm,5gm) M. P-A: n-HEXANE62335841422 CENC-005 / 01WO 360899-2046
[0337] Step-1: Synthesis of rac-N-((4R,5R)-7-ethyl-4-(4-fluorophenyl)-3-formyl-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide (6):
[0338] To a stirred solution of compound-5 (3.0 g, 5.43 mmol) in DMF (30.0 mL) at 0°C, pyridinium dichromate (2.50 g, 6.51 mmol) was added slowly. The reaction mixture was stirred at 25°C for 16 h. After consumption of the starting material (by TLC), the reaction mixture was quenched with ice cold water (50 mL) and extracted with ethyl acetate (3 x 40 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude material was purified by medium pressure liquid chromatography by eluting 15- 30% EtOAc / heptane to afford compound (6) (2.20 g, 67%) as an off-white solid.
[0339] 'll NMR (400 MHz, CHLOROFORM-d, 27°C): 6988 (s, 1H), 861 (d, J= 7.2 Hz, 1H), 8.16 - 8.13 (m, 2H), 7.92 - 7.90 (m, 1H), 7.83 -7.82 (m, 2H), 7.72 -7.64 (m, 4H), 7.10 (t, J = 8.4 Hz, 2H), 7.01 (t, J= 5.2 Hz, 2H), 5.57 (t, J= 7.2 Hz, 1H), 4.90 (d, J = 7.2 Hz, 1H), 3.91 - 3.85 (m, 1H), 3.05 - 3.00 (m, 1H), 0.89 (t, J= 6.8 Hz, 3H).
[0340] LC-MS (Method-B) = 551.1 [M+H]+; 91.53 % atRT 2.45 min.
[0341] HPLC(Method-B) = 97.30 % at RT 9.32 min.
[0342] Chiral HPLC(Method-C) = Peak-1: 14.17 % at RT 4.28 min.
[0343] Peak-2: 85.83 % at RT 6.47 min.
[0344] Step-2: Synthesis of N-((4RS,5RS)-3-((E)-(((S)-tert-butylsulfinyl)imino)methyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide (7a):
[0345] To a stirred solution of compound (6) (2.2 g, 4.0 mmol) in THF (22 mL) was added (s)-2-methylpropane-2-sulfmamide (0.97 g, 8.0 mmol) followed by titanium (IV) ethoxide (1.9 g, 8.0 mmol) at 0 °C. The reaction mixture was stirred at 80°C for 16 h. Progress of the reaction was monitored by TLC. After consumption of the reaction, the reaction mixture was poured into ice cold NH4CI solution (150 mL) and extracted with EtOAc (2 x 150 mL). The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure. The crude material was washed with diethyl ether, fdtered, and dried to afford compound (7a) (2.70 g, 96.00 %) as an off-white solid.
[0346] 1H NMR (400 MHz, DMSO-d6) 6 = 8.52 (d, J= 6.4 Hz, 1H), 8.39 (s, 1H), 8.12-8.10 (m, 2H), 7.92 (d, J= 7.6 Hz, 1H), 7.83 - 7.81 (m, 2H), 7.72 - 7.62 (m, 4H), 7.10 (t, J= 8.8 Hz,63335841422 CENC-005 / 01WO 360899-20462H), 6.96 - 6.93 (m, 2H), 5.57 (t, J= 6.8 Hz, 1H), 4.99 (d, J = 7.2 Hz, 1H), 3.90 - 3.88 (m, 1H), 3.04 - 3.02 (m, 1H), 1.17 (s, 9H), 0.94 -0.84 (m, 3H).[003471 LC-MS (Method-B) = 654.1 [M+H]+; 97.29 % at RT 2.51 min.
[0348] HPLC(Method-B) = 87.97 % at RT 9.60 min.
[0349] Chiral HPLC(Method-C) = 98.99 % at RT 7.60 min.
[0350] Step-3: Synthesis of N-((4RS,5RS)-3-((R)-l-(((S)-tert-butylsulfinyl)amino)ethyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide (7b):
[0351] To a stirred solution of compound (7a) (2.70 g, 4.13 mmol) in DCM (54 mL) was added CH3MgBr (3.0 M in diethyl ether) (4.3 g, 12.4 mmol) at -58°C. Reaction was stirred at same temperature for 1 h and then allowed to room temperature, reaction was stirred for 2 h. After consumption of the starting material (by TLC), the reaction was poured into ice cold NH4CI solution (25 mL) and extracted with DCM (2 x 125 mL). The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure. The obtained crude material was washed with diethyl ether to afford (7b) (2.4 g, 69 %) as an off-white solid. Obtained crude material was used for the next step without any further purification.
[0352] 1H NMR (400 MHz, DMSO-d6) 6 = 8.50 - 8.42 (m, 1H), 8.15 - 8.11 (m, 1H), 7.97 -7.91 (m, 1H), 7.73 - 7.52 (m, 6H), 7.18 - 7.09 (m, 2H), 6.98 - 6.95 (m, 2H), 5.46 (t, J= 7.2 Hz, 1H), 5.17- 5.15 (m, 1H), 4.75 (d, J= 6.8 Hz, 1H), 4.23 -4.19 (m, 2H), 3.90 -3.85 (m, 1H), 3.09 - 3.04 (m, 1H), 1.47 (d,.7= 6.8 Hz, 2H), 1.32- 1.14 (m, 2H), 1.07 - 0.81 (m, 11H).
[0353] LC-MS (Method-A) = 670.39 [M+H]+; 81.08 % atRT 2.48, 2.51 min.
[0354] HPLC(Method-B) = 58.15 % atRT 9.14 min.
[0355] Chiral HPLC(Method-C) = Peak-1: 87.82% at RT 5.85 min.
[0356] Peak-2: 10.23 % at RT 8.93 min.
[0357] Step-4: Synthesis of N-((4S,5S)-3-((R)-l-aminoethyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)beiizamide (Compound A):
[0358] To a stirring solution of compound (7b) (2.4 g, 3.3 mmol) in dichloromethane (25 mL) was added (4M Dioxane in HC1, 3.3 mL) at room temperature under inert atmosphere. The reaction mixture was stirred at 25°C for 16 h. Progress of the reaction was monitored by TLC. After consumption of the starting material (by TLC), reaction mixture was concentrated under reduced 64335841422 CENC-005 / 01WO 360899-2046pressure to get crude compound. The Obtained crude compound was purified by Chiral HPLC. Peak-4 from Chiral HPLC was evaporated under reduced pressure to afford compound A (0.7 g, 40 %) as an off-white solid.
[0359] ’H NMR (400 MHz, DMSO-d6) 5 = 8.53 (d, J = 7.2 Hz, 1H), 8.16 - 8.13 (m, 2H), 7.92 (d, J= 8.0 Hz, 1H), 7.73 - 7.53 ( m, 6H), 7.11 (t, J= 8.8 Hz, 2H), 7.01 - 6.99 (m, 2H), 5.50 (t, J= 7.2 Hz, 1H), 4.71 (d, J= 6.8 Hz, 1H), 4.04 (d, J= 6.0 Hz, 1H), 3.91 - 3.86 (m, 2H), 3.08 -3.03 (m, 2H), 1.13 - 1.04 (m, 3H), 0.92 (t, J = 6.0 Hz, 3H).
[0360] LC-MS (Method-B) = 566.3 [M+H]+; 83.40 % at RT 2.42 min.
[0361] HPLC(Method-B) = 97.11% at RT 8.75 min.
[0362] Crude Chiral HPLC(Method-D):
[0363] Peak-1: 8.20% at RT 5.45min. Peak-2: 0.6% at RT 7.47 min.
[0364] Peak-3:27.89% at RT 9.06 min. Peak-4= 63.22% at RT 11.46 min (desired).
[0365] Step-5: Synthesis of N-((4S,5S)-3-((R)-l-cyanamidoethyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide (Compound I):
[0366] To a stirring solution of compound (compound A) (Peak-4 from step-4) (350 mg, 0.618 mmol) in dichloromethane (18 mL) were added pyridine (0.14 g, 1.85 mmol) and cyanogen bromide 5M in I (0.24 g, 0.61 mmol) at 0 °C under inert atmosphere. The reaction mixture was stirred at room temperature for 16 h. Progress of the reaction was monitored by LCMS and TLC. After consumption of the starting material (monitored by TLC), the reaction mixture was quenched with ice cold solution of saturated NaHCCh (10 mL), extracted with DCM (2 x 10 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to get crude compound and was purified by medium pressure liquid chromatography eluting with 0- 45% EA in Heptane, product containing fractions were collected to afford Compound I (90.00 mg, 23.8%) as a light brown solid.
[0367] 1HNMR(400MHz, DMSO-d6) 68.53 (d, J= 7.2Hz, 1H), 8.16- 8.13 (m, 2H), 7.92 (d, J = 8.0 Hz, 1H), 7.73 - 7.68 (m, 3H), 7.62 - 7.52 (m, 3H), 7.26 (d, J= 5.2 Hz, 1H), 7.11 (t, J = 4.8 Hz, 2H), 7.01 - 6.97 (m, 2H), 5.54 (t, J = 7.6 Hz, 1H), 4.67 (d, J= 6.8 Hz, 1H), 4.33 - 4.27 (m, 1H), 3.91 - 3.85 (m, 1H), 3.09 - 3.02 (m, 1H), 1.23 - 1.20 (m, 3H), 0.91 (t, J= 7.2 Hz, 3H).
[0368] LC-MS (Method-B) = 591.24 [M+H]+; 98.75 % at RT 2.17 min.
[0369] HPLC(Method-B) = 97.09% at RT 8.91 min.65335841422 CENC-005 / 01WO 360899-2046
[0370] Chiral HPLC(Method-E) = 99.30 % at RT 5.74 min.Example 3: Compound I Polymorph ScreeningChemical abbreviations:ACN AcetonitrileCPME Cyclopentyl Methyl EtherCYH CyclohexaneDCM DichloromethaneDMC Dimethyl carbonateDMSO Dimethyl SulfoxideEtOH EthanolEt2O EtherEA Ethyl AcetateHept / / -HeptaneIPA IsopropanolIPE Isopropyl etherIP Ac Isopropyl AcetateMeCYH MethylcyclohexaneMeOH MethanolMEK 2-ButanoneMTBE tert-Butyl Methyl EtherMIBK 4-Methyl-2-pentanonePE Petroleum etherTHF Tetrahydrofuran2-MeTHF 2-MethyltetrahydrofuranOther abbreviations (alphabetical order):awWater Activityd Dayeq. Equivalent66335841422 CENC-005 / 01WO 360899-2046h Hourmin MinuteDSC Differential Scanning CalorimetryDVS Dynamic Vapor Sorption1H-NMR. Proton Nuclear Magnetic ResonanceN / A Not AvailableNP New PatternPLM Polarized Light MicroscopyRT Room Temperature (20 - 25 °C)RH Relative HumidityTGA Thermogravimetric AnalysisXRPD X-ray Powder DiffractionSummary
[0371] The objective of this study was to conduct polymorph screen of Compound I to find a suitable crystalline form for pharmaceutical development and manufacturing.
[0372] The sample of Compound I received for polymorph screen was amorphous with glass transition temperature of ~96 °C. Polymorph screening was carried out using commonly used solvents and various crystallization methods, including slurry conversion, cooling, evaporation, anti-solvent precipitation and cyclic heating-cooling. A total of six polymorphs were identified, including one anhydrate (Form C), and five solvates or hydrates (Forms A, B and D - F). Among them, Form A and Form C show better solid-state properties than the others. Form A is an isostructural solvate obtained from several solvents and could exist as a channel hydrate after desolvation. Form C is anhydrate but it was only obtained in solvent system containing IPE, likely through desolvation of IPE. The characterization data of Compound I crystal forms are summarized in Summary Table 3.1. A Conversion Map among different forms is proposed (FIG.1).
[0373] DVS result showed that Form A was hygroscopic with reversible water sorption of 0 -2.6% at RH 0 - 80%, while Form C and amorphous solid were slightly hygroscopic. All the three solid forms (including amorphous) remained unchanged after DVS testing.
[0374] Solid-state properties of three solid forms are presented in Summary Table 3.2. Form 67335841422 CENC-005 / 01WO 360899-2046C was both physically and chemically stable at 60 °C (capped) and 40 °C / 75%RH (open) for one week. Slight degradation was observed for the amorphous solid at 60 °C (capped) condition, and crystallinity of Form A slightly decreased under 60 °C (capped) for 1 week.
[0375] Overall, both Form A and Form C show acceptable solid-state properties and stability. Form A is a hydrate and will lose crystallinity at elevated temperature. Form C was only obtained in IPE in this work, the slight difference of XRPD pattern between wet and dry sample suggests that Form C might be prepared through desolvation while IPE is not suitable for scale-up. Scale-up of both forms are challenging because Compound I does not crystallize readily.Summary Table 3.1 - Characterization Data of Compound I Polymorphs68335841422 CENC-005 / 01WO 360899-2046Summary Table 3.2 - Characterization Data of Compound I Three Solid Forms1 Introduction
[0376] In this study, polymorph screening of Compound I was performed to find potential crystal forms, and to identify a suitable form for pharmaceutical development and manufacturing.2 Materials2.1 Drug Compound
[0377] The sample information of Compound I is listed in Table 3.1.Table 3.1. Information of Compound I69335841422 CENC-005 / 01WO 360899-20462.2 Solvents
[0378] The solvents used for polymorph screening are given in Table 3.2.Table 3.2. List of Solvents3. Results and Discussion3.1 Characterization of Starting Material
[0379] Compound I received was characterized by XRPD, PLM DSC, TGA, H-NMR and DVS. The characterization data are summarized in Table 3.3. This batch of sample received was used as the starting material for polymorph screening.
[0380] The sample was amorphous with no birefringence under microscope. XRPD confirmed the material was amorphous. Negligible solvent residue was detected by 'H-NMR. TGA result showed 0.1 % weight loss at 90 - 120 °C, due to loss of residual solvent. DSC curve showed one endothermic peak at 94 °C, and glass transition temperature (Tg) is ~ 96 °C (midpoint). DVS result 70335841422 CENC-005 / 01WO 360899-2046showed that the sample was slightly hygroscopic, and it remained as amorphous after DVS analysis.Table 3.3. Characterization Data of Compound I as Received3.2 Characterization and Definition of Crystal Forms
[0381] A total of six crystal forms were identified in this study, including one anhydrate (Form C), and five solvates or hydrates (Forms A, B and D - F). The overlaid XRPD patterns are presented in FIG. 2 and the characterization data are summarized in Summary Table 1. The detailed characterization results of each form are presented in the following parts.3.2.1 Form A
[0382] Form A samples with similar XRPD pattern were obtained from various solvent systems and were postulated to be a hydrate in most conditions, and incorporate Hept in one batch of sample. Hence, Form A is postulated to be an isostructural solvate / hydrate. The characterization data are shown in FIG. 3 and Table 3.4.Table 3.4. ¹H NMR Results of Form A Samples71335841422 CENC-005 / 01WO 360899-2046
[0383] Four batches of Form A samples were characterized and the results are described in following part.
[0384] Form A sample #1, obtained by slurry in acetone / water (1 / 2, v / v), was characterized by XRPD, PLM, TGA, DSC and 'H-NMR. FIG. 4 XRPD confirmed the sample #1 was Form A with high crystallinity and the peak data was listed in Table 1.1. The sample #1 was irregular shaped crystal under microscope. No acetone residue was detected by 'H-NMR. FIG. 5 TGA result showed 0.7% weight loss at 35 - 120 °C. FIG. 5 DSC curve showed two endothermic peaks at 76 °C and 100 °C (onset). Thermal treatment of Form A was performed. After heating to 85 °C, the crystallinity decreased significantly and the small peak at 76 °C in DSC curve disappeared. Hence, Form A sample #1 was postulated to be a hydrate. Similar DSC data of Form A sample #2, obtained from EtOH / water (1 / 1, v / v), was collected by DSC (FIG. 6).
[0385] Form A sample #3, obtained by slurry in EtOH / water (1 / 3, v / v), was characterized by XRPD, PLM, TGA, DSC, 'H-NMR and DVS. FIG. 7 XRPD confirmed the sample #3 was Form A with high crystallinity and the peak data was listed in Table 1.2. The sample #3 was small crystal under microscope. No EtOH residue was detected by 'H-NMR. FIG. 8 TGA result showed 0.8% weight loss before 120 °C. FIG. 8 DSC curve showed two endothermic peaks at 64 °C and 102 °C (onset), respectively. Hence, Form A sample #3 is postulated to be a hydrate. DVS result showed that Form A was hygroscopic, and the XRPD pattern remained unchanged after DVS testing.
[0386] Form A sample #4, obtained by slurry in DCM / Hept (1 / 5, v / v), was characterized by TGA, DSC and 'H-NMR. About 6.3% (0.40 eq.) Hept was detected by 'H-NMR. FIG. 9 TGA result showed 5.4% weight loss before 120 °C. FIG. 9 DSC curve showed two endothermic peaks at 70 °C and 102 °C (onset), respectively. Hence, Form A sample #4 was postulated to be a solvate of Hept.3.2.2 Form B
[0387] Form B samples with similar XRPD pattern were obtained from various solvent systems and contained the corresponding solvent, such as toluene and xylene. Hence, Form B is postulated to be an isostructural solvate. The characterization data are shown in FIG. 10 and Table 3.5.72335841422 CENC-005 / 01WO 360899-2046Table 3.5. ¹H-NMR Results of Form B Samples
[0388] Form B sample #1 was characterized by XRPD, TGA, DSC and 'H-NMR FIG. 11 XRPD confirmed the sample was Form B with high crystallinity and the peak data was listed in Table 1.3. About 3.7% (0.25 eq.) toluene was detected by 'H-NMR. FIG. 12 TGA result showed 3.8% weight loss at 80 - 225 °C. FIG. 12 DSC curve showed one broad endothermic peak at 96 °C (onset). Hence, Form B sample #1 is a solvate of toluene. Another Form B sample (#2) has similar thermal events in TGA and DSC (FIG. 13).3.2.3 Form C
[0389] Form C sample was obtained from IPE or mixed solvent system containing IPE.
[0390] Form C sample #1 was characterized by XRPD, PLM, TGA, DSC, 'H-NMR and DVS. FIG. 14 XRPD confirmed the sample was Form C with high crystallinity and the peak data was listed in Table 1.4. The sample was irregular shaped crystal under microscope. About 1.60% (0.09 eq.) IPE was detected by ’H-NMR. FIG. 15 TGA result showed 1.7% weight loss at 95 - 160 °C. FIG. 15 DSC curve showed one endothermic peak at 110 °C (onset). Thermal treatment of Form C was performed. After heating to 100 °C and then cooling to RT, the XRPD pattern of Form C remained unchanged. Hence, Form C is postulated to be an anhydrate. DVS result showed that Form C was slightly hygroscopic, and the crystal form remained unchanged after DVS analysis. Form C adsorbed 0.6% moisture at 90% RH. Another Form C sample (#2) has similar thermal events in TGA and DSC (FIG. 16).
[0391] Form C was first observed in IPE by slurry study. There was 0.6% weight loss at 95 -185 °C, and one endothermic peak at 111 °C was observed in DSC curve. Hence, a slurry study was conducted for further investigation of Form C. Form C was stirred in PE and / / -pentane for 3 d at RT. Solid sample was collected by filtration and analyzed by XRPD and ’H-NMR. The crystal form of Form C remained unchanged after stirring in PE for 3 d, and the amount of IPE decreased from 2.1% to 0.14%. Hence, Form C is an anhydrate. However, there is still 0.8% wt. loss in TGA curve at 90 - 190 °C.
[0392] Form C was scaled up to 100 mg scale by slurry conversion. About 100 mg of 73335841422 CENC-005 / 01WO 360899-2046Compound I was seeded with 1-2 mg of Form C and stirred in 3 mL of IPE / Hept (1 / 2, v / v) for 1 day. A sample was collected by filtration and vacuum dried at 40 °C for 8 h, then analyzed. Form C was prepared successfully with a yield of 74%. Slight differences of XRPD pattern were observed before and after drying of Form C sample, indicating the exists of unstable precursor (solvate / hydrate). Hence, Form C might be prepared through desolvation.3.2.4 Form D
[0393] Form D was obtained from / / -Butyl ether by slurry conversion. Form D was characterized by XRPD, TGA, DSC and1H-NMR. FIG. 17 XRPD confirmed the sample was Form D with moderate crystallinity and the peak data of dry sample was listed in Table 1.5. The XRPD pattern slightly changed after vacuum drying. About 7.2% (0.35 eq.) / / -Butyl ether was detected by 'H-NMR. FIG. 18 TGA result showed 5.9% weight loss at 75 - 220 °C. FIG. 18 DSC curve showed one endothermic peak at 102 °C (onset), due to desolvation. Hence, Form D is postulated to be an / / -Butyl ether solvate.3.2.5 Form E
[0394] Form E was obtained from mixture of CPME and Hept by slurry conversion. Form E was characterized by XRPD, TGA, DSC and 'H-NMR. FIG. 19 XRPD confirmed the sample was Form E with low crystallinity and the peak data of wet cake was listed in Table 1.6. The XRPD pattern slightly changed after vacuum drying. About 3.75% (0.23 eq.) CPME and 2.96% (0.18 eq.) Hept were detected by 'H-NMR. FIG. 20 TGA result showed 7.1% weight loss at 30 - 135 °C. FIG. 20 DSC curve showed one broad endothermic peak at 74 °C (onset), due to desolvation. Hence, Form E is postulated to be a heterosolvate of CPME and Hept.3.2.6 Form F
[0395] Form F was obtained from DMSO / water by slurry conversion. Form F was characterized by XRPD, TGA, DSC and 'H-NMR. FIG. 21 XRPD confirmed the sample was Form F with high crystallinity and the peak data was listed in Table 1.7. About 12.6% (1.08 eq.) DMSO was detected by 'H-NMR. FIG. 22 TGA result showed 5.7% weight loss at 110 - 250 °C. FIG. 22 DSC curve showed two endothermic peaks at 85 °C and 130 °C (onset), likely due to phase transition and desolvation, respectively. Hence, Form F is postulated to be a DMSO solvate.74335841422 CENC-005 / 01WO 360899-20463.3 Evaluation of Lead Forms3.3.1 Solid-state Stability Study
[0396] A total of six crystal forms were identified in this study. Among all the crystal forms, Form A and Form C show better solid-state properties. Form A is an isostructural solvate, and could exist as hydrate. Form C is an anhydrate, but is not easy to prepare. Solid-state stability of amorphous solid, Forms A and C were evaluated at 60 °C (capped) and 40 °C / 75%RH (open) for 1 week. The sample was dissolved in ACN / water (1 / 1, v / v) at 0.5 mg / mL and analyzed by HPLC to check the purity. The solid was analyzed by XRPD to check the crystal form. The results are summarized in Table 3.6.
[0397] Form C was both physically and chemically stable at 60 °C (capped) and 40 °C / 75%RH (open) for one week. However, slight degradation was observed for amorphous solid at 60 °C (capped) condition and the crystallinity of Form A slightly decreased under 60 °C (capped) for 1 week.Table 3.6. Stability Evaluation Results of Three Solid Forms3.3.2 Mechanical Treatment
[0398] Appropriate amount of Form A and Form C was manually ground by pestle and mortar for up to 2 min, respectively. The ground sample was analyzed by XRPD. The crystal form of Forms A and C both remained unchanged after grinding, but the crystallinity decreased.3.4 Polymorph Screening
[0399] The results of polymorph screening experiments are summarized in Table 3.7. A total 75335841422 CENC-005 / 01WO 360899-2046of six crystal forms were identified, including one anhydrate (Form C), and five solvates (Forms A, B and D - F).Table 3.7. Summary of Polymorph Screening3.4.1 Preliminary Solubility Test
[0400] The solubility of Compound I received was estimated at RT by visual observation in common solvent systems. Approximately 5 mg of solid was weighed into 8-mL glass vial, and then solvent was added stepwise until solid was dissolved completely or total of solvent volume reached to 5 mL. The results are summarized in Table 3.8. Starting material showed high solubility (> 50 mg / mL) in most tested solvent and low solubility (< 5 mg / mL) in water, MeCYH, PE, xylene, toluene and peanut oil. The solubility was estimated and for reference only.Table 3.8. Estimated Solubility of Compound I Starting Material at RTValues are reported as “<” if dissolution was not observed, and as “>” if dissolution occurred after addition of first aliquot.76335841422 CENC-005 / 01WO 360899-20463.4.2 Slurry Conversion
[0401] An appropriate amount of starting material Compound I was added into different solvents to make suspensions which were kept stirring at RT, 50 °C and 80 °C for days. Solid sample was collected by filtration and analyzed by XRPD. The wet sample was dried at 40 °C under vacuum for ~4 h. Four crystal forms (Forms A - D) were obtained by slurry study at RT. Three crystal forms (Forms B, C and D) were obtained by slurry study at 50 °C. Only one crystal form (Form B) was observed in slurry study at 80 °C. The results are summarized in Table 3.9 -Table 3.11.Table 3.9. Results of Slurry at RT77335841422 CENC-005 / 01WO 360899-2046Sample was checked by PLM; “ / ” means no sample was tested; LC: Low crystallinity; Wet sample: sample obtained without any drying; Dry sample: Sample after vacuum drying.Table 3.10. Results of Slurry at 50 °CSample was checked by PLM; AM: Amorphous; LC: Low crystallinity; “a”: the sample was stirred at RT and no precipitation occurred.78335841422 CENC-005 / 01WO 360899-2046Table 3.11. Results of Slurry at 80 °C*” Sample was checked by PLM; AM: Amorphous; “A”: The sample was stirred at RT for 1 day3.4.3 Cooling Crystallization
[0402] Cooling crystallization was performed in six selected solvent systems. About 20 mg of starting material Compound I was slurried in selected temperature for 0.5 h. Saturated drug solution was collected by filtration, and then the filtrate was directly cooled to RT for 5 days. Solid sample was collected by filtration and analyzed by XRPD.
[0403] One crystal form was identified (Forms B) in cooling crystallization. The results are summarized in Table 3.12.Table 3.12. Results of Cooling Crystallization79335841422 CENC-005 / 01WO 360899-20463.4.4 Anti-solvent Precipitation
[0404] About 20 mg of starting material Compound I was weighed into glass vials and then selected solvent was added to make nearly saturated solution. After filtration, anti-solvent was added into the filtrate gradually until solids precipitated. If precipitation occurred, the solid was checked by XRPD after stirring for ~1 h, and then the suspension was continued to stir for 1 day, the remaining solid was checked by XRPD again. The result is summarized in Table 3.13. Form A or oil was obtained by anti-solvent precipitation.Table 3.13. Results of Anti-solvent Precipitation00405] *: Gel was easily obtained after anti-solvent added and solution was obtained after 80335841422 CENC-005 / 01WO 360899-2046MTBE added3.4.5 Slow Evaporation
[0406] Evaporation was performed in selected solvents according to the solubility data. A clear solution was prepared by filtration and transferred to a glass vial. Then the vial was covered with pin-hole film and placed at ambient condition for slow evaporation until solid precipitation. There were two crystal forms of Forms A and D obtained in slow evaporation. The results are summarized in Table 3.14.Table 3.14. Results of Slow Evaporation3.4.6 Cyclic Heating-cooling
[0407] Cyclic heating-cooling experiments were carried out in Crystal 16 Parallel Crystallizer. About 20 - 40 mg of Compound I was added into 1 mL solvent to make suspension, and a heatingcooling program was performed:1) Equilibrate at 25 °C first, and heat to 80 or 100 °C over 5 h (the elevated temperature is set according to boiling point of solvent);2) Hold for 1 h;3) Cool to 25 °C over 5 h, and hold for 1 h;4) Repeat the above procedures twice;5) Collect the remaining solid and characterize it by XRPD.
[0408] The results are summarized in Table 3.15. There was one crystal form of Form B obtained by cyclic heating-cooling.Table 3.15. Results of Cyclic Heating-cooling81335841422 CENC-005 / 01WO 360899-20463.4.7 Repetition Trials of Crystal Forms
[0409] To obtain the characterization data of some crystal forms, repetition experiments were set up. The detailed experimental process and results are summarized in Table 3.16. Forms A and C were obtained successfully by slurry conversion.Table 3.16. Results of Repetition Trials of Crystal Forms4 Analysis Methods4.1 PLM
[0410] Light microscopy analysis was performed using an ECLIPSE LV100POL (Nikon, JPN) microscope. Each sample was placed on a glass slide with a drop of immersion oil and covered with a glass slip. The sample was observed using a 4 - 20x objective with polarized light.4.2 XRPD
[0411] XRPD diffractograms were collected with an X-ray diffractometer. The sample was prepared on a zero-background silicon wafer by gently pressing onto the flat surface. The parameters of XRPD diffraction are given in Table 3.17.82335841422 CENC-005 / 01WO 360899-2046Table 3.17. Parameters for XRPD Testing4.3 TGA
[0412] TGA analysis was performed using a TA Instrument. About 1 - 5 mg of the sample was loaded onto a pre-tared aluminum pan and heated with the parameters in Table 3.18. The data was analyzed using TRIOS.Table 3.18. Parameters for TGA Testing4.4 DSC
[0413] DSC analysis was performed with a TA Instrument. About 1 - 3 mg of the sample was placed into an aluminum pan with pin-hole and heated with the parameters in Table 3.19. The data was analyzed using TRIOS.Table 3.19. Parameters for DSC Testing83335841422 CENC-005 / 01WO 360899-20464.5 DVS
[0414] Moisture sorption-desorption data were collected on a DVS instrument. An appropriate amount of the sample was placed into a tared sample chamber and automatically weighed. The sample was analyzed with the setting parameters in Table 3.20 and Table 3.21, respectively.Table 3.20. Parameters of DVS Analysis for Form C and Amorphous SolidTable 3.21. Parameters of DVS Analysis for Form A84335841422 CENC-005 / 01WO 360899-20464.6 ¹H-NMR
[0415] 1H-NMR spectra were collected on a Bruker 400 MHz instrument. Unless specified, samples were prepared in DMSO-d₆ solvent and measured with the parameters in Table 3.22. The data was analyzed using MestReNova.Table 3.22. Parameters for 'H-NMR Analysis4.7 HPLC
[0416] HPLC analysis was performed with an Agilent HPLC 1260 series instrument. HPLC method for purity testing is presented in Table 3.23.Table 3.23. HPLC Method85335841422 CENC-005 / 01WO 360899-2046Example 4: Solid Form EvaluationAbbreviationsChemicals abbreviations:ACN AcetonitrileCapryol 90 Propylene Glycol CaprylateCremophor RH40 Polyoxyl 40 Hydrogenated Castor oilTPGS Tocopherol Polyethylene Glycol SuccinateMC Methyl celluloseOther abbreviations (alphabetical order):Cone. Concentrationd Dayh HourHPLC High Performance Liquid Chromatographymin MinutePK PharmacokineticsPLM Polarized Light MicroscopyRT Room Temperature (20 - 25 °C)XRPD X-ray Powder DiffractionSummary
[0417] Compound I amorphous form, Form A and Form C samples were characterized by DSC, TGA, PLM and XRPD. Form A is a channel hydrate with up to 2.5 % weight loss dehydration at RT -100 °C. Two endothermic peaks were detected by DSC, due to dehydration86335841422 CENC-005 / 01WO 360899-2046and melting, respectively. Form C is an anhydrate form with onset melting point of 104 °C and 1.2% weight loss from 100 - 160 °C, due to loss of residual solvent. The detailed characterization data of three solid forms are listed in Summary Table 4.1.
[0418] The results of solubility test indicated that there was no significant difference of solubility in aqueous formulation (5% or 10% TPGS + MC) and bio-relevant media (FaSSIF and FeSSIF) for these three different forms. In addition, the solubility in 10% TPGS vehicle was more than two times higher than in 5% TPGS vehicle. The crystal form remained unchanged after solubility test in all media tested.
[0419] A dissolution rate test in lipid vehicle (Capryol 90: Cremophor RH 40: Transcutol HP (50:35:15)) was also conducted for comparison of these three solid forms. Form A showed the fastest dissolution rate (~5 min), while the amorphous sample showed the lowest dissolution rate (60 min). The amorphous sample after grinding showed slightly higher dissolution rate than the sample without grinding. Clear lipid solution was obtained with three solid forms at 100 mg / mL and 300 mg / mL. The emulsions obtained after dilution with water at 10 and 30 mg / mL were all physically stable at RT for 24 h.
[0420] Overall, for aqueous solubility, there is no significant difference between the three solid forms. In the selected lipid vehicle, the crystalline form showed higher dissolution rate than the amorphous material because of poor dispersibility of amorphous solids. The final selection of the solid form will be determined from the results of both in vivo and in vitro studies, as well as solid-state properties and manufacturability of the three solid forms.Summary Table 4.1. Physicochemical Properties of Compound I Solid Forms87335841422 CENC-005 / 01WO 360899-2046a. Form A is a channel hydrate and its water content can vary between 1 - 3% depending on drying.Form C has trapped solvent which releases at high temperature.b. These two formulations were used in previous studies.F# 1: 5% TPGS + 95% 0.5% MC (400 cp);F# 2: 10% TPGS + 90% 0.5% MC (400 cp).88335841422 CENC-005 / 01WO 360899-2046c. Capryol 90: Cremophor RH 40: Transcutol HP (50:35:15), amorphous solids showed poor dispersibility, easily form clumps.1 Introduction
[0421] In this study, solid form evaluation was conducted with amorphous, Form A and Form C to support solid form selection and formulation development.2 Materials2.1 Drug Compound
[0422] Compound I solid form samples are listed in Table 4.1.Table 4.1. Information of Compound I Solid Form Samples2.2 Reagents
[0423] The reagents used for solid form evaluation are given in Table 4.2.Table 4.2. List of Reagents89335841422 CENC-005 / 01WO 360899-20463 Results and Discussion3.1 Characterization of Starting Material
[0424] Compound I solid form samples described above were used as starting material for solid form evaluation. All the three forms were characterized by DSC, TGA, PLM and XRPD. The characterization data are summarized in Table 4.1.
[0425] The amorphous sample has no birefringence under polarized microscope. XRPD confirmed the material was amorphous. TGA result showed no obvious weight loss prior to 200 °C. DSC curve showed two endothermic peaks at 33.4 and 98.3 °C.
[0426] The Form A sample showed irregular shaped crystals under polarized microscope. XRPD confirmed the material was consistent with Form A. About 0.92% weight loss from 30 to 160 °C was observed in TGA profile, and two endothermic peaks at 70.6 and 93.2 °C were observed in DSC curve.
[0427] The Form C sample showed irregular shaped crystals under polarized microscope. XRPD confirmed the material was consistent with Form C. About 1.2% weight loss from 40 to 150 °C was observed in TGA profile. One endothermic peak at 104 °C was observed in DSC curve, due to melting.Table 4.3. Characterization Results of Compound I Solid Form Samples3.2 Solubility in Aqueous Formulation3.2.1 Solubility in 5% TPGS + 95% 0.5% MC (400 cp)
[0428] About 100 mg of MC (400 cp) and 1.0 mL of TPGS were dissolved in 19.0 mL of water. Suspended 10 mg of drug substance in 1 mL of premixed vehicle (Target Cone. = 10 mg / mL), the mixture was stirred at RT for 0.5 h. Samples were prepared in triplicate for each 90335841422 CENC-005 / 01WO 360899-2046medium. The suspension was filtered and the drug concentration of filtrates was analyzed by HPLC. The solubility of three forms in 5% TPGS + 95% 0.5% MC (400 cp) is summarized in Table 4.4.
[0429] There was no significant difference of solubility in 5% TPGS + 95% 0.5% MC (400 cp) for three different forms. The crystal form remained unchanged after solubility test.Table 4.4. Solubility in 5% TPGS + 95% 0.5% MC (400 cp)3.2.2 Solubility in 10% TPGS + 90% 0.5% MC (400 cp)
[0430] About 100 mg of MC (400 cp) and 2.0 mL of TPGS were dissolved in 18.0 mL of water. Suspended 20 mg of drug substance in 1 mL of premixed vehicle (Target Cone. = 20 mg / mL), the mixture was stirred at RT for 2 h. Samples were prepared in triplicate for each medium. The filtrate was collected by centrifuge tube filters with 0.45 pm membrane and the drug concentration of filtrates was analyzed by HPLC. The solubility of three forms in 10% TPGS + 90% 0.5% MC (400 cp) is summarized in Table 4.5.
[0431] There was no significant difference of solubility in 10% TPGS + 90% 0.5% MC (400 cp) for three different forms. The solubility of Compound I in 10% TPGS is more than two times higher than in 5% TPGS. The crystal form remained unchanged after solubility test.Table 4.5. Solubility in 10% TPGS + 90% 0.5% MC (400 cp)91335841422 CENC-005 / 01WO 360899-20463.3 Solubility in Bio-relevant Media
[0432] About 15 mg of drug substance was suspended in 3 mL of FaSSIF and FeSSIF. Samples were prepared in triplicate for each medium. All the samples were shaken at 37 °C with 500 rpm for up to 24 h. Part of suspension was filtered at 0.5, 2 and 24 h. The suspension was filtered and the filtrates were analyzed by HPLC and pH. The collected solids were analyzed by XRPD. The solubility of three forms in bio-relevant media is summarized in Table 4.6.
[0433] There was no significant difference of solubility in FaSSIF and FeSSIF for three different forms. The crystal form remained unchanged in FaSSIF and FeSSIF after solubility test.Table 4.6. Solubility in Bio-relevant Media3.4 Dissolution Rate in Selected Lipid Vehicle
[0434] About 100 mg of amorphous solid (with or without grinding), Form A or Form C was added into 0.2 mL of Vehicle (Capryol 90: Cremophor RH 40: Transcutol HP (50:35:15)). The mixture was stirred / sonicated / vortexed at RT to make a clear solution. The result of dissolution rate in selected lipid vehicle is summarized in Table 4.7.
[0435] The amorphous solid was characterized by PLM before and after grinding. Particle size decreased after grinding, and aggregation was still observed under PLM. Clear solution was92335841422 CENC-005 / 01WO 360899-2046obtained at 500 mg / mL with all the three solid forms of Compound T. Form A showed the fastest dissolution rate in the selected lipid vehicle, the amorphous sample after grinding showed slightly higher dissolution rate than the sample without grinding. Two crystal forms showed higher dissolution rate than amorphous solid, likely due to the aggregation of amorphous solid.Table 4.7. Dissolution Rate in Selected Lipid Vehicle3.5 Physical Stability of Lipid Formulations
[0436] About 20 / 60 mg of Form A, Form C or amorphous solid was added in 200 pL of lipid vehicle to make a clear lipid solution at 100 and 300 mg / mL (Step 1). About 900 pL of water was added into 100 pL of step 1 lipid solution, and the mixture was stirred at RT for 30 min. The emulsion formulations were kept at RT for 24 h. The formulation was checked by visual observation and PLM. The results of physical stability study are summarized in Table 4.8.
[0437] Clear lipid solution was obtained with three forms at 100 mg / mL and 300 mg / mL. The emulsions at 10 and 30 mg / mL were all physically stable at RT for 24 h.Table 4.8. Physical Stability of Lead Formulations93335841422 CENC-005 / 01WO 360899-20464 Analysis Method4.1 PLM
[0438] Light microscopy analysis was performed using an ECLIPSE LV100POL (Nikon, JPN) polarizing microscope. A small amount of the sample was placed on a glass slide with a drop of immersion oil and covered with a glass slip. The sample was observed using a 4 - 20x objective with polarized light.4.2 XRPD
[0439] XRPD diffractograms were collected with an X-ray diffractometer. The sample was prepared on a zero-background silicon wafer by gently pressing onto the flat surface. The sample was analyzed with the parameters in Table 4.9.Table 4.9. Parameters for XRPD Testing4.3 pH Meter
[0440] The pH of the sample solution was measured by Mettler Toledo pH meter. The pH meter was calibrated with standard solution before using. The pH electrode was inserted into solutions and held until the electrode response reached a balance.4.4 HPLC
[0441] HPLC analysis was performed with an Agilent HPLC 1260 series instrument. HPLC 94335841422 CENC-005 / 01WO 360899-2046methods for solubility and stability testing are presented in Table 4.10.Table 4.10. HPLC Method for Solubility and Stability TestingExample 5: Crystallization Process DevelopmentAbbreviationsChemicals abbreviation:MeOH MethanolEtOH EthanolIPA IsopropanolEA Ethyl acetateIPAc Isopropyl acetateMEK ButanoneMIBK Methyl isobutyl ketoneMTBE / c / 7-Butyl methyl etherIPE isopropyl etherACN AcetonitrileDMSO Dimethyl sulfoxide2-Me-THF 2-Methy 1 -tetrahydrofuranCYH Cyclohexane95335841422 CENC-005 / 01WO 360899-2046MCYH MethylcyclohexaneOther abbreviations:DSC Differential Scanning CalorimetryHPLC High Performance Liquid ChromatographyML Mother liquorNMR Nuclear Magnetic ResonancePLM Polarized Light MicroscopyTGA Thermogravimetric AnalysisXRPD X-ray Powder DiffractionAH EnthalpyT Temperature
[0442] Summary
[0443] The objective of this study is to develop a reliable crystallization process of Form C for scale-up manufacture.
[0444] Form C has a high solubility in most commonly used organic solvents, except in n-heptane, IPE and water (<10 mg / mL). IPE was the solvent used to generate Form C during screening but it is not preferred in the plant and water may lead to Form A, thus, n-heptane was selected as the antisolvent. According to the preliminary slurry experiments in different solvent mixtures, sticky or gel-like material were formed in most solvent systems, except in MTBE / n-heptane where a good suspension was obtained. Therefore, MTBE / n-heptane sol vent / anti solvent system was selected as the crystallization solvent system.
[0445] In the MTBE / n-heptane system, both normal and parallel antisolvent addition were attempted. Oil and / or sticky solids were obtained which could not be avoided with adjustment of crystallization temperature, addition rate or seed loading.
[0446] Reverse anti-solvent addition in MTBE / n-heptane was also attempted for crystallization of Form C. In the preliminary reverse addition experiment, amorphous suspension was obtained at 25 °C which converted to Form C after being heated to 50 °C. Unfortunately, the phase conversion went through an oil state. Therefore, the effects of crystallization temperature, seed loading and addition rate were evaluated. The results showed that high crystallization temperature (70 °C), slow addition rate of API solution (<0.5 V / h) and high seed loading (5wt.%) were beneficial for preparation of Form C without oil formation.96335841422 CENC-005 / 01WO 360899-2046
[0447] To remove the residual solvents, drying condition was evaluated. It was found that 70 °C with N2 flow was effective but the MTBE residual level was still >1 %. Post slurry of Form C in n-heptane at 70 °C could reduce the residual solvent content to an acceptable limit of <1%, however, the mixing efficiency on large scale might be potential risk.
[0448] Overall, crystallization of Form C was challenging since solvent selection is limited and the material easily oils out. A reverse anti-solvent addition crystallization in MTBE / n-heptane at 70 °C was eventually developed, and the proposed procedures are shown below. Form C was successfully prepared at 7 g scale with a yield of 96%. Although the residual solvent level (~1% MTBE and -0.5% n-heptane) was acceptable to the client, more optimization work could be conducted to reduce the residual solvent to meet ICH guideline.
[0449] Developed procedure:1) Dissolve starting material into 4 V of MTBE at 25 °C in Reactor 1 (Rl).2) Perform polish filtration if needed.3) Suspend 5 wt.% Form C seeds into 8 V of n-heptane at 70 °C in Reactor 1. (R2).4) Charge API MTBE solution (Rl) into the seed bed (R2) at a rate of 0.5 V / h.5) Stir at 70 °C for 2 h.6) Cool to 20 °C at 10 °C / h (5h) and stir for lOh or until the mother liquor (ML) concentration <1 mg / mL.7) Filter and wash by 4 V MTBE / n-heptane (1 / 2, v / v) twice then vacuum dry at 70 °C with N2 flow for 20 h or until the residual solvent content meet acceptable limit.1 Starting Material1.1 Amount and Color of Starting Material
[0450] The information on Compound I amorphous starting material samples is given in Table 5.1.Table 5.1 Information of Starting Material335841422 CENC-005 / 01WO 360899-20461.2 Characterization of Starting Material
[0451] The characterization data of the starting materials are presented in Table 5.2. The amorphous material were used as starting material for crystallization study.Table 5.2 Characterization Data of Starting Material2 Crystallization Process Condition Study2.1 Preparation of Form C
[0452] Form C was initially prepared in IPE / n-heptane (1 / 1, v / v) solvent at 40 °C. The product was used for solubility measurement and as seed. The detailed procedure is shown below.Table 5.3 Preparation of Form C2.2 Solubility Measurement of Form C98335841422 CENC-005 / 01WO 360899-20462.2.1 Solubility of Form C in Single Solvent
[0453] The solubility of Form C was estimated by visual observation or measured by HPLC. The samples with solubility > 83 mg / mL were observed visually with the method as follows. An appropriate amount of Form C was weighed into a 2-mL vial at 20 °C. Solvent was added gradually until sample dissolved. The others were measured by HPLC with the method as follows. An appropriate amount of Form C was suspended in the selected solvent systems and stirred for 3 d (over weekend). After that, the suspensions were filtered and the filtrates were collected for solubility measurement by HPLC. The results in Table 5.4 indicated that Form C had a high solubility in most of the selected solvents, except in n-heptane, Water and IPE.Table 5.4 Solubility Data of Form C in Single Solvents at 20 °C2.2.2 Phase Stability Study of Form C in Binary Solvent Systems
[0454] According to the solubility data of Form C in single solvents, the phase stability of Form C in binary solvent was evaluated. Excess Form C was added into the selected solvent systems and stirred for 16 h. The suspension was filtered and the residual solids were tested by XRPD. The results in Table 5.5 showed that oil and sticky solids were observed from most of the conditions. Form C remained unchanged after slurry in EA / IPE, 2-Me-THF / IPE, MTBE / IPE and MTBE / n-heptane, and the optimal state of suspension was found in MTBE / IPE and MTBE / n-heptane because of no oil / sticky solids were formed in these two systems. Therefore, these two solvent systems were99335841422 CENC-005 / 01WO 360899-2046selected for further investigation.Table 5.5 Phase Stability Study of Form C in Binary Solvent Systems2.2.3 Solubility of Form C in MTBE-based Solvent Systems
[0455] Considering the phase stability of Form C, MTBE / IPE and MTBE / n-heptane were selected for further solubility measurement. As IPE is a Class II solvent and has low flash point, it is not preferred to be use in the plant but MTBE / IPE solvent was still investigated to have as many options as possible. The solubility of Form C was estimated by visual observation or measured by HPLC at evaluated temperatures. The samples with solubility > 167 mg / mL were observed visually, and the others were measured by HPLC. Form C converted to a low crystalline unknown form after slurry in MTBE / IPE with high MTBE content (> 25%, v / v). The solubility data and XRPD results are given in Table 5.6, and reverse anti-solvent addition in MTBE / n-heptane (1 / 2, v / v) system was proposed.100335841422 CENC-005 / 01WO 360899-2046Table 5.6 Solubility of Form C in MTBE-based Solvent Systems*LC: low crystallinity2.3 Phase Conversion Study in MTBE / n-heptane Systems
[0456] The phase conversion rate of amorphous form to Form C was evaluated in MTBE / n-heptane at 20 °C and 50 °C. 30 mg of amorphous material was weighed into a 2-mL vial at 20 °C and 50 °C. Then, 200 pL of solvent was added into the vial, and then 5 mg of Form C was added as seed and stirred for 16 h. The suspension was filtered and the residual solids were tested by XRPD. The results are shown in Table 5.7. Form C with high crystallinity was obtained after slurry at 50 °C.Table 5.7 Slurry Study of Form C in MTBE / n-heptane Systems101335841422 CENC-005 / 01WO 360899-2046*LC: low crystallinity2.4 Solution Stability of API in MTBE and MTBE / n-heptane Solvents
[0457] Considering solubility and physical stability of Form C, MTBE / n-heptane was selected as the crystallization solvent system. Solution stability of Compound I was evaluated in MTBE / n-heptane at 25 °C, 40 °C and 50 °C. 250 mg of material was dissolved into 4 V of MTBE at 25 °C and 5 mg of material was dissolved into 200 V of MTBE / n-heptane (1 / 2, v / v) at 70 °C. Then these two clear solutions were stirred at 25 °C and 70 °C for up to 24 h. The HPLC purity was monitored at different time points. The data indicated that Compound I was stable in MTBE at 25 °C for 24 h, but 0.6% of degradation of Compound I was found after stirring at 70 °C in MTBE / n-heptane (1 / 2, v / v) for 24 h.Table 5.8 Solution Stability of API in MTBE and MTBE / n-heptane Solvent Systems3 Crystallization Process Development and Optimization3.1 Normal addition
[0458] According to the solubility data, one preliminary normal addition crystallization was carried out in MTBE / n-heptane system. 1 g of amorphous material was fully dissolved into 4 V MTBE at 20 °C, followed by addition of 1 V of n-heptane by one portion to generate supersaturation 102335841422 CENC-005 / 01WO 360899-2046for seeding (clear solution). After that, 2 wt.% of Form C seed was charged and the seed suspension in 4V MTBE and IV n-heptane was aged at 20 °C for 0.5 h. Then, the remaining 7 V of n-heptane was added (0.875 V / h) into the suspension over 8 h. During the addition of n-heptane, oil was formed which attached on the wall. The oil and sticky solids were difficult to convert to good suspension. In an attempt to suppress formation of oil and sticky solids, the crystallization temperature was raised to 60 °C (refluxing), however, oil was still formed. The behavior of normal addition was consistent with the observation during solubility measurement, therefore, the normal addition was not deemed appropriate to generate Form C.Table 5.9 Results of Crystallization in MTBE / n-heptane System (Normal Addition)*The temperature is for seeds holding.3.2 Parallel addition
[0459] Since good suspension was observed when Form C was slurried in MTBE / n-heptane (1 / 2, v / v) at 25 °C, parallel addition was attempted to prepare Form C. One preliminary crystallization experiment was performed with the details as follows. 2wt.% Form C seed was suspended in 5V of pre-saturated MTBE / n-heptane (1 / 2, v / v) at 25 °C in Reactor 1. The starting material was dissolved into 4V of MTBE at 25 °C in Reactor 2 and 8V of n-heptane was charged 103335841422 CENC-005 / 01WO 360899-2046into Reactor 3 directly. After that, the API MTBE solution in Reactor 2 and n-heptane solvent in Reactor 3 were charged into the seed bed at 0.5V / h and 1 V / h, respectively. The ratio of MTBE and n-heptane remained unchanged during the entire crystallization process. After addition of the API solution and n-heptane solvent, a good suspension was obtained, but the PLM image and XRPD results showed it was amorphous, not Form C. The amorphous suspension was heated to 40 °C at 10 °C / h and then aged for further 4h, however, no crystals were observed by PLM. Therefore, the suspension was further heated to 50 °C but sticky solids were formed. The sticky solids were characterized as Form C by XRPD. In order to suppress formation of sticky solid, an experiment was performed by employing more seeds (5wt% vs 2wt%). However, the sticky solids were still formed when the suspension was heated to 50 °C. As a result, the parallel addition process was not deemed suitable for scale-up.Table 5.10 Results of Crystallization in MTBE-based System (Parallel addition)104335841422 CENC-005 / 01WO 360899-20463.3 Reverse addition
[0460] According to the solubility data, one preliminary reverse addition crystallization was performed in MTBE / n-heptane system. The starting material was dissolved into 4 V MTBE at 25 °C in Reactor 1 and 2wt % Form C seed was suspended in 8V of n-heptane as seed bed in Reactor 2. Afterwards, the API MTBE solution was charged into the seed bed at 0.5V / h (8h). A good suspension was obtained and stirring was continued for 16h at 25 °C. PLM image showed it was amorphous not crystalline material. The suspension was heated to 50 °C, but the suspension converted to sticky solids quickly.
[0461] Two experiments were performed at 0 °C and 70 °C to study the effect of crystallization temperature on crystallization behavior. Oil was formed after crystallization at 0°C, and good suspension with few sticky solids were obtained at 70 °C. The solids in suspension were characterized as Form C by XRPD. In order to avoid formation of sticky solid completely, higher seed loading (5wt%) was employed, and no sticky solids or oil were formed during the whole crystallization process but residual n-heptane and MTBE in the product after drying was found to be high. Post slurry process in n-heptane at 70 °C was carried out to reduce the residual solvents. After slurry and vacuum drying, residual MTBE and n-heptane met the acceptable limit (<5000 ppm).
[0462] The qualified Form C was provided for dissolution study. Nevertheless, insoluble impurity was observed during the dissolution. Therefore, the hazy solution was filtered and the insoluble impurity was collected for XRPD test. The result indicated that the insoluble impurity might be Teflon from the half-moon impeller. Thus, Experiment was performed using the stainless paddle to mitigate the risk of mechanical impurities. After crystallization and drying, this batch of Form C was also used for dissolution test and a clear solution was obtained.
[0463] For the post slurry process, Form C with high solvent residue was suspended into 10V of n-heptane at 70 °C and slurried for ~20h. Then, the suspension was cooled down to 20 °C at 25°C / h for filtration. After vacuum drying for 16hat 40 °C, the MTBE residue was reduced to 0.13% from 1.6%. It was found from the experiments that mixing efficiency during slurry might be critical to residual solvent removal. With poor mixing efficiency of EasyMax, the residual solvent content of Form C after drying at 70 °C with nitrogen blowing for 48h was still above the acceptable limit 105335841422 CENC-005 / 01WO 360899-2046according to the ICH guideline. All of the results are given in Table 5.11.Table 5.11 Results of Crystallization in MTBE-based System (Reverse Addition)106335841422 CENC-005 / 01WO 360899-2046107335841422 CENC-005 / 01WO 360899-2046Table 5.12 Removal of Solvent Residue by Slurry in N-heptane108335841422 CENC-005 / 01WO 360899-2046
[0464] The drying stability and efficiency were evaluated under different conditions and the results are shown in Table 5.13. For the recrystallized products, several drying conditions were evaluated, including drying temperature (40 °C vs 70°C), nitrogen purging and humidity. It was found that drying at high temperature with N2 flow is more efficient than that at low temperature without N2 flow. High humidity did not lower the residual solvents.
[0465] As drying at high temperature with nitrogen flow did not lower the residual solvents to ICH guidelines, a hot n-heptane slurry was used to lower the MTBE and n-heptane levels to <0.5% after drying at 40 °C and 70 °C. During these studies it was found that after a slurry with anchor paddle (EasyMax) was less effective which might be due to the poor mixing efficiency. This raised the risk of n-heptane different result in the plant, as scale-up effects might be observed.Table 5. 13 Results of Drying Stability and Efficiency Study109335841422 CENC-005 / 01WO 360899-2046110335841422 CENC-005 / 01WO 360899-20464 Instrument and Parameters4.1 PLM
[0466] Light microscopy analysis was performed using an ECLIPSE LV100POL (Nikon, JPN) microscope. Each sample was placed on a glass slide with a drop of immersion oil and covered with a glass slip. The sample was observed using a 10x objective with polarized light.4.2 SEM
[0467] Scanning electron microscope analysis was performed using an TM 4000 Tabletop Microscope. A small amount of the sample was placed on the sample holder with electrically conductive tape. The sample was electroplated with gold spray instrument for 45 s. The sample was observed in vacuum mode.4.3 XRPD
[0468] XRPD diffract grams were collected with an X-ray diffractometer. The sample was prepared on a zero-background silicon wafer by gently pressing onto the flat surface. The parameters of XRPD diffraction are given in Table 5.15.Table 5.15 Parameters for XRPD Testing with Bruker D8 Advance111335841422 CENC-005 / 01WO 360899-20464.4 TGA
[0469] TGA analysis was performed using a TA Instrument. About 1-3 mg of a sample was loaded onto a pre-tared aluminum pan and heated with the parameters in Table 5.16. The data was analyzed using TRIOS.Table 5.16 Parameters of TGA Testing4.5 DSC
[0470] DSC analysis was performed with a TA Instrument. About 1-3 mg of a sample was placed into an aluminum pan with pin-hole and heated with the parameters in Table 5.17. The data was analyzed using TRIOS.Table 5.17 Parameters of DSC Testing4.61H-NMR
[0471] 1H-NMR spectra were collected on a Bruker 400 MHz instrument. Unless specified, samples were prepared in DMSO-d6 solvent and measured with the parameters in Table 5.18.The data was analyzed using MestReNova.Table 5.18 Parameters for1H-NMR Analysis112335841422 CENC-005 / 01WO 360899-20464.7 HPLC
[0472] HPLC analysis was performed with an Agilent HPLC 1260 series instrument. The methods are presented in Table 5.19.Table 5.19 HPLC MethodExample 6: TR-FRET assay
[0473] The TR-FRET assay was designed following the Scott et al. protocol (Scott et al., Nat Chem Biol. 2017 August; 13(8): 850-857. Doi:10.1038 / nchembio.2386). The recombinant form of the DCN1 (DCUND1) protein PONY domain was produced using an E.coli expression system at Viva Biotech (China). The DCN1 protein was biotinylated (EZ sulfo-NHS-LC-biotin; Thermofisher) for labeling with streptavidin terbium (Tb) cryptate in the reaction. The probe was changed to a non-covalent DCN1 inhibitor labeled with carboxyfluorescein (FAM; Zhou et al., Nat Commun. 2017; 8: 1150. Doi: 10.1038 / s41467-017-01243-7). Buffer conditions were modified to enhance protein stability by exchanging Tween20 for TritonX and increasing NaCl to 200 mM. The compounds were screened against 5 nM DCN1 and 20 nM FAM-probe or 0.31 nM DCN1 and 900 nM total probe (100 nM FAM-labeled plus 800 nM unlabeled). The TR-FRET 113335841422 CENC-005 / 01WO 360899-2046ratio between Tb-DCN1 and the FAM-labeled probe was measured in a 384-well opti-plate (Perkin Elmer) using a plate reader (BMG) at 1, 5, and 24 hrs after treatment with compound (final DMSO concentration of 0.1%). The ratio was normalized to the high (DCN1 and FAM-probe) and low (DCN1 and no probe) controls for a readout of % activity (= 100* (x - low) / (high - low).Example 7: Intact Protein MS Analysis with the RapidFire-TOF system
[0474] DCN1 protein, His-TEV-DCN1, were expressed in E. coli. The His-tagged protein was first purified with an Ni-NTA column. The His-tag was cleaved using His-tag TEV protease and the His-tags were removed using a second Ni-NTA column. Protein purity was verified with SDS-PAGE and intact MS. DCN1 was dissolved in a buffer containing 25 mM Tris-HCI, 200 mM NaCl, and 1 mM DTT at 400 nM. 11 concentrations of compounds were added to the DCN1 solution and incubated at room temperature for 3 hours, unless otherwise specified. The reaction plates were quenched by adding 0.2% formic acid. Quenched assay plates were analyzed with an Agilent RapidFire 360 system connected to an Agilent 6545 Q-TOF mass spectrometer equipped with an AJS source. 10 pL of sample volume was loaded onto a custom packed cartridge (4 pL, PLRP-S 30 µm / 1000Å pore; Optimize Technologies) with loading buffer (ddH₂O with 0.09% (vol / vol) formic acid and 0.01% (vol / vol) trifluoroacetic acid; 1.25 ml / min) for 6 seconds before being eluted directly into the mass spectrometer in elution buffer (80% acetonitrile with 0.09% (vol / vol) formic acid and 0.01% (vol / vol) trifluoroacetic acid; 0.5 ml / min) for 7 seconds. The cartridge was re-equilibrated with loading buffer for 1 second before collection of the next sample. The Q-TOF was operated in TOF-only positive ionization mode set to the following parameters: Gas Temp = 350 C, Drying Gas = 7 l / min, Nebulizer = 50 psi, Sheath Gas Temp = 400 C, Sheath Gas Flow = 12 l / min, Vcap = 4000 V, Nozzle Voltage = 1000 V, Fragmentor = 125 V, Skimmer = 65 V and Oct 1 RF Vpp = 750V. Raw MS data files were deconvoluted and analyzed using the Agilent MassHunter Bioconfirm software package to identify both parent protein and expected compound adduct mass signatures.Example 8: Induction of fetal hemoglobin in a humanized mouse model
[0475] A humanized mouse model was developed in which the clinical standard of care treatment, hydroxyurea (HU), was demonstrated to induce both fetal hemoglobin mRNA (HBG1) and protein (HbF). An exemplified compound, Compound I, was shown to achieve in vivo serum 114335841422 CENC-005 / 01WO 360899-2046exposure levels in wild-type mice predicted to be sufficient for fetal hemoglobin induction. Upon treatment with Compound I, an induction of both HBG1 mRNA and HbF protein was observed in human erythroid progenitor cells in the humanized mouse model. The ratio of fetal HBG1 hemoglobin mRNA to adult hemoglobin mRNA (HBB) induced by Compound I is significantly greater than HU standard of care.
[0476] Results: To evaluate induction of target cell activity in the bone marrow, a humanized mouse model was developed. This model entails the reconstitution of human hematopoietic progenitor cells within the bone marrow of immunodeficient nonirradiated NOD. Cg-Kitw'41JTyr+PrkdcscidI Il2rgtm1Wjl / ThomJ (NBSGW) strain recipient mice. These mice are competent to engraft and differentiate human erythroid progenitor cells that express human adult hemoglobin mRNA and protein subunits within bone marrow. Notably, this model does not permit the final differentiation of erythroid precursor cells into enucleated circulating erythrocytes and, hence, precludes the evaluation of human hemoglobin in circulating blood. Hydroxyurea, a small molecule used as the standard of care in the treatment of Sickle Cell Disease, significantly induces fetal hemoglobin mRNA and protein within the human progenitor cell compartment providing confidence in translational relevance of the model.
[0477] In preliminary pharmacokinetic studies, dosing of Compound I at 25 and 100 mg / kg was found to achieve serum concentrations equivalent to or greater than that required to inhibit DCN-1. Based on these exposure results, humanized mice were treated with either the clinical standard of care compound, hydroxyurea (50 mg / kg; bid), or Compound I, at 25 and 100 mg / kg (bid), by oral gavage over a three-week period. At the end of the treatment period, bone marrow was harvested for flow cytometry, as well as for assessment of HbF protein and fetal hemoglobin (HBG1) mRNA levels. Levels of both HbF protein and HBG1 mRNA were normalized to the percentage of human erythroid progenitor cells in the bone marrow of each mouse as determined by immunofluorescence staining for human Glycophorin A cell membrane expression. When compared to vehicle-treated mice, Compound I at both the 25 and 100 mg / kg (bid) dosing regimens significantly increases HbF protein levels in bone marrow as detected by AlphaLISA™ (FIG.23 A). Notably, no significant difference in HbF protein levels was observed between mice treated with the 25 and the 100 mg / kg doses, suggesting that 25 mg / kg may represent a maximally effective dose. Similarly, detection of HBG1 mRNA by Nanostring™ demonstrated enhanced transcript levels following treatment with both doses of Compound I (FIG. 23B). In addition,115335841422 CENC-005 / 01WO 360899-2046relative levels of fetal hemoglobin to those of potentially sickling-prone adult hemoglobin (HBB) was assessed. At both doses, Compound I induced significantly greater ratios of HBG1 to HBB mRNA than did hydroxyurea (FIG. 23 C).
[0478] Results from this study support the hypothesis of DCN-1 as a potentially important modulator of fetal hemoglobin and demonstrate that one such covalent DCN-1 inhibitor, Compound I, shows promising activity in a relevant in vivo model.Materials and Methods: NBSGW Humanized mouse model for HbF inductionAnimals
[0479] Female, 6-week-old NOD. Cg-Kitw'41JTyr+PrkdcscidIl2rgtm1Wjl / ThomJ (NBSGW) mice (Jackson Laboratory strain #02662) were used for these studies. The mice were acclimatized to laboratory conditions for 5 days prior to inoculation.Cell Preparation and Inoculation
[0480] GCSF-mobilized human CD34+ cells were removed from liquid nitrogen storage, thawed in a 37°C water bath and transferred quickly into a 50 mL conical tube. Cryovial was rinsed once with thaw buffer, 0.1% BSA in phosphate buffered saline (PBS), and buffer was transferred and combined with the original contents in the 50 mL conical tube. Next, doubling volumes of thaw buffer was added to the conical and gently swirled for ~30 seconds to one minute until the volume in the conical was 32 mL. Cells and buffer were centrifuged at 300G for 8 minutes, and the supernatants were aspirated. Cells were counted by resuspending in 1 mL of thawing buffer per million of cells to a target concentration range of 0.5 to 2M / ml and counting with AOPI (1:1) on a luna cell counter to confirm the concentration of cells / mL. The cell concentration was adjusted to 3x106cells / ml. For each mouse, 300 thousand cells in 0.1 ml were injected into the tail vein with a 25-gauge needle.
[0481] Engraftment Checkpoint
[0482] On day 56 after human cell adoptive transfer, whole blood was collected from each mouse by submandibular bleed and a 100µL sample of EDTA whole blood was transferred to a 2ml tube containing 1.8 mL ACK Lysing Buffer at room temperature (RT), and then inverted to mix. Samples were incubated at RT for 15 min in the dark to lyse. After lysis, samples are centrifuged at 500xg for 5 minutes at RT to enable supernatant decanting. Remaining cells were washed with 1 mL of PBS-0.5% BSA and centrifuged at 500xg for 5 minutes at 4°C. Supernatant was decanted and cells were stained with leukocyte markers (human and mouse CD45 antibodies;116335841422 CENC-005 / 01WO 360899-2046BD347464, BD557659) to confirm human cell engraftment. Mice having less than one percent, or greater than ten percent, human CD45 positive cells were excluded from the subsequent study. Remaining mice were then randomized into treatment groups based on percentage of human cell engraftment. Each treatment group included 10-11 mice.Compound Administration
[0483] Compound I was dissolved in a 5% Cremophor RH40, 20% hydroxypropyl-β-cyclodextrin solution. Hydroxyurea was solubilized in PBS. Formulations were prepared fresh daily. Commencing on day 84 post human cell engraftment, mice were treated by oral gavage with either Compound I, hydroxyurea or their respective vehicles, for a period of three weeks using either once daily (QD) or twice daily (BID) dosing regimens. Mice were monitored daily for body weight and condition. Mice which lost greater than 20% body weight prior to study completion were removed from the study and humanely euthanized.Bone Marrow Collection and Analysis
[0484] After 21 days of dosing, all mice were euthanized and prepared for bone marrow collection. Both femurs were collected from each mouse by first disinfecting the skin with 70% ethanol and then, using a pair of scissors and forceps, removing the limb and dissecting the muscles both above and below the femur and tibia, taking care not to damage the bone. Femurs were placed in PBS-0.5%BSA-2mM EDTA-containing tubes on ice during collections. Each femur was flushed to extract marrow with 1 mL of 0.5% BSA-PBS 2mM EDTA using a 27 gauge needle a total of three times. Extracted cells were counted and aliquoted to prepare for analysis. For detection of fetal (HbF) and adult (HbB) hemoglobin protein, bone marrow cells expressing human glycophorin A (GlyA) were isolated by flow cytometry and frozen. Frozen cells were submitted to the HPLC core facility at the University of Alabama at Birmingham for analysis. For assessment of fetal hemoglobin mRNA (HBG1) expression by Nanostring™, whole RBC-lysed bone marrow cells were used. Resulting mRNA expression levels were normalized based on the percentage of GlyA positive cells in the bone marrow of each mouse.Example 9: HBG1 Nanostring Assay
[0485] A Nanostring Assay was performed to evaluate the ability of the compounds to induce expression of the fetal hemoglobin gene HBG1 in cells. The data are shown as EC50, with stronger inducers having a lower EC50 value and higher YMax.117335841422 CENC-005 / 01WO 360899-2046CD34 culture and sample preparation
[0486] Mobilized peripheral blood (mPB) derived CD34+ hematopoietic stem and progenitor cells (HSPCs) were thawed and plated at 500,000 cells / ml on day of cell thaw (day -4) in StemSpan (StemCell Tech, 09600) complete media supplemented with 1% StemSpan CC100 (StemCell Tech, 02690), and 0.2% human recombinant thrombopoietin (StemCell Tech, 02822). Forty eight hours later (day -2), the cells were passaged at a density of 200,000 cells / ml (lOOul / well in 96well culture plate) in complete expantion media. The cells were plated at 200,000 cells / ml on day 0 and day 3, 400,000 cells / ml on day 5 in phase 1 erythroid differentiation containing StemSpan with 2.5U / mL of EPO (R& D systems, 287-TC-500), 0.5 mg / mL of Holo-Transferrin (Sigma, T0665-500MG), lx Glutamine (Gluta-Max) (Gibco, 35050-061), 5 pL / mL Lipid Mixture (Sigma, L0288-100ML), 50 ng / mL SCF (R& D Systems, 255-SV-050), 10 ng / mL IL-3 (R& D Systems, 203-IL010) and 10 ng / mL Insulin (Sigma, I9278-5ML) all 200pl per well in 96 well culture plate. Cells were then passaged at 500,000 cells / ml and 200pl per well on day 7 in phase 2 Erythroid differentiation (Phase 1 erythroid differentiation removing IL-3) until collection day (Day 10). The culture conditions were used for both control DMSO as well as experimental treatments.
[0487] For all cell passagings, cells were centrifuged at 300g for 8 minutes at room temperature and cell number were normalized by MANTIS and Integra VIAFLO 384. All the compounds are diluted in DMSO and added to complete media by Formulatrix FAST and mixed starting from day -2. Cells were counted by Luna cell counter with AOPI Staining Solution (Nexcelom Bioscience, CS2-0106-25mL) on day-2. Cells were counted by BD FACSCelesta Flow Cytometer with CountBright™ Plus Absolute Counting Beads (Thermal Fisher Scientific, C36995) and SYTOX AADvanced™ Ready Flow™ Reagent (Invitrogen, R37173) for other passages. Cells were cultured at 37°C and 5% CO2. DMSO concentration was kept at 0.1% to minimize any effects to the cells by the vehicle. Due to the insolubility of positive control, it was freshly made every 6 weeks with stock concentration at 3mM while stock concentration for other compounds are lOmM. Compound plates were kept at room temperature to protect from light to avoid multiple freeze and thaw cycle.
[0488] On the collection day (DaylO), 100K cells were collected and stored at -80 °C. For direct hybridization for Nanostring, 100K cell pellet was lyzed in 25 pL of RLT (QIAGEN, 79216)118335841422 CENC-005 / 01WO 360899-2046with lx P-Mercaptoethanol (Gibco, 21985-023) and shaked at 300-500 RPM for 5 minutes at room temperature. Cell lysate was stored in -80°C after lysis.Hybridization and imaging
[0489] All hybridizations were done in a total volume of 15 pL (3 pL of RNA lysate added to master mix of 12 pL probe A / B, capture probe / reporter probes, proteinase K and attenuation oligos suspended in hybridization buffer). Samples were hybridized at 67 °C for 22 hr. Following hybridization, the tripartite complexes were purified, immobilized by nCounter Prep Station and imaged by Digital Analyzer (nCounter MAX / FLEX Analysis System), to generate digital counts of barcodes corresponding to each target in the multiplexed reaction. Labeled barcodes obtained from unamplified extracts were counted at 555 images or field of view (FOV). The barcode counts for each sample were recorded in Reporter Code Count (RCC) files that are imported into nSolver analysis software (provided with CodeSet by NS) for quality control evaluation.Quality control (QC) metrics and data analysis
[0490] The quality control (QC) metric included limit of detection QC by checking for wells with less than 100 total counts for positive controls.
[0491] Hybridization signals were normalized against the ERCC positive controls and CodeSet Content (housekeeping gene). Briefly, this involved first calculating a sample-specific scaling factor by calculating arithmetic mean of geomeans of all ERCC positive controls with counts more than zero in all samples. Then this arithmetic mean was divided by the geometric mean of each lane to generate a lane-specific normalization factor. All negative controls and target-specific signal values were then normalized by multiplying counts values with their samplespecific scaling factor. The acceptable range for scaling factors is 0.3-3.0. For housekeeping gene(s) normalization, first calculating the arithmetic mean of geometric means of selected housekeeping genes for each lane for all samples. Then this arithmetic mean was divided by the geometric mean of each lane to generate a lane-specific normalization factor followed by multiplying the counts for every gene by its lane-specific normalization factor. The acceptable range for housekeeping genes normalization scaling factors is 0.1-10.
[0492] HBG1 dose-response curves, %Emax and EC50 values were generated by Dotmatic with setting control DMSO as 0% and biology control as 100%. When reporting EC50, Top will be fixed as 100% for compounds with observed Emax>=50%. For compounds with observed Emax<50% is reporting either inactive or max observed Emax.119335841422 CENC-005 / 01WO 360899-2046
[0493] Compounds with an EC50 less than or equal to 100.0 nM are designated as “+++”. Compounds with an EC50greater than 100.0 nM and less than or equal to 1000.0 nM are designated Compounds with an EC50 greater than 1000.0 nM are designated asThe results are shown in Table 1-1 below.
[0494] The Nanostring Ymax observed data is relative to a control compound (Cl shown in Example 17), presented in % which is shown in Table 1-1 below. Compounds with a Nanostring Ymax greater than or equal to 0.0 and less than or equal to 50.0 are designated asCompounds with a Nanostring Ymax greater than 50.0 and less than or equal to 100.0 are designated asCompounds with a Nanostring Ymax greater than 100.0 are designated as “+++.” ND means not determined.Table 1-1 HBG1 Nanostring AssayExample 10: AlphaLISA Assay
[0495] An AlphaLISA assay was performed to evaluate the ability of the compounds to suppress neddylation, which is downstream from DCN-1 and DCN-2. A stronger inhibition of DCN-1 and DCN-2 is expected to result in a suppression of neddylation as shown by a lower AlphaLISA signal. The AlphaLISA assay for detecting Cullin-3 (CUL3) neddylation was performed according to manufacturer instructions (Revvity, Hopkinton, MA). Briefly, TF1 cells (ATCC) were plated in Iscove’s Modified Dulbecco’s Medium (IMDM) without supplements in 384-well plates. These cells were treated with 11 concentrations for 3 hours before lysing them with AlphaLISA lysis buffer, 5X (Revvity). To detect the level of CUL3 neddylation, biotinylated anti-NEDD8 antibody, was added followed by AlphaLISA Acceptor beads conjugated with anti-CUL3 antibody. After overnight incubation, Streptavidin-coated Alpha Donor beads were added and incubated for 1 hour. The AlphaLISA signal was then read on a VICTOR Nivo Multimode Microplate Reader (Revvity, Hopkinton, MA). The positive control was 1 pM DL1548, which is reported to reduce CUL3 neddylation, also referred to as C-l in Example 17 (Zhou et al. Nature Comm. 2021). The neddylation signal was normalized such that the percent inhibition is 0% for120335841422 CENC-005 / 01WO 360899-2046vehicle control and 100% for positive control. The dose-response curves were fitted with the Hill equation to obtain IC50 values (Graphpad Prism).
[0496] Compounds with an IC50 less than or equal to 100.0 nM are designated as “+++”. Compounds with an IC50 greater than 100.0 nM and less than or equal to 1000.0 nM are designated Compounds with an IC50 greater than 1000.0 nM are designatedThe results are shown in Table l-II below.Table 1-11. AlphaLlSA AssayExample 11: HbF HPLC Cell Culture and Analysis[00497J A Cell Culture Assay was performed to evaluate the ability of compounds to induce fetal hemoglobin in a cell culture. The amount fetal hemoglobin protein induced was measured by HPLC.
[0498] Cell culture began on Day -4 (thaw day). Thaw buffer was prepared by sterile filtering 6 mL of Human Serum Albumin and 144 mL of PBS to make sterile 1% I / PBS. Cells were removed from liquid nitrogen storage and mostly thawed in a 37°C water bath. Once the ice in the cryovials was melted, cells were transferred quickly into a 50 mL conical tube. Cryovial was rinsed once with thaw buffer and buffer was transferred over to the conical tube as well. Next, doubling volumes of thaw buffer was added to the conical and gently swirled for ~30 seconds to one minute (for example: 2 mL was added and swirled, then 4 mL, then 8 mL, and so on) until the volume in the conical is 32 mL. Cells and buffer were centrifuged at 300G for 8 minutes, and the supernatant was aspirated. Another 32 mL of thaw buffer was added slowly, swirling the tube. The tube was again centrifuged at 300G for 8 minutes and the supernatant was aspirated. Cells were counted by resuspending in 1 mL of expansion media and counting with AOPI to determine the concentration of cells / mL.
[0499] On day 2, Passage & Treatment Day, each cell culture well was counted. Next fresh CD34 Expansion Media was made which contained StemSpan SFEM, CC100 and TPO all from StemCell technologies. Appropriate volume of cells was collected, centrifuged at 300g and resuspended in fresh media. Cells were plated in treatment format at a density of 200,000 cells / ml,121335841422 CENC-005 / 01WO 360899-204625,000 cell s / well. Finally, they were treated with test compounds as well as positive and negative controls.
[0500] On Days 0, 3 & 5 the same process was carried out. First, each cell culture well was counted. Next Phase 1 Erythroid Differentiation Media was freshly made, which contained StemSpan SFEM, 2.5U / ml EPO, 0.5mg / ml Holo-TF, lx Glutamax, 5pl / ml chemically defined lipid mixture, lOng / ml insulin, 50ng / ml SCF, lOng / ml IL-3. Appropriate volume of cells was collected, centrifuged at 300g and resuspended in fresh media. Cells should now be in fresh wells at a density of 100,000 cells / ml. 60,000 cells, 60,000 cells and 100,000 cells for days 0, 3, 5 respectively. Finally, fresh compound was added to each well at each timepoint (Days 0, 3 & 5).
[0501] On Day 7 media and cell culture density changes. Each cell culture well was counted. Next, Phase 2 Erythroid Differentiation Media was freshly made, which contains StemSpan SFEM, 2.5U / ml EPO, 0.5mg / ml Holo-TF, lx Glutamax, 5pl / ml chemically defined lipid mixture, lOng / ml insulin, 50ng / ml SCF. Appropriate volume of cells was collected, centrifuged at 300g and resuspended in fresh media. Cells were plated in fresh wells at a density of 500,000 cells / ml, 300,000 cells / well. Finally, fresh compound was added to each well at Day 7 timepoint.
[0502] On Day 10 media formulation is once again changed. Each cell culture well was counted. Fresh Phase 3 Erythroid Differentiation Media was made which contains StemSpan SFEM, 2.5U / ml EPO, 0.5mg / ml Holo-TF, lx Glutamax, 5pl / ml chemically defined lipid mixture, lOng / ml insulin. Appropriate volume of cells was collected, centrifuged at 300g and resuspended in fresh media. Cells were plated in fresh wells at a density of 500,000 cells / ml, 500,000 cells / well. Finally, fresh compound was added to each well at Day 10 timepoint.
[0503] On Day 12 the cell density is once again changed. Each cell culture well was counted. Fresh Phase 3 Erythroid Differentiation Media was made. Appropriate volume of cells was collected, centrifuged at 300g and resuspended in fresh media. Cells were plated in fresh wells at a density of 1,000,000 cells / ml, 1,000,000 cells / well. Finally fresh compound was added to each well.
[0504] Day 14 (18thday of experiment) refers to the terminal day of culture. Each cell culture well was counted. Next between 150K and 650K cells were placed in a uniquely labeled 1.5ml standard tube. Cells were centrifuged in media at 300g for 8 minutes, then as much of the media as possible was removed without disturbing the pellet. The pellet was washed with 500pl dPBS and once again spun at 300g for 8 minutes. As much of the supernatant as possible was removed 122335841422 CENC-005 / 01WO 360899-2046without disturbing the pellet and immediately frozen at -80°C. Cell pellets are now ready for HPLC lysis and analysis.
[0505] All centrifugations were run at 300x G for 8 minutes at room temperature. Cells were cultured in a standard incubator at 37°C and 5% CO₂. Cell culture plates were either a 96-well treated plate for Day -2 or 24-well cell culture treated plates for day 0 through 14. Culture wells were counted using a 1:1 mix of cells and AOPI. Counting was done on Nexcelom Cellaca.
[0506] Methods for assaying %HBF and %F+ cells are well known in the art. Non-limiting examples include high performance liquid chromatography (HPLC), flow cytometry, or ionexchange chromatography. The HbF% is usually measured by HPLC. The flow cytometry assay, the standard clinical method, may be used for assaying %F+ cells by immunofluorescent techniques. Tn addition to flow cytometry, ion-exchange chromatography may be used to measure the fraction HbF relative to all other hemoglobin (HbF / HbA+HbF).
[0507] Compounds with an EC50 less than or equal to 50.0 nM are designated as “+++”. Compounds with an EC50 greater than 50.0 nM and less than or equal to 200.0 nM are designated Compounds with an EC50 greater than 200.0 nM are designatedThe results are shown in Table l-III below.
[0508] The Hemoglobin HPLC Ymax observed data is relative to a control compound, presented in % which is shown in Table 1 -III below. Compounds with a Hemoglobin HPLC Ymax greater than or equal to 0.0 and less than or equal to 65.0 are designated as “+.” Compounds with a Hemoglobin HPLC Ymax greater than 65.0 and less than or equal to 100.0 are designated as Compounds with a Hemoglobin HPLC Ymax greater than 100.0 are designated as “+++.”Table 1-IIL HbF HPLC Cell Culture AssayExample 12: TR-FRET assay
[0509] A TR-FRET assay was performed to evaluate the ability of the compounds to bind the DCN-1 protein.
[0510] The TR-FRET assay was designed following the Scott et al. protocol (Scott et al., Nat Chem Biol. 2017 August; 13(8): 850-857. Doi:10.1038 / nchembio.2386). The recombinant form 123335841422 CENC-005 / 01WO 360899-2046of the DCN1 (DCUND1) protein PONY domain was produced using an E.coli expression system at Viva Biotech (China). The DCN1 protein was biotinylated (EZ sulfo-NHS-LC-biotin; Thermofisher) for labeling with streptavidin terbium (Tb) cryptate in the reaction. The probe was changed to a non-covalent DCN1 inhibitor labeled with carboxyfluorescein (FAM; Zhou et al., Nat Commun. 2017; 8: 1150. Doi: 10.1038 / s41467-017-01243-7). Buffer conditions were modified to enhance protein stability by exchanging Tween20 for TritonX and increasing NaCl to 200 mM. The compounds were screened against 5 nM DCN1 and 20 nM FAM-probe or 0.31 nM DCN1 and 900 nM total probe (100 nM FAM-labeled plus 800 nM unlabeled). The TR-FRET ratio between Tb-DCN1 and the FAM-labeled probe was measured in a 384-well opti-plate (Perkin Elmer) using a plate reader (BMG) at 1, 5, and 24 hrs after treatment with compound (final DMSO concentration of 0.1%). The ratio was normalized to the high (DCN1 and FAM-probe) and low (DCN1 and no probe) controls for a readout of % activity (= 100* (x - low) / (high - low). The % activity across concentrations is used to determine the IC50.
[0511] Compounds with an ICso less than or equal to 200.0 nM are designated as “++++”. Compounds with an ICso greater than 200.0 nM and less than or equal to 1000.0 nM are designated as “+++”. Compounds with an ICso greater than 1000.0 nM and less than or equal to 3000.0 nM are designated as “++”. Compounds with an ICso greater than 3000.0 nM are designated as “+”. The results are shown in Table 2 below.Table 2. TR-FRET AssayExample 13: Intact Protein MS Analysis with the RapidFire-TOF system[00512J An MS assay was performed to evaluate the ability of the compounds to covalently modify DCN-1.
[0513] DCN1 protein, His-TEV-DCN1, were expressed in E. coli. The His-tagged protein was first purified with an Ni-NTA column. The His-tag was cleaved using His-tag TEV protease and the His-tags were removed using a second Ni-NTA column. Protein purity was verified with SDS-PAGE and intact MS. DCN1 was dissolved in a buffer containing 25 mM Tris-HCI, 200 mM124335841422 CENC-005 / 01WO 360899-2046NaCl, and 1 mM DTT at 400 nM. 11 concentrations of compounds were added to the DCN1 solution and incubated at room temperature for 3 hours, unless otherwise specified. The reaction plates were quenched by adding 0.2% formic acid. Quenched assay plates were analyzed with an Agilent RapidFire 360 system connected to an Agilent 6545 Q-TOF mass spectrometer equipped with an AJS source. 10 pL of sample volume was loaded onto a custom packed cartridge (4 pL, PLRP-S 30 µm / 1000Å pore; Optimize Technologies) with loading buffer (ddH₂O with 0.09% (vol / vol) formic acid and 0.01% (vol / vol) trifluoroacetic acid; 1.25 ml / min) for 6 seconds before being eluted directly into the mass spectrometer in elution buffer (80% acetonitrile with 0.09% (vol / vol) formic acid and 0.01% (vol / vol) trifluoroacetic acid; 0.5 ml / min) for 7 seconds. The cartridge was re-equilibrated with loading buffer for 1 second before collection of the next sample. The Q-TOF was operated in TOF-only positive ionization mode set to the following parameters: Gas Temp = 350 C, Drying Gas = 7 l / min, Nebulizer = 50 psi, Sheath Gas Temp = 400 C, Sheath Gas Flow = 12 l / min, Vcap = 4000 V, Nozzle Voltage = 1000 V, Fragmentor = 125 V, Skimmer = 65 V and Oct 1 RF Vpp = 750V. Raw MS data files were deconvoluted and analyzed using the Agilent MassHunter Bioconfirm software package to identify both parent protein and expected compound adduct mass signatures.
[0514] The MS data is presented in % adduct formation which is shown in Table 3 below. Compounds with an MS Emax % adduct formation greater than or equal to 0.0 and less than or equal to 30.0 are designated as “+.” Compounds with an MS Emax % adduct formation greater than 30.0 and less than or equal to 80.0 are designated as “++.” Compounds with an MS Emax % adduct formation greater than 80.0 and less than or equal to 100.0 are designated as “+++.”Table 3. Intact Protein MS AnalysisExample 14: Materials and Methods: NBSGW Humanized mouse model for HbF induction
[0515] Animals125335841422 CENC-005 / 01WO 360899-2046
[0516] Female, 6-week-old NOD. Cg-KitW-41 J Tyr+ Prkdcscid T12rgtml Wjl / ThomJ (NBSGW) mice (Jackson Laboratory strain #02662) were used for these studies. The mice were acclimatized to laboratory conditions for 5 days prior to inoculation.
[0517] Cell Preparation and Inoculation
[0518] GCSF-mobilized human CD34+ cells were removed from liquid nitrogen storage, thawed in a 37C water bath and transferred quickly into a 50 mL conical tube. Cryovial was rinsed once with thaw buffer, 0.1% BSA in phosphate buffered saline (PBS), and buffer was transferred combined with the original contents in the 50 mL conical tube. Next, doubling volumes of thaw buffer was added to the conical and gently swirled for ~30 seconds to one minute until the volume in the conical was 32 mL. Cells and buffer were centrifuged at 300G for 8 minutes, and the supernatants were aspirated. Cells were counted by resuspending in 1 mL of thawing buffer per million of cells to a target concentration range of 0.5 to 2M / ml) and counting with AOPI (1: 1) on a luna cell counter to confirm the concentration of cells / mL. The cell concentration was adjusted to 3x106cells / ml. For each mouse, 300 thousand cells in 0.1 ml were injected into the tail vein with a 25 -gauge needle.
[0519] Engraftment Checkpoint
[0520] On day 56 after human cell adoptive transfer, whole blood was collected from each mouse by submandibular bleed and a 100 pL sample of EDTA whole blood was transferred to a 2 ml tube containing 1.8 mL ACK Lysing Buffer at room temperature (RT), and then inverted to mix. Samples were incubated at RT for 15 min in the dark to lyse. After lysis, samples were centrifuged at 500xg for 5 minutes at RT to enable supernatant decanting. Remaining cells were washed with 1 mL of PBS-0.5% BSA and centrifuged at 500xg for 5 minutes at 4C. Supernatant was decanted and cells were stained with leukocyte markers (human and mouse CD45 antibodies; BD347464, BD557659) to confirm human cell engraftment. Mice having less than one percent, or greater than ten percent, human CD45 positive cells were excluded from the subsequent study. The remaining mice were then randomized into treatment groups based on percentage of human cell engraftment. Each treatment group included 10-11 mice.
[0521] Compound Administration
[0522] Compound I, Compound Rl, Compound R2, or Compound R3 was dissolved in a 5% Cremophor RH40, 20% hydroxypropyl- beta-cyclodextrin solution. Hydroxyurea was solubilized in PBS. Formulations were prepared fresh daily. Commencing on day 84 post human cell 126335841422 CENC-005 / 01WO 360899-2046engraftment, mice were treated by oral gavage with either Compound I, Compound R1, Compound R2, or Compound R3 hydroxyurea or their respective vehicles, for a period of three weeks using either once daily (QD) or twice daily (BID) dosing regimens. Mice were monitored daily for body weight and condition. Mice which lost greater than 20% body weight prior to study completion were removed from the study and humanely euthanized.
[0523] Compound R1 is N-((4S,5S)-3-((lR,3S,5R)-3-cyano-2-azabicyclo[3.1.0]hexane-2-carbonyl)-4-cy cl opropyl-7-ethyl-6-oxo- 1 -(tetrahy dro-2H-pyran-4-yl)-4, 5,6, 7 -tetrahydro- 1 H-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide, which is compound 1-256 in the International Patent Application No. PCT / US2024 / 054133 (the ‘133 application, the entirety of which is incorporated herein by reference).Compound R1
[0524] Compound R2 is N-((4S,5S)-3-((lR,3S,5R)-3-cyano-2-azabicyclo[3.1.0]hexane-2-carbonyl)-4-cyclopropyl-7-ethyl-6-oxo-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-ethylbenzamide, which is compound 1-552 in the International Patent Application No. PCI7US2024 / 054133 (the ‘133 application, the entirety of which is incorporated herein by reference).Compound R2127335841422 CENC-005 / 01WO 360899-2046
[0525] Compound R3 is N-((4S,5S)-3-((S)-2-cyanopiperazine-l-carbonyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide, which is compound 1-363 in the International Patent Application No. PCT / US2024 / 054133 (the ‘133 application, the entirety of which is incorporated herein by reference).Compound R3
[0526] Bone Marrow Collection and Analysis
[0527] After 21 days of dosing, all mice were euthanized and prepared for bone marrow collection. Femurs were collected from each mouse by first disinfecting the skin with 70% ethanol and then, using a pair of scissors and forceps, removing the limb and dissecting the muscles both above and below the femur and tibia, taking care not to damage the bone. Femurs were placed in PBS-0.5%BSA-2mM EDTA-containing tubes on ice during collections. Each femur was flushed to extract marrow with 1 mL of 0.5% BSA-PBS 2mM EDTA using a 27 gauge needle a total of three times. Extracted cells were counted and aliquoted to prepare for analysis. Whole bone marrow cells were used to analyze the levels of HbF protein and gene levels (HBG1 and HBB). HbF protein levels were analyzed by flow cytometry (%F-cells) or by AlphaLisa. HbF gene (HBG1) expression was analyzed by Nanostring. (The details for the Nanostring and AlphaLisa assays are provided in the preceding examples). An antibody against Glycophorin A (GlyA), a marker for human red blood cells, was used to purify GlyA positive cells by magnetic sorting. Cell lysate from GlyA positive cells was used for HPLC analysis and percentage of fetal HbF and adult HbB was calculated.
[0528] The data can be found in FIG. 23A-23C, FIG. 24, FIG. 25A-25C, FIG. 26A-26B, FIG.27, FIG. 32A-32B, FIG. 33A-33C, FIG. 34A-34B and FIG. 35A-35C.128335841422 CENC-005 / 01WO 360899-2046Example 15: Induction of Fetal Hemoglobin by Hydroxyurea and Compound I in Human CD34+ Cell Reconstituted Immunodeficient Mice and Analysis of Hypothesized Synergistic Effect between Hydroxyurea and Compound I
[0529] In vivo Pharmacology Report
[0530] Study Overview
[0531] The clinical standard of care in the treatment of sickle cell disease (SCD), hydroxyurea (HU), ameliorates symptoms by increasing the levels of non-sickling fetal hemoglobin within the erythroid cells of patients. However, HU is often associated with adverse reactions due to its cytotoxic nature. Hence, it remains of high interest to identify alternative treatments for SCD employing less toxic mechanisms of action.
[0532] The current study was undertaken to determine the effect of Compound I, when treated in combination with HU, on levels of HBG1 and HbF induction in the humanized mice. Following a three-week treatment period, it was observed that both fetal hemoglobin mRNA and protein were greater in mice treated with the Compound I / HU combination than those treated with either of these compounds alone.
[0533] Experimental Design
[0534] Humanized mouse model
[0535] The model employed for assessment of induction of fetal hemoglobin by Compound I and hydroxyurea involved the use of human stem cell-reconstituted immunodeficient mice. Specifically, three hundred thousand human CD34-positive cells from G-CSF-mobilized human peripheral blood monocytes (PBMCs) were injected into the tail veins of NOD. Cg-KitW-41J Tyr + Prkdcscid I12rgtmlWjl / ThomJ (NBSGW) mice (J AX Strain No. 026622) on day 0. Twelve weeks later, mice were checked for human cell engraftment by sampling PBMCs from blood taken from the tail vein and staining for expression of murine or human CD45 by flow cytometry. After removing from the study those mice having greater than 10% human cells or less than 1% human cells in their peripheral blood, the remaining mice were randomized into treatment groups based on the human cell percentage. Thirteen weeks post engraftment, treatment was initiated with either hydroxyurea, Compound I, or a combination of both compounds. Hydroxyurea was formulated in PBS (pH 7.4) and Compound I was formulated in 5% Cremophor RH 40 / 20% hydroxypropyl-P-cyclodextrin (Crem-CD) daily. Mice received either PBS or hydroxyurea each morning and 129335841422 CENC-005 / 01WO 360899-2046Compound I or Crem-CD each afternoon by oral gavage. After twenty days of daily treatment, the mice were euthanized and their bone marrow (femurs, tibia and critae) were individually collected for subsequent analysis.
[0536] HBG1 mRNA induction
[0537] Bone marrow cell pellets (total 500K cells) were lysed in 20 pL of RLT (QIAGEN, 79216) with lx |3-mercaptoethanol (Gibco, 21985-023) and H2O followed by hybridizations. Hybridizations were done in a total volume of 15 pL [3 pL of RNA lysate added to master mix of 12 pL probe A / B (purchased from IDT), capture probe / reporter probes (NanoStringTM, XT TagSet-24, 121000602), proteinase K (Fisher Scientific, EO0491) and H2O suspended in hybridization buffer]. Samples were hybridized at 65 °C for 22 hr. Following hybridization, the tripartite complexes were purified, immobilized by nCounter Prep Station and imaged by Digital Analyzer (nCounter MAX / FLEX Analysis System), to generate digital counts of barcodes corresponding to each target in the multiplexed reaction. Labeled barcodes obtained from unamplified extracts were counted at 555 images or field of view (FOV). The barcode counts for each sample were recorded in Reporter Code Count (RCC) files that are imported into nSolver analysis software (provided with CodeSet by NS) for quality control evaluation.
[0538] Fetal hemoglobin induction
[0539] To assess levels of fetal hemoglobin by AlphaLISA, cells (200k bone marrow cells / well) were lysed by resuspending pellets in 200uL of lysis buffer plus protease inhibitor cocktail (lOOx), mixed well and incubating at room temperature for 30 minutes on the plate shaker @ 300 RPMs. Samples were then diluted 1: 10 in a new 96-well round bottom plate by taking lOuL of lysate and adding 90 uL of AlphaLISA immunoassay buffer. To create the “reaction plate,” 20uL of Acceptor Beads (50 ug / mL final concentration) was added to each well using a multichannel pipet. lOuL of diluted cell lysate was added to the wells and mixed well. 20uL of AlphaLISA immunoassay buffer was added to each well. Biotinylated antibody (final concentration) was then added to each well. The reaction plate on then placed on a plate shaker at 300 rpm for one hour to incubate at room temperature. After the first incubation was complete, 50uL of Donor Beads (80mg / mL final concentration) was added to each well and mixed well, keeping the plate in the dark. The covered plate was placed on a shaker at 350rpm for 30minutes to incubate at room temperature. After incubation, all lOOuL in each to an AlphaPlate in the dark.130335841422 CENC-005 / 01WO 360899-2046Plates were read on a VictorNIVO using the “Alpha 96 Well” setting. Alpha reading was programmed as the default setting with emission at 700 ms and 575 / 110n.
[0540] For determination of HbF levels by high performance liquid chromatography (HPLC), approximately 1 million GlyA-positive sorted cells were placed in 1,5mL Eppendorf tubes, washed once with PBS and supernatant was aspirated. Samples were shipped to Augusta University on dry ice to be analyzed using standard HPLC methods.
[0541] Strati fi cation / Randomizati on
[0542] Following the human cell engraftment check at week 12, mice were randomized into groups based on percentage of human CD45+ cells within the PBMC compartment.
[0543] In-life endpoints
[0544] Individual mouse body weights, general body condition and behavior were assessed daily. Mice losing greater than 20% of their body weight since initiation of treatment were removed from the study and humanely euthanized.
[0545] Organ / tissue / blood collection
[0546] Blood was collected from individual mice by submandibular bleeding on day 21 of dosing. The next day, bone marrow was collected from femurs, tibia and critae from both hind legs of euthanized mice (6 bones per animal) and filtered through a 40 uM cell strainer.
[0547] Formulation
[0548] 30mg Compound I were added to 6mL 10% Cremphor RH40, vortexed and sonicated for 30min. An equal volume of 40% HP- -CD, vortex was added, and the tube was vortexed and sonicated for an additional 10 min. Fresh suspensions were prepared daily.
[0549] Statistical Analysis
[0550] Nanostring data were analyzed using GraphPad Prism software, Version 10.0.0. Normality was tested via a Shapiro-Wilk normality test, and visual inspection of Log transformed data and residuals. If samples are normally distributed, statistical significance was determined using ordinary one-way ANOVA and Tukey’s ad hoc testing versus DMSO was performed. Data without a normal distribution were Log transformed and then analyzed using an ordinary One-way ANOVA and Tukey’s ad hoc testing versus DMSO. Statistical significance was determined for AlphaLISA and HPLC data by non-parametric t-test (Kolmogrov-Smirnov).
[0551] Results
[0552] Induction of HBG1 mRNA131335841422 CENC-005 / 01WO 360899-2046
[0553] The ratio of fetal hemoglobin mRNA to total beta hemoglobin mRNA (HBG1 / (HBG1 plus HBB) was greatly enhanced in mice treated with a combination of HU and Compound I. As shown in FIG. 28, ratio of fetal to adult beta-hemoglobin mRNA in bone marrow cells of humanized mice treated with hydroxyurea and / or Compound I. Treatment combination of HU and Compound I induced a greater ratio of fetal HBG1 to total beta hemoglobin mRNA (fetal HBG1 plus adult-type HBB) than in mice treated with either compound alone. Statistical differences were determined using ordinary one-way ANOVA and Tukey’s ad hoc testing versus DMSO. ns: non statistically significant, ***p<0.001 and ****p<0.0001.
[0554] Induction of Fetal Hemopoietic Protein as determined by HPLC
[0555] To assess levels of fetal hemoglobin using a method orthogonal to AlphaLISA, GlyA-positive bone marrow cells were isolated by flow cytometry and analyzed for hemoglobin type by HPLC. Results shown in FIG. 29 demonstrate that treatment of humanized mice with hydroxyurea or Compound I resulted in a significant increase in the percentage of HbF protein as compared with levels in the vehicle treatment group. Notably, those mice treated with a combination of HU and Compound I demonstrated much higher percentage of HbF than those mice treated with either compound alone.
[0556] Conclusion
[0557] Treatment of humanized mice with hydroxyurea or Compound I did not alter the percentage of bone marrow cells expressing human CD45. In contrast, treatment with HU, either alone or in combination with Compound I, led to a dose-dependent increase in the percentage of bone marrow cells expressing the erythroid cell marker, glycophorin A, suggesting an expansion of this population.
[0558] Within the erythroid progenitor cell compartment, both compounds induced significant levels of fetal hemoglobin in human stem cell -engrafted mice when compared with levels in vehicle-treated mice. The current study extends these findings by demonstrating that treatment with a combination of HU and Compound I greatly enhances HBG1 and HbF induction as compared with those levels in mice treated with either compound alone, as determined by orthogonal methods. Whereas, on a per erythroid progenitor cell basis, Compound I treatment alone induced increased levels of HbF as determined by AlphaLISA, HU treatment mediated an apparent expansion of the erythroid progenitor cell population but with less HbF induction on a per GlyA-positive cell basis. Hence, treatment with a combination of Compound I and HU, leading 132335841422 CENC-005 / 01WO 360899-2046to greatly enhanced HbF levels in the total bone marrow population, may result from both of these mechanisms acting in concert.
[0559] The data from this study demonstrate the capability of Compound I, alone or when combined with HU, to induce high levels of fetal hemoglobin expression and support the potential of this compound to treat patients with Sickle cell disease.
[0560] Analysis of Synergistic Effect
[0561] Introduction
[0562] This study was a pharmacological study to investigate the effect of Compound I on the selective induction of fetal hemoglobin mRNA (HBG1) and fetal hemoglobin protein (HbF) in stem cell-engrafted mice when administered alone or in combination with Hydroxyurea (HU). Mice were randomized to receive either Vehicle, HU 75 mg / kg, or HU 100 mg / kg in the morning, and either Vehicle or Compound I 25 mg / kg in the afternoon.
[0563] Objective
[0564] The objective of this analysis was to assess the presence of a synergistic effect between Compound I and HU administered in combination on levels of HBG1 and HbF induction. The outcomes of interest were: HbF%, HBG1 normalized to GlyA+, HBG1 / (HBG1+HBB), HBG1, AlphaLISA counts, and AlphaLISA counts normalized to GlyA+.
[0565] Methods
[0566] Each outcome of interest was analyzed using a two-factor analysis of variance (ANOVA) with interaction terms. The two factors in the model were level of HU (Vehicle, HU 75 mg / kg, or HU 100 mg / kg) and level of Compound I (Vehicle or Compound 125 mg / kg). Interaction terms between HU and Compound I were included to model the hypothesized synergistic effect. Residual plots and diagnostics were used to assess the validity of the statistical assumptions, namely homoscedasticity (constant variance) and normality of the residuals. When there was clear evidence of heteroscedasticity (non-constant variance) with the residual variance increasing as the predicted value of the outcome increased, a weighted least squares (WLS) ANOVA was utilized in lieu of an ordinary least squares (OLS) ANOVA. When the residuals displayed a significant deviation from normality, the outcome of interest was transformed using an appropriate (e.g., square root) transformation. For each outcome, a synergistic effect between Compound I and a given level of HU was declared statistically significant if the interaction term had a positive estimate and the p-value was <0.05.133335841422 CENC-005 / 01WO 360899-2046
[0567] Results
[0568] HbF %
[0569] HbF % was analyzed using WLS ANOVA to account for heteroscedasticity in the residuals. The interaction terms for HbF % were significant (p<0.0001 and p=0.0033), indicating statistically significant synergistic effects. The estimates and 95% confidence intervals (Cis) for the synergistic effects between Compound I and HU 75 mg / kg and between Compound I and HU 100 mg / kg were 0.86 (0.48, 1.24) and 1.00 (0.35, 1.65), respectively. For example, treating a mouse with Compound I 25 mg / kg alone will on average increase HbF % over vehicle by 1.11. Treating a mouse with HU 75 mg / kg alone will on average increase HbF % over vehicle by 0.59. When a mouse is treated with HU 75 mg / kg in combination with Compound I 25 mg / kg, HbF % will on average increase over vehicle by 2.56 (1.11 + 0.59 + 0.86). Treating mice with HU 75 mg / kg in combination with Compound I 25 mg / kg induces a synergistic effect increasing HbF % by an additional 0.86.
[0570] HBG1 / GlyA+
[0571] HBG1 normalized to GlyA+ (HBG1 / GlyA+) was analyzed using OLS ANOVA without any data transformation. The interaction terms for HBG1 / GlyA+ were significant (p=0.0125 and p=0.0084), indicating statistically significant synergistic effects. The estimates and 95% Cis for the synergistic effects between Compound I and HU 75 mg / kg and between Compound I and HU 100 mg / kg were 619 (140, 1098) and 751 (202, 1300), respectively.
[0572] HBG1 / (HBG1 + HBB)
[0573] The ratio HBG1 / (HBG1 + HBB) was analyzed using WLS ANOVA to account for heteroscedasticity in the residuals. The interaction terms for HBG1 / (HBG1 + HBB) were significant (p<0.0001 and p<0.0001), indicating statistically significant synergistic effects. The estimates and 95% Cis for the synergistic effects between Compound I and HU 75 mg / kg and between Compound I and HU 100 mg / kg were 0.054 (0.036, 0.072) and 0.057 (0.031, 0.082), respectively.
[0574] HBG1
[0575] HBG1 values were first analyzed with OLS ANOVA; however, the residuals displayed a significant deviation from normality. To address non-normality of the residuals, the HBG1 values were transformed using a square root transformation, and the residual diagnostics were examined. The residuals from the transformed data satisfied the assumption of normality, but still displayed 134335841422 CENC-005 / 01WO 360899-2046heteroscedasticity. To account for heteroscedasticity, the square root transformed values were analyzed using WLS ANOVA. The interaction terms for square root of HBG1 were significant (p<0.0001 and p=0.0034), indicating statistically significant synergistic effects. The estimates and confidence intervals were back transformed and presented on the original scale. The estimates and 95% Cis for the synergistic effects between Compound I and HU 75 mg / kg and between Compound I and HU 100 mg / kg were 2113 (609, 4525) and 3268 (395, 8925), respectively.
[0576] AlphaLISA counts
[0577] AlphaLISA counts were analyzed using WLS ANOVA to account for heteroscedasticity in the residuals. The interaction terms were significant (p<0.0001 and p<0.0001), indicating statistically significant synergistic effects. The estimates and 95% Cis for the synergistic effects between Compound I and HU 75 mg / kg and between Compound I and HU 100 mg / kg were 35087 (22257, 47916) and 60983 (41675, 80290), respectively.
[0578] AlphaLISA counts / GlyA+
[0579] AlphaLISA counts normalized to GlyA+ were analyzed with OLS ANOVA and without any data transformation. The interaction terms were not statistically significant at the alpha = 0.05 level. However, the estimated interaction terms were positive, and the p-values were relatively small (p=0.1425 and p=0.0594), suggesting that there may be a synergistic effect. The estimates and 95% Cis for the synergistic effects between Compound I and HU 75 mg / kg and between Compound I and HU 100 mg / kg were 873 (-304, 2050) and 1295 (-54, 2644), respectively.
[0580] Conclusion
[0581] These results when taken together demonstrate strong evidence for the presence of synergistic effects between Compound I and HU 75 mg / kg and between Compound I and HU 100 mg / kg. The point estimates for these effects were consistently positive across all endpoints, and were statistically significant for five of the six total measures (HbF %, HBG1 normalized to GlyA+, HBG1 / (HBG1+HBB), HBG1, and AlphaLISA counts).Example 16: Assay to Measure the Off-Rate of Reversible Covalent Molecules Description
[0582] A TR-FRET assay was performed to classify the compounds as an irreversible covalent binder, a reversible covalent binder, or a reversible binder.135335841422 CENC-005 / 01WO 360899-2046
[0583] An assay to measure the off-rate of reversible covalent molecules was developed. A typical covalent compound is assumed to stay bound to a protein for at least the life of that protein in the cell. In reality, there is a range of how long a covalent compounds remains bound before a reverse reaction takes place. Thus, some covalent bonds can be labeled as reversible as their reverse reaction takes place in a measurable amount of time under physiological conditions. The assay capitalizes on the range of covalent binders by using a high affinity covalent binder as a probe to displace the more reversible binders in an adaptation of the jump dilution method.
[0584] In this version of the jump dilution method, the increase in covalent probe binding over time was measured through a TR-FRET reaction between the covalent probe and the biotinylated target protein.Methods
[0585] Target protein preparation
[0586] The recombinant form of the DCN1 (DCUND1) protein PONY domain was produced using an E.coli expression system at Viva Biotech (China). The DCN1 protein was biotinylated (EZ sulfo-NHS-LC-biotin; Thermofisher) for labeling with streptavidin terbium (Tb) cryptate in the reaction. This biotinylated protein was used in two forms of the TR-FRET assay as described below.
[0587] TR-FRET with FAM probe
[0588] This version of the TR-FRET assay was used to measure compound potency to the target, specifically to measure the potency of the Cy5 probe (P-1). A non-covalent DCN1 inhibitor (Zhou et al., 2017) labeled with carboxyfluorescein (FAM) was used as the FRET acceptor probe. Displacement of the covalent probe, and thus decrease in the FRET signal, was indicative of compound activity on the target protein. Buffer conditions were optimized to enhance compound and protein stability (200 mM NaCl, 25 mM Tris, 0.5 mM DTT, 0.05% Tween20, 5% DMSO, 5% PEG-3350, pH 7.5) and concentrations of protein (0.31 nM) and probe (100 nM labeled, 800 nM unlabeled) were optimized for detection of potent molecules. The TR-FRET ratio between Tb-DCN1 and the FAM-labeled probe was measured in a 384-well opti-plate (Perkin Elmer) using a plate reader (BMG) at 1, 5, and 24 hrs after treatment with compound. The ratio was normalized to the high (DCN1 and FAM-probe) and low (DCN1 and no probe) controls for a readout of % activity (= 100* (x - low) / (high - low)).
[0589] TR-FRET with Cy5 probe136335841422 CENC-005 / 01WO 360899-2046
[0590] This version of the TR-FRET assay was used to measure both the potency of the molecules to the target and the off-rate of the compounds from the target. All potency measurements in this assay condition were used to determine the concentrations used in the off-rate assay. A covalent probe labeled with Cy5 was used as the FRET acceptor. Similar conditions were used as for the TR-FRET with FAM probe. The only differences include, 0.625 nM protein, 2.5 nM probe, and detection timepoints at 0.5, 1, 2, 4, 24 hrs. Calculations were the same.
[0591] Off-rate measurement
[0592] The off-rate measurement is executed in two steps based on the jump dilution method. Step one, test compounds were incubated 1 hour at room temperature with Tb and 6 nM protein at a concentration 10-fold higher than the EC50 determined in the TR-FRET with Cy5 probe assay. Step two, the mixture in Step one was diluted into a new reaction buffer containing the Cy5 probe at a concentration of 150 nM » its Kd (EC5023.2 nM). The degree of dilution (20, 50, or 100-fold) was dependent on the EC50 of the test compound. The greatest dilution allowed within the constraints of the assay was chosen. These factors allow a competitive advantage for the covalent probe to replace the test compound when that compound releases from the target protein. The actual measure is the rate of increased TR-FRET signal as the covalent probe replaces the test compound over time. The TR-FRET signal is measured every 0.5 minutes up to 0.5 hours; every 5 minutes up to 2 hours; every 15 minutes up to 2 hours with a BMG Labtech plate reader (Optic module: LanthaScreen 337 / 665 / 620). The resulting time dependent curve of the TR-FRET signal is fit to the following equation:Y=Y0 + (Plateau-Y0)*(1-exp(-K*x))
[0593] K is the rate constant (1 / unit of time). The residence time is defined as the inverse of K, the rate constant. The half-life is calculated as ln(2) / K.
[0594] The structures of tool compounds 1 and 2 respectively are shown below.137335841422 CENC-005 / 01WO 360899-2046Tool compound 1 Tool compound 2Table 4. AssayExample 17: Measurement of Kinact / KI in the DCN2 TR-FRET AssayMethods
[0595] A TR-FRET Assay was performed to evaluate the ability of the compounds to bind DCN-2.
[0596] The time resolved - Forster’s resonance energy transfer (TR-FRET) assay was designed following the protocol established in (Scott et al., Nat Chem Biol. 2017 August; 13(8): 850-857). A recombinant form of the DCN2 (DCUND2) protein PONY domain was produced using an E.coli expression system at Viva Biotech China. The DCN2 protein was biotinylated (EZ sulfo-NHS-LC-biotin; Thermofisher) for labeling with 2.5 nM streptavidin terbium (Tb) cryptate in the reaction. The probe was changed to a non-covalent DCN1 inhibitor labeled with carboxyfluorescein (FAM; Zhou et al., Nat Commun. 2017; 8: 1150). Buffer conditions were modified to enhance protein stability by replacing TritonX with 0.05% Tween20 and increasing NaCl to 200 mM. The compounds were screened against 0.31 nM DCN 1 and 40 nM FAM-labeled probe in a 40 ul reaction volume. The TR-FRET ratio between Tb-DCN1 and the FAM-labeled probe was measured in a 384-well opti-plate (Perkin Elmer) using a plate reader (BMG) at after treatment with compound (final DMSO concentration of 0.1%). The ratio was normalized to the high (DCN1 and FAM-probe) and low (DCN1 and no probe) controls for a readout of % activity (= 100* (x - low) / (high - low)).
[0597] The Kinact and KI measurements were taken to allow for continuous reads over 24 hrs. Plates were read every 5 min up to 1 hr, every 15 min up to 5 hr, and every hour up to 10 hours. Kinact and KI were calculated based on the following equations (Krippendorff BF, et al. Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50)138335841422 CENC-005 / 01WO 360899-2046values. J BiomolScreen. 2009; Mons E et al. A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations. CurrProtoc. 2022) where the KM of the probe against DCN2 is 21.62 nM. The Kinact and KI values could be estimated from the tight curves of the IC50 values over time.
[0598] The structure of Cl is shown below.Table 5. Measurement of Kinact / KI in the DCN2 TR-FRET Assay
[0599] While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the application and claims rather than by the specific embodiments that have been represented by way of example.Example 18: Compound I Additional Polymorph ScreeningChemical abbreviations:ACN AcetonitrileDCM Dichloromethane139335841422 CENC-005 / 01WO 360899-2046DMF N, N-Dimethyl formamideDMSO Dimethyl sulfoxideEtOAc Ethyl acetateEtOH EthanolFaSSIF Fasted-state simulated intestinal fluidFeSSIF Fed-state simulated intestinal fluidIPA IsopropanolIPAC Isopropyl acetateMeOH MethanolMTBE Methyl tertiary butyl etherNPA n -PropanolSGF Simulated gastric fluidTHF TetrahydrofuranOther abbreviations:'H-NMR Proton nuclear magnetic resonanceDSC Differential scanning calorimetryDVS Dynamic vapor sorptionHPLC High performance liquid chromatographyTGA Thermogravimetric analysisXRPD X-ray powder diffractionSummary
[0600] The objective of this study was to conduct polymorph screen of Compound I to find a suitable crystalline form for pharmaceutical development and manufacturing.
[0601] The sample of Compound I received for polymorph screen was consistent with Form C as described in Example 3. The polymorph screen was performed using methods including slow evaporation, slurry conversion, anti-solvent crystallization, humidity-induced crystallization, vapor-solid diffusion, vapor-liquid diffusion and cooling crystallization. Through these experiments, four new forms - Form G, Form H, Form J and Form K, solvate Form B, and anhydrous Form A were found. However, Form G, Form H, Form J were solvates and Form K 140335841422 CENC-005 / 01WO 360899-2046was unstable and potentially a solvate.
[0602] Anhydrous Forms A and C were evaluated. Solubility results indicated that there was no significant difference in the solubility of Form A and Form C. The crystal form of Form A changed to the amorphous form after the solubility test in FeSSIF and water. The crystal form of Form C changed to the amorphous form after the solubility test in FeSSIF, SGF, and water.
[0603] Stability results showed that Form C was physically and chemically stable at 25 °C / 60% RH (uncapped), 40 °C / 75% RH (uncapped), and 60 °C (capped) for one week. However, slight degradation (from 99.8% to 99.6%) was observed for Form A at 60 °C (capped), and the crystallinity of Form C slightly decreased at 60 °C (capped) for 1 week.
[0604] Overall, both Form A and Form C are anhydrate forms with acceptable solid-state properties, and there is no significant difference in solubility or stability.Starting Material
[0605] The information on Compound I starting material sample is given in Table 18.1.Table 18.1 Information on Starting MaterialAnalytical MethodX-ray Powder Diffraction
[0606] X-ray powder diffraction analysis was performed in reflection mode using a D8 ADVANCE diffractometer with Cu Kt(X = 1.5406 A, generator settings: 40 kV and40 mA) radiation at RT. The sample was prepared on a poli shed, zero-background sample holder by gently pressing onto the flat surface. Measurements were carried out from 3 to 42° (20), at a scanning speed of 005 s / step and step size of 0.02° (20). The diffraction patterns were analyzed using DIFFRAC EVA.Diffraction Scanning Calorimetry141335841422 CENC-005 / 01WO 360899-2046
[0607] DSC thermograms were recorded on a Discovery DSC25 (TA Instruments, USA) equipped with a RCS90 chiller. Typically, samples of approximately 0.5-5 mg were heated at a rate of 10 °C / min in pin-holed aluminium pans from 25 °C to the final temperature. Measurements were performed at a constant nitrogen flow rate of 60 mL / min. The DSC data were analyzed using TRIOS.Thermogravimetric Analysis
[0608] TGA analysis was performed on a Discovery TGA55O (TA Instruments, USA). Typically, 1-5 mg of each sample was loaded onto a pre-tared aluminium oxide pan and heated at 10 °C / min from room temperature to 300 °C. A nitrogen purge at 60 mL / min was maintained over the sample. The TGA data were analyzed using TRIOS.Dynamic Vapor Sorption
[0609] Sorption-desorption isotherms were obtained using a DVS Intrinsic moisture sorption analyzer (Surface Measurement Systems, UK). Typically, 10-30 mg of sample was placed in a tared mesh stainless steel basket under ambient conditions. The standard isotherm was performed at 25 °C at 10% RH intervals over a 0-90% RH range. Data analysis was carried out within Microsoft Excel using the DVS Analysis Suite.Table 18.2 Method for DVS AnalysisProton Nuclear Magnetic Resonance142335841422 CENC-005 / 01WO 360899-2046
[0610] 'H-NMR spectra were collected on a Varian Mercury plus 400 MHz spectrometer (Varian, USA). Unless otherwise stated, DMSO-< / 6 was used as the solvent. The data was analyzed using MestReNova.High Performance Liquid Chromatography
[0611] Agilent 1200 HPLC (Agilent, USA) with DAD detector was utilized and the detailed chromatographic condition is listed in Table 18.3.Table 18.3 Chromatographic Conditions and ParametersCharacterization of Starting MaterialResults of Characterization
[0612] The XRPD pattern is presented in FIG. 36, the sample is crystalline and has high crystallinity. The starting material is consistent with Form C from the earlier study. As shown in FIG. 37, there was one single endothermic peak at 111.23 °C in the DSC 143335841422 CENC-005 / 01WO 360899-2046curve due to melting. 0.474% weight loss before 200 °C was observed in TGA profile.Slurry Conversion[00613J The slurry conversion experiments were performed in 10 single or binary solvents at RT and 50 °C. Approximately 40 mg of the starting material was weighed in a 4-mL vial. Subsequently, 0.5 mL of the solvent was added, and the vials were left to equilibrate with continuous stirring for 1 week at RT and 50 °C, respectively. The remaining solids were isolated by suction filtration for XRPD analysis. The summary is shown in Table 18.4 and FIGS. 38 and 39. Form C were formed in Heptane at 50 °C and EtOAc: Heptane (1:10) at RT. Form H and Form J were found through slurry conversion. Form H was formed in IPA: Heptane (1:10) and turned amorphous after drying at 50 °C for 16 h. Form J was formed in EtOAc: Heptane (1:10) and became Form K after drying at 50 °C for 16 h. All other conditions resulted in amorphous material.Table 18.4 Summary of Slurry ConversionAnti-Solvent Crystallization144335841422 CENC-005 / 01WO 360899-2046
[0614] The anti-solvent crystallization experiments were conducted under 18 conditions at RT. About 60 mg of the starting material was dissolved in different solvents to get a clear, near saturated solution at RT. The solution was stirred followed by addition of anti-solvent stepwise until precipitate appeared at RT, or the total amount of antisolvent reached 6 mL. The solutions were stirred for about 20 h. The solid was isolated and characterized by XRPD. The detailed experiments are shown in Table 18.5 and FIG. 40. Form G and Form B were found through anti-solvent crystallization. Form G was nearly amorphous after drying at 50 °C for 16 h. The crystallinity of Form B decreased after drying at 50 °C for 16 h. Form G may be an 1,4-dioxane / heptane solvate, and Form B may be an anisole / heptane solvate.Table 18.5 Summary of Anti-Solvent Crystallization145335841422 CENC-005 / 01WO 360899-2046Vapor-Solid Diffusion[00615J The vapor-solid diffusion experiments were performed using 3 different solvents at RT. About 30 mg of the starting material was weighed in a 4-mL uncapped vial, which was placed into a 30-mL vial with 5 mL of volatile solvent. The 30-mL vial was sealed with a cap and kept under ambient conditions for 7 days allowing solvent vapor to interact with sample. The resulting solids were analyzed by XRPD. The detailed experiments are shown in Table 18.6 and FIG. 41. Form H was found through vapor-solid diffusion using NPA, which appeared amorphous after drying at 50 °C for 16 h, and may be an NPA solvate.Table 18.6 Summary of Vapor-Solid DiffusionVapor-Liquid Diffusion
[0616] The vapor-liquid diffusion experiments were performed using 3 different solvent systems at RT. About 60 mg of the starting material was dissolved in 0.4 mL of solvent in a 4-mL uncapped vial, which was placed into a 30-mL vial with 5 mL of volatile anti-solvent. The 30-mL vial was sealed with a cap and kept under ambient conditions for 7 days. The detailed experiments are shown in Table 18.7. No solids were precipitated in the vapor-liquid diffusion.Table 18.7 Summary of Vapor-Liquid Diffusion146335841422 CENC-005 / 01WO 360899-2046Slow EvaporationSingle Solvent
[0617] The slow evaporation experiments were carried out in 12 solvents at RT. Clear solutions were prepared by dissolving 200 mg of the starting material in 1.5 mb of different solvents at RT. The solutions were allowed to slowly evaporate under ambient conditions. The solids were collected and analyzed by XRPD. The detailed experiments are shown in Table 18.8 and FIG. 42. Form A was found through slow evaporation in DCM and Form B was found through slow evaporation in toluene. The crystallinity of Form A and Form B improved after drying at 50 °C for 16 h.Table 18.8 Summary of Slow Evaporation - Single SolventBinary Solvent
[0618] The slow evaporation experiments in binary solvent were carried out in 45 solvents at RT. Clear solutions were prepared by dissolving 200 mg of the starting material in 1.5 mb of solvent at RT. Two filtered solutions were distributed into a 96-well plate, the amount of a single solvent in each well was 100 pL. Solvents 1 to 10 represent MeOH, EtOH, THF, ACN, MTBE, Acetone, EtOAc, IP AC, DCM, MIBK, respectively. All solids obtained were amorphous, and no new form was found through147335841422 CENC-005 / 01WO 360899-2046binary solvent slow evaporation.Cooling Crystallization
[0619] The cooling crystallization with hot filtration experiments comprised two solvent mixtures. Supersaturated solutions were prepared by stirring slurries (initial solid loading of 50-300 mg / mL) at 50 °C for 0.5 hour and then filtering the slurries with a 0.22 pm PTFE membrane. All the solutions were then placed in a shaker to undergo a cooling process from 50 °C to 5 °C at 0.1 °C / min. The solution was then held at 5 °C for 12 h. No solids were precipitated in these experiments as shown in Table 18.9.Table 18.9 Summary of Cooling CrystallizationPreparation and Characterization of New Forms
[0620] Four new forms (Form G, Form H, Form J and Form K) were found. All new forms were solvates as shown in Table 18.10.Table 18.10 Summary of Solid FormsForm A148335841422 CENC-005 / 01WO 360899-2046
[0621] Form A was obtained by dissolving the starting material in DCM and allowing the solvent to evaporate. Form A had a single endothermic peak at 93.75 °C in the DSC curve, and 0.090% weight loss before 150 °C in the TGA profile FIG. 43. TheDVS curve in FIG. 44 and XRPD in FIG. 45 showed that Form A was anhydrous with 1.977% of water uptake at 80% RH. Sorption and desorption were reversible. The crystal form remained unchanged after DVS test.Form G
[0622] About 60 mg of the starting material was dissolved in 0.4 mb of 1,4-dioxane, resulting in a clear solution at RT. The solution was stirred followed by stepwise addition of 4 mb heptane until precipitate appeared at RT. The solutions were stirred for about 20 h. The solid was isolated and characterized by XRPD. As shown in FIG. 46. The solid was still Form G, and the crystallinity increased. FIG. 47 depicts an XRPD pattern of Form G. As shown in FIG. 48, there was a single endothermic peak at 89.65 °C in the DSC curve, and 12.849% weight loss before 150 °C in TGA profile. TGA / DSC overlay and 'II-NMR suggest Form G is a 1,4-dioxane solvate (0.94 eq.).
[0623] About 60 mg of the starting material was dissolved in 0.4 mb of 1,4-dioxane, resulting in a clear solution at RT. The solution was stirred followed by stepwise addition of 4 mb heptane until precipitate appeared at RT. Meanwhile, the temperature was cycled (25 °C-50 °C -5 °C -50 °C -5 °C). The solid was isolated and characterized by XRPD. As shown in FIG. 46, the obtained solid was still Form G, but with preferred orientation. As shown in FIG. 49, there was a single endothermic peak at 87.54 °C in the DSC curve, and 8.245% weight loss before 150 °C in the TGA profile.Form FT
[0624] Approximately 40 mg of the starting material was weighed in a 4-mL vial. Subsequently, 0.5 mb of IPA: Heptane (1:10) was added, and the vial was left to equilibrate with continuous stirring for 7 days at RT. As shown in FIG. 50, the obtained solid was Form A. FIG. 51 depicts an XRPD pattern of Form H. After repeated slurry conversion in IPA: Heptane (1:10) at RT, the obtained solid was Form A.Form J
[0625] Approximately 40 mg of the starting material was weighed in a 4-mL vial.149335841422 CENC-005 / 01WO 360899-2046Subsequently, 0.5 rnL of EtOAc: Heptane (1:10) was added, and the vial was left to equilibrate with continuous stirring for 1 day at 50 °C. The remaining solids were isolated by suction filtration for XRPD analysis. As shown in FIG. 52, the solid was still Form J, but the crystallinity did not increase. FIG. 53 depicts an XRPD pattern of Form J. As shown in FIG. 54, there was a single endothermic peak at 106.95 °C in the DSC curve, and 5.766% weight loss before 150 °C in the TGA profile. The 'H-NMR spectrum indicated there was 6.1% residual EtOAc. TGA / DSC overlay and 'H-NMR suggest Form J is a EtOAc solvate (0.47eq.).Form K
[0626] Form J became Form K after drying at 50 °C for 16 h. As shown in FIG. 55, there were two endothermic peaks at 33.02 °C and 102.47 °C in the DSC curve, and 0.879% weight loss before 150 °C in the TGA profile. As shown in FIG. 56, Form K was amorphous after heating 90 °C. Form K is unstable and potentially a solvate. FIG. 57 depicts an XRPD pattern of Form K. The 'H-NMR spectrum indicated 0.54% residual EtOAc.Competitive Slurry
[0627] Competitive slurry was performed by suspending about 8 mg of Form A and Form C in 0,8 mL of solvent presaturated with Form C. Then the suspensions were stirred at RT and 50 °C for 3 days. The detailed experiments are shown in Table 18.11 and FIG. 58-FIG. 61.
[0628] F orm A was found through competitive slurry conversion in 1PA: Heptane (1:4) and DCM: Heptane (1:4). Form C was found through competitive slurry conversion in the MTBE: Heptane system at 50 °C. All other conditions resulted in amorphous material.Table 18.11 Summary of Competitive Slurry150335841422 CENC-005 / 01WO 360899-2046Kinetic Solubility
[0629] Kinetic Solubility was performed in FaSSIF, FeSSIF, SGF, and water with sampling time at 2 h and 24 h at 37 °C. About 10 mg of solid was suspended into 2 ml, of each medium with an initial cone, of ~5 mg / mL. Approximately 1 mL of the suspension was extracted at each time point and filtered to obtain precipitate and mother liquor. Solubility' was tested for the mother liquor at 2 h and 24 h, XRPD and pH were tested for precipitate and the mother liquor at 24 h.
[0630] There was no significant difference in solubility of Form A and Form C, as shown in Table 18.12. The crystal form of Form A changed to an amorphous form after the solubility testing in FeSSIF and water. Form C changed to an amorphous form after the solubility test in FeSSIF, SGF and water. XRPD patterns are shown in FIG. 62-FIG. 63.Table 18.12 Solubility Results of Form A and Form C at 37 °C151335841422 CENC-005 / 01WO 360899-2046Note: LOQ=0.000285 mg / mLPhysical and Chemical Stability
[0631] About 20 mg of solid was placed into a glass vial. The vials were stored under stress test conditions of 25 °C / 60% RH (uncapped), 40 °C / 75% RH (uncapped), and 60 °C (capped). After one week, solids were checked by XRPD and HPLC to evaluate the physical and chemical stability, respectively.
[0632] Stability results summarized in Table 18 13 and FIG. 64-FIG. 65 indicate that Form C is physically and chemically stable at 25 °C / 60% RH (uncapped), 40 °C / 75% RH (uncapped), and at 60 °C (capped) for one week. However, slight degradation was observed for Form A at 60 °C (capped), and the crystallinity of Form A slightly decreased at 60 °C (capped) for 1 week.Table 18.13 Stability Results of Leading FormsConclusion
[0633] The starting material is consistent with Form C. A total of 105 experiments were performed in the polymorph screen. Through these experiments, 4 new forms (Form 152335841422 CENC-005 / 01WO 360899-2046G, Form H, Form J and Form K) were found, but Form G, Form H, Form J were solvates and Form K was unstable and potentially a solvate.[006341 Solubility results indicated that there is no significant difference in the solubility of Form A and Form C. The crystal form of Form A changed to an amorphous form after the solubility test in FeSSIF and water. And Form C changed to an amorphous form after the solubility test in FeSSIF, SGF and water.
[0635] Stability results showed that Form C was physically and chemically stable at 25 °C / 60% RH (uncapped), 40 °C / 75% RH (uncapped) and 60 °C (capped) for one week. However, slight degradation (from 99.8% to 99.6%) was observed for Form A at 60 °C (capped), and the crystallinity of Form A slightly decreased at 60 °C (capped) for 1 week.
[0636] Overall, Form C and Form A are anhydrate forms with acceptable solid-state properties, and there is no significant difference in solubility or stability.153335841422 CENC-005 / 01WO 360899-2046
Claims
CLAIMS1. A solid form of Compound I:Ior a solvate thereof.
2. The solid form according to claim 1, wherein said solid form is a crystalline solid.
3. The solid form according to claim 1, wherein said solid form is a crystalline solid substantially free of amorphous Compound I.
4. The solid form according to claim 1, wherein said solid form is substantially free of impurities.
5. The solid form according to claim 1 or 2, having one, or two, or three peaks in its XRPD selected from those at about 7.9, about 6.7, and about 10.3 degrees 2-theta.
6. The solid form according to claim 1, 2, or 5, having one, or two, or three peaks in its XRPD selected from those at about 8.5, about 7.8, and about 20.7 degrees 2-theta.
7. The solid form according to claim 5 or 6, wherein said solid form is of Form A.
8. The solid form according to claim 7, wherein Form A is an isostructural solvate or hydrate.
9. The solid form according to claim 7, wherein Form A is an anhydrate.154335841422 CENC-005 / 01WO 360899-204610. The solid form according to claim 7 or 8, wherein the solid form exhibits an XRPD substantially similar to FIG. 4 or 7.
11. The solid form according to claim 1 or 2, having one, or two, or three peaks in its XRPD selected from those at about 18.0, about 6.5, and about 7.0 degrees 2-theta.
12. The solid form according to claim 11, wherein said solid form is of Form B.
13. The solid form according to claim 12, wherein Form B is an isostructural solvate.
14. The solid form according to claim 12 or 13, wherein the solid form exhibits an XRPD substantially similar to FIG. 11.
15. The solid form according to claim 1 or 2, having one, or two, or three peaks in its XRPD selected from those at about 6.6, about 24.5, and about 17.8 degrees 2-theta.
16. The solid form according to claim 15, wherein said solid form is of Form C.
17. The solid form according to claim 16, wherein Form C is an anhydrate.
18. The solid form according to claim 16 or 17, wherein the solid form exhibits an XRPD substantially similar to FIG. 14.
19. The solid form according to claim 1 or 2, having one, or two, or three peaks in its XRPD selected from those at about 7.6, about 6.6, and about 20.7 degrees 2-theta.
20. The solid form according to claim 19, wherein said solid form is of Form D.
21. The solid form according to claim 20, wherein Form D is a solvate.155335841422 CENC-005 / 01WO 360899-204622. The solid form according to claim 20 or 21, wherein the solid form exhibits an XRPD substantially similar to FIG. 17.
23. The solid form according to claim 1 or 2, having one, or two, or three peaks in its XRPD selected from those at about 5.2, about 20.7, and about 11.6 degrees 2-theta.
24. The solid form according to claim 23, wherein said solid form is of Form E.
25. The solid form according to claim 24, wherein Form E is a solvate.
26. The solid form according to claim 23 or 24, wherein the solid form exhibits an XRPD substantially similar to FIG. 19.
27. The solid form according to claim 1 or 2, having one, or two, or three peaks in its XRPD selected from those at about 6.4, about 13.5, and about 19.8 degrees 2-theta.
28. The solid form according to claim 27, wherein said solid form is of Form F.
29. The solid form according to claim 28, wherein Form F is a solvate.
30. The solid form according to claim 28 or 29, wherein the solid form exhibits an XRPD substantially similar to FIG. 21.
31. The solid form according to claim 1 or 2, having one, or two, or three peaks in its XRPD selected from those at about 5.9, about 19.9, and about 17.8 degrees 2-theta.
32. The solid form according to claim 31, wherein said solid form is of Form G.
33. The solid form according to claim 32, wherein Form G is a solvate.156335841422 CENC-005 / 01WO 360899-204634. The solid form according to claim 32 or 33, wherein the solid form exhibits an XRPD substantially similar to FIG. 48.
35. The solid form according to claim 1 or 2, having one, or two, or three peaks in its XRPD selected from those at about 18.1, about 5.4, and about 9.6 degrees 2-theta.
36. The solid form according to claim 35, wherein said solid form is of Form H.
37. The solid form according to claim 36, wherein Form H is a solvate.
38. The solid form according to claim 36 or 37, wherein the solid form exhibits an XRPD substantially similar to FIG. 52.
39. The solid form according to claim 1 or 2, having one, or two, or three peaks in its XRPD selected from those at about 8.4, about 18.8, and about 12.1 degrees 2-theta.
40. The solid form according to claim 39, wherein said solid form is of Form J.
41. The solid form according to claim 40, wherein Form J is a solvate.
42. The solid form according to claim 39 or 40, wherein the solid form exhibits an XRPD substantially similar to FIG. 54.
43. The solid form according to claim 1 or 2, having one, or two, or three peaks in its XRPD selected from those at about 18.1, about 8.8, and about 17.8 degrees 2-theta.
44. The solid form according to claim 43, wherein said solid form is of Form K.
45. The solid form according to claim 44, wherein Form K is a solvate.157335841422 CENC-005 / 01WO 360899-204646. The solid form according to claim 44 or 45, wherein the solid form exhibits an XRPD substantially similar to FIG. 58.
47. A pharmaceutical composition comprising the solid form of any one of the preceding claims, or a solvate thereof, and a pharmaceutically acceptable carrier.
48. A method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof the solid form of any one of claims 1-46, or a solvate thereof, or the pharmaceutical composition of claim 47.
49. The method of claim 48, wherein the hemoglobinopathy is a sickle cell disorder or disease.
50. The method of claim 48, wherein the hemoglobinopathy is a thalassemia disorder or disease.
51. A method to increase red blood cell levels and / or hemoglobin levels in a subject in need thereof, treat or prevent an anemia in a subject in need thereof, treat sickle-cell disease in a subject in need thereof, or treat one or more complications of sickle-cell disease in a subject in need thereof, comprising administering to a subject in need thereof the solid form of any one of claims 1-46, or a solvate thereof, or the pharmaceutical composition of claim 47, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.
52. A method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof the solid form of any one of claims 1-46, or a solvate thereof, or the pharmaceutical composition of claim 47, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.
53. The method of claim 52, wherein the hemoglobinopathy is a sickle cell disorder or disease.
54. The method of claim 52, wherein the hemoglobinopathy is a thalassemia disorder or disease.158335841422 CENC-005 / 01WO 360899-204655. The method of claim 52, wherein the solid form or pharmaceutically acceptable salt thereof and the hydroxyurea or a pharmaceutically acceptable salt thereof act synergistically.
56. A method of increasing efficacy and / or reducing toxicity of hydroxyurea treatment in a subject undergoing said treatment, comprising administering to the subject the solid form of any one of claims 1-46, or a solvate thereof, or the pharmaceutical composition of claim 47.
57. The method of claim 56, further comprising the step of decreasing an amount of hydroxyurea being administered to the subject.
58. The method of claim 57, wherein the amount of hydroxyurea being administered is decreased by 10-90%.
59. A method of decreasing the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof the solid form of any one of claims 1-46, or a solvate thereof, or the pharmaceutical composition of claim 47, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof, wherein the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of the hemoglobinopathy disorder or disease is less than the dose needed for treatment in the subject using hydroxyurea or a pharmaceutically acceptable salt thereof as a monotherapy.
60. The method of claim 59, wherein the dose of hydroxyurea or a pharmaceutically acceptable salt thereof co-administered with the solid form, or a solvate thereof, or the pharmaceutical composition, is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% relative to the dose needed for treatment in the subject using hydroxyurea or a pharmaceutically acceptable salt thereof as a monotherapy.159335841422 CENC-005 / 01WO 360899-2046
